



PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-47-0 CAPLUS
 CN Acetamide, N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733781-48-1 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-49-2 CAPLUS
 CN 2-Butenamide, N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-50-5 CAPLUS
 CN 3-Furancarboxamide, N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733781-51-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-(dimethylamino)propyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733781-52-7 CAPLUS

CN 3-Furancarboxamide, N-[3-(dimethylamino)propyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733781-53-8 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733781-54-9 CAPLUS

CN Piperazine, 1-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733781-55-0 CAPLUS


CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733781-56-1 CAPLUS
 CN Piperazine, 1-[[[trans-4-[[[(3R,5S)-3,5-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733781-57-2 CAPLUS
 CN Piperazine, 1-[[[trans-4-[[[(3R,5S)-3,5-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733781-58-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(3R,5R)-3,5-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733781-59-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(3R,5R)-3,5-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733781-60-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(3R,5R)-3,5-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733781-61-8 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-2,2-dimethyl-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-62-9 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733781-63-0 CAPLUS
CN Acetamide, N-[2-(dimethylamino)ethyl]-2-methoxy-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-64-1 CAPLUS
CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-65-2 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-66-3 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-2,2-dimethyl-, hydrochloride (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-67-4 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733781-68-5 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-2-methoxy-, hydrochloride (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-69-6 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-70-9 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-71-0 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-72-1 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-73-2 CAPLUS

CN Propanamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-74-3 CAPLUS
 CN Propanamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-2,2-dimethyl-, hydrochloride (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-75-4 CAPLUS
 CN 2-Butenamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 2-A

●x HCl


RN 733781-76-5 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-4-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




●x HCl

RN 733781-77-6 CAPLUS
 CN 2-Butenamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-78-7 CAPLUS
 CN Propanamide, N- [3- (dimethylamino)propyl] -N- [[trans-4- [[4- [1- [(3-ethoxyphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] -1-piperazinyl]carbonyl]cyclohexyl]methyl]-2,2-dimethyl-, hydrochloride (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-79-8 CAPLUS
CN Propanamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-80-1 CAPLUS
CN 2-Butenamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-81-2 CAPLUS

CN 2-Butenamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 2-A

●x HCl


RN 733781-82-3 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-4-methoxy-, hydrochloride (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




●x HCl

RN 733781-83-4 CAPLUS
 CN Propanamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-2,2-dimethyl-, hydrochloride (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-84-5 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-85-6 CAPLUS

CN Butanamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-86-7 CAPLUS

CN Cyclopentanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-87-8 CAPLUS
 CN Piperazine, 1-acetyl-4-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-88-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[4-(1-oxopropyl)-1-piperazinyl]cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A




PAGE 2-A

●x HCl


RN 733781-89-0 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-90-3 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[4-[1-[(3-ethoxy-2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-91-4 CAPLUS
 CN Piperazine, 1-[4-[(ethylamino)methyl]benzoyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733781-92-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxy-2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(ethylamino)methyl]benzoyl]-, hydrochloride (9CI)
 (CA INDEX NAME)




RN 733781-93-6 CAPLUS
 CN Piperazine, 1-[4-[(ethylamino)methyl]benzoyl]-4-[1-[[3-(1-oxopropyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733781-94-7 CAPLUS

CN Piperazine, 1-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733781-95-8 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxy-2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●x HCl

RN 733781-96-9 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl) (2-methoxyethyl) amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 733781-97-0 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl) (2-methoxyethyl) amino] methyl] cyclohexyl] carbonyl]-4-[1-[(3-ethoxy-2-fluorophenyl) methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● x HCl

RN 733781-98-1 CAPLUS
CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[[3-(1-oxopropyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 2-A


●x HCl

RN 733781-99-2 CAPLUS
CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[[3-(1-oxopropyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733782-00-8 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733782-01-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[[3-(1-oxopropyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733782-02-0 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733782-05-3 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-oxopropyl)phenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733782-07-5 CAPLUS
 CN Piperazine, 1-[3-[2-(diethylamino)ethoxy]-4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733782-08-6 CAPLUS
 CN Piperazine, 1-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




●2 HCl

RN 733782-09-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[[2-(diethylamino)ethyl]ethylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733782-10-0 CAPLUS

CN Piperazine, 1-[[trans-4-[[[2-(diethylamino)ethyl](1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●x HCl

RN 733782-11-1 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[2-(diethylamino)ethyl]ethylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●x HCl

RN 733782-12-2 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[2-(diethylamino)ethyl](1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 733782-13-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[[3-(dimethylamino)propyl]ethylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733782-14-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[[3-(dimethylamino)propyl](1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733782-15-5 CAPLUS

CN Piperazine, 1-[[trans-4-[[[3-(dimethylamino)propyl]ethylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733782-16-6 CAPLUS

CN Piperazine, 1-[[trans-4-[[[3-(dimethylamino)propyl](1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride

(9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733782-17-7 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● x HCl


RN 733782-18-8 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733782-19-9 CAPLUS

CN Piperazine, 1-[[2-[[2-bis(1-methylethyl)amino]ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A

●x HCl

RN 733782-20-2 CAPLUS


CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-methyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 733782-21-3 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-methyl-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733782-22-4 CAPLUS
 CN Piperazine, 1-[[2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

●x HCl


RN 733782-23-5 CAPLUS
 CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733782-24-6 CAPLUS

CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733782-25-7 CAPLUS


CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733782-26-8 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


OEt

●x HCl

RN 733782-27-9 CAPLUS

CN Piperazine, 1-[[2-[[2-[bis(1-methylethyl)amino]ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●_x HCl

RN 733782-28-0 CAPLUS
 CN Piperazine, 1-[[2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 733782-29-1 CAPLUS
 CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733782-30-4 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

●x HCl

RN 733782-31-5 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733782-32-6 CAPLUS

CN Piperazine, 1-[[2-[[2-[bis(1-methylethyl)amino]ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733782-33-7 CAPLUS

CN Piperazine, 1-[[2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


●x HCl

RN 733782-34-8 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733782-35-9 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733782-36-0 CAPLUS
 CN Piperazine, 1-[[2-[[2-[bis(1-methylethyl)amino]ethyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733782-37-1 CAPLUS
 CN Piperazine, 1-[[2-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-4-methyl-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733782-38-2 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733782-39-3 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733785-81-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(2E)-3-[1-(1-methylethyl)-4-piperidinyl]-1-oxo-2-propenyl]- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 733785-82-5 CAPLUS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733785-83-6 CAPLUS

CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733785-84-7 CAPLUS
 CN Acetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733785-85-8 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI)
 (CA INDEX NAME)



RN 733785-86-9 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733785-87-0 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733785-88-1 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 733785-89-2 CAPLUS


CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733785-92-7 CAPLUS


CN Piperazine, 1-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733785-93-8 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733785-94-9 CAPLUS

CN Piperazine, 1-[(3,3-dimethyl[1,4'-bipiperidin]-1'-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733785-95-0 CAPLUS
 CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733785-96-1 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl) (2-hydroxyethyl) amino] methyl] cyclohexyl] carbonyl] -4- [1- [(3-ethoxyphenyl) methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] - (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733785-97-2 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl] (methylsulfonyl) amino] cyclohexyl] carbonyl] -4- [1- [(6-propyl-2-pyridinyl) methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] - (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733785-98-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733785-99-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 733786-00-0 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-2,2-dimethyl-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733786-01-1 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733786-02-2 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733786-03-3 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxy-2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Relative stereochemistry.




Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 733786-06-6 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxy-2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 733770-10-0P 733782-40-6P 733782-42-8P
 733782-43-9P 733782-44-0P 733782-45-1P
 733782-47-3P 733782-49-5P 733782-50-8P
 733782-51-9P 733782-52-0P 733782-53-1P
 733782-54-2P 733782-55-3P 733782-56-4P
 733782-57-5P 733782-60-0P 733782-61-1P
 733782-62-2P 733782-64-4P 733782-65-5P
 733782-66-6P 733782-68-8P 733782-69-9P


733782-70-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as a small conductance potassium channel (SK channel) blocking agents)


RN 733770-10-0 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733782-40-6 CAPLUS

CN Benzoic acid, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 733782-42-8 CAPLUS

CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 733782-43-9 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-(4-hydroxybenzoyl)- (9CI) (CA INDEX NAME)



RN 733782-44-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A





RN 733782-45-1 CAPLUS


CN Carbamic acid, [[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl)methyl]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 733782-47-3 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733782-49-5 CAPLUS


CN Carbamic acid, [[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733782-50-8 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]amino]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733782-51-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 733782-52-0 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 733782-53-1 CAPLUS
 CN Carbamic acid, [[1-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenoxy]methyl]cyclopropyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 733782-54-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(methoxymethoxy)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733782-55-3 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-4-hydroxycyclohexyl)carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733782-56-4 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenoxy]-4-methylpentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 733782-57-5 CAPLUS

CN Carbamic acid, [(1S)-1-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenoxy]-4-methylpentyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733782-60-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(4-oxo-1-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 733782-61-1 CAPLUS
 CN Piperazine, 1-[[4-(dimethylamino)-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733782-62-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 733782-64-4 CAPLUS

CN Carbamimidic acid, N'-cyano-N-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-N-ethyl-, phenyl ester (9CI) (CA INDEX NAME)



RN 733782-65-5 CAPLUS

CN Piperazine, 1-[4-[[[(cyanoimino) (dimethylamino)methyl]ethylamino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)




RN 733782-66-6 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, methyl ester,


trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733782-68-8 CAPLUS

CN Carbamic acid, [3-[[2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]amino]-3-oxopropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 733782-69-9 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[4-[(2-nitrophenyl)sulfonyl]-1-

piperazinyllcyclohexylcarbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733782-70-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperazinyllcyclohexyl)carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L66 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:307614 CAPLUS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

DOCUMENT NUMBER: 140:332509
 TITLE: **Pharmaceutical compositions**
 containing spiroisoquinolines as small-conductance
 calcium-activated potassium channel (SK channel)
 blockers and acetylcholine esterase inhibitors
 INVENTOR(S): Takamuro, Iwao; Honma, Koichi; Ishida, Akihiko;
 Taniguchi, Hiroyuki; Onoda, Yuichi
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 334 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004115450	A2	20040415	JP 2002-282311	20020927
PRIORITY APPLN. INFO.:			JP 2002-282311	20020927
OTHER SOURCE(S):	MARPAT 140:332509			
GI				



AB Title comps., useful for treatment of digestive tract function failure, central nervous disorders, myotonic dystrophy, etc., contain spiroisoquinolines I [ring A may be substituted; R10 = H, ZR1; R1 = H, (un)substituted lower alkyl, (un)substituted lower alkenyl; Y, Z = CH2, CO; R2 H, (un)substituted heterocyclyl; B = N, CH; R3 = (un)substituted NH2, (un)substituted N-containing aliphatic heterocyclyl] or their pharmacol. acceptable salts as active ingredients. Thus, (1R*,2R*(S*),4R*)-2'-[3-(methylamino)propionyl]-3',4'-dihydro-6',7'-dimethoxy-2-(2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolyl)-4-[4-[1-(4-pyridylmethyl)-1H-pyrazolol-[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl-spiro[cyclohexane-1,1'(2'H)isoquinoline] difumarate inhibited binding of 125I-apamin to SK channel in guinea pigs with IC50 value of 0.05 μ M.

IT 470428-54-7P 470428-55-8P 470428-83-2P
 470428-96-7P 470428-97-8P 470428-98-9P
 470428-99-0P 470429-00-6P 470429-01-7P
 470429-02-8P 470429-05-1P 470429-06-2P
 470429-07-3P 470429-08-4P 470429-10-8P
 470429-12-0P 470429-13-1P 470429-14-2P
 470429-15-3P 470429-16-4P 470429-17-5P
 470429-18-6P 470429-19-7P 470429-20-0P
 470429-21-1P 470429-22-2P 470429-23-3P
 470429-24-4P 470429-25-5P 470429-26-6P
 470429-27-7P 470429-28-8P 470429-29-9P

470429-39-1P 470429-41-5P 470429-43-7P
470429-44-8P 470429-46-0P 470429-58-4P
470429-59-5P 470429-60-8P 470429-61-9P
470429-62-0P 470429-63-1P 470429-64-2P
470429-65-3P 470429-67-5P 470429-68-6P
470429-70-0P 470429-71-1P 470429-72-2P
470429-73-3P 470429-74-4P 470429-75-5P
470429-76-6P 470429-77-7P 470429-78-8P
470429-79-9P 470429-80-2P 470429-81-3P
470429-82-4P 470429-83-5P 470429-84-6P
470429-85-7P 470429-86-8P 470429-87-9P
470430-01-4P 470430-02-5P 470430-03-6P
470430-04-7P 470430-31-0P 470430-32-1P
470430-38-7P 470430-39-8P 470430-40-1P
470430-41-2P 470430-42-3P 470430-43-4P
470430-45-6P 470430-48-9P 470430-49-0P
470430-50-3P 470430-60-5P 470430-75-2P
470430-76-3P 470430-80-9P 470430-81-0P
470430-82-1P 470430-83-2P 470430-84-3P
470430-85-4P 470430-86-5P 470430-87-6P
470430-88-7P 470430-89-8P 470430-90-1P
470430-91-2P 470430-92-3P 470430-93-4P
470430-94-5P 470430-95-6P 470430-96-7P
470430-97-8P 470430-98-9P 470431-00-6P
470431-01-7P 470431-02-8P 470431-03-9P
470431-04-0P 470431-05-1P 470431-06-2P
470431-07-3P 470431-08-4P 470431-09-5P
470431-10-8P 470431-12-0P 470431-13-1P
470431-14-2P 470431-15-3P 470431-16-4P
470431-17-5P 470431-18-6P 470431-32-4P
470431-33-5P 470431-34-6P 470431-36-8P
470431-37-9P 470431-39-1P 470431-40-4P
470431-41-5P 470431-42-6P 470431-44-8P
470431-45-9P 470431-46-0P 470431-47-1P
470431-48-2P 470431-49-3P 470431-50-6P
470431-51-7P 470431-52-8P 470431-53-9P
470431-54-0P 470431-55-1P 470431-56-2P
470431-57-3P 470431-58-4P 470431-59-5P
470431-60-8P 470431-61-9P 470431-62-0P
470431-63-1P 470431-64-2P 470431-65-3P
470431-66-4P 470431-67-5P 470431-68-6P
470431-69-7P 470431-70-0P 470431-74-4P
470431-75-5P 470431-76-6P 470431-77-7P
470431-78-8P 470431-79-9P 470431-80-2P
470431-81-3P 470431-82-4P 470431-83-5P
470431-84-6P 470431-85-7P 470431-86-8P
470431-87-9P 470431-88-0P 470431-89-1P
470431-90-4P 470431-91-5P 470431-92-6P
470431-94-8P 470431-95-9P 470431-96-0P
470431-98-2P 470431-99-3P 470432-00-9P
470432-01-0P 470432-02-1P 470432-03-2P
470432-04-3P 470432-05-4P 470432-06-5P
470432-08-7P 470432-10-1P 470432-11-2P
470432-12-3P 470432-13-4P 470432-14-5P
470432-15-6P 470432-16-7P 470432-17-8P
470432-18-9P 470432-19-0P 470432-20-3P
470432-21-4P 470432-22-5P 470432-23-6P
470432-24-7P 470432-25-8P 470432-26-9P
470432-27-0P 470432-28-1P 470432-29-2P
470432-30-5P 470432-31-6P 470432-32-7P

470432-33-8P 470432-34-9P 470432-35-0P
 470432-36-1P 470432-37-2P 470432-38-3P
 470432-39-4P 470432-40-7P 470432-41-8P
 470432-42-9P 470432-43-0P 470432-44-1P
 470432-45-2P 470432-46-3P 470432-47-4P
 470432-48-5P 470432-49-6P 470432-50-9P
 470432-51-0P 470432-52-1P 470432-53-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of spiroisoquinolines as small-conductance Ca^{2+} -activated K^{+}
 channel blockers and acetylcholine esterase inhibitors for treatment of
 diseases)

RN 470428-54-7 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-
 dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1H-
 pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-
 1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester,
 rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470428-55-8 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-
 dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-methyl-
 1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-
 1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester,
 rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470428-83-2 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470428-96-7 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470428-97-8 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470428-98-9 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470428-99-0 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-00-6 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-4-[[4-(1-hexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-01-7 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-02-8 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-pentyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-05-1 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-06-2 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-07-3 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-08-4 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-10-8 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-propenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-12-0 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-13-1 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470429-14-2 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




— Ph


RN 470429-15-3 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470429-16-4 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-4-[[4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




— Ph

RN 470429-17-5 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




— Ph


RN 470429-18-6 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]]-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



PAGE 2-A




RN 470429-19-7 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-20-0 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A





RN 470429-21-1 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470429-22-2 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-23-3 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-24-4 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[2-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-25-5 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-[1-[(2,6-dichlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-26-6 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl)methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A





RN 470429-27-7 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-[1-(cyclopropylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470429-28-8 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 470429-29-9 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel-(+)- (9CI) (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 470429-39-1 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-41-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470429-43-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-44-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI)

(CA INDEX NAME)

Relative stereochemistry.




RN 470429-46-0 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(1-oxido-4-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




—Ph

RN 470429-58-4 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4S)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-59-5 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-

isoquinolin]-4-yl]carbonyl]-4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-60-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-61-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-62-0 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-63-1 CAPLUS

CN Piperazine, 1-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-64-2 CAPLUS

CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-65-3 CAPLUS

CN Piperazine, 1-[[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-67-5 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[[trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-68-6 CAPLUS

CN Piperazine, 1-[[trans-2'-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-70-0 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA

INDEX NAME)

Relative stereochemistry.




RN 470429-71-1 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-propenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-72-2 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[(2-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-73-3 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470429-74-4 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-75-5 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-


isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470429-76-6 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-4-[[4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470429-77-7 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-78-8 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)


piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-79-9 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-80-2 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-81-3 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470429-82-4 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470429-83-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470429-84-6 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[2-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)


1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-,
(1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470429-85-7 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2,6-dichlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-86-8 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470429-87-9 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-(cyclopropylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470430-01-4 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(-)-(9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 470430-02-5 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(+)-(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




RN 470430-03-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[(1-oxido-4-pyridinyl)methyl]-1H-

pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-04-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-31-0 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470430-32-1 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-38-7 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-39-8 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-40-1 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-41-2 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-42-3 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-4-[[4-(1-hexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-43-4 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-45-6 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-pentyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-48-9 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-49-0 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-50-3 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470430-60-5 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470430-75-2 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(ethylmethylamino)-1-oxopropyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-76-3 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470430-80-9 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-

yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-81-0 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-82-1 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-83-2 CAPLUS


CN Piperazine, 1-[[trans-2'-(2-aminoethyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470430-84-3 CAPLUS
 CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470430-85-4 CAPLUS
 CN Piperazine, 1-[[trans-2'-(4-aminobutyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-86-5 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-87-6 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470430-88-7 CAPLUS
 CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470430-89-8 CAPLUS
 CN Piperazine, 1-[[trans-2'-(4-aminobutyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-90-1 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-91-2 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-92-3 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-93-4 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-94-5 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(dimethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl] - (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470430-95-6 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl] - (9CI)
(CA INDEX NAME)

Relative stereochemistry.



RN 470430-96-7 CAPLUS
 CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[4-(dimethylamino)butyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 470430-97-8 CAPLUS
 CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

piperaziny]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470430-98-9 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-00-6 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[4-(methylamino)butyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-01-7 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[[(cyanoamino)iminomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-02-8 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-03-9 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[[(cyanoamino)(dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-04-0 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470431-05-1 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)iminomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-06-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[(cyanoamino) (methylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-07-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[4-[[(cyanoamino) iminomethyl] amino] butyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]- (9CI) (CA INDEX NAME)

yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-08-4 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-
[[[(cyanoamino)(methylimino)methyl]methylamino]-1-oxopropyl]-2-[(1R)-2-
ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-
6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-09-5 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-


yl]-4-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-
dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 470431-10-8 CAPLUS
CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-
yl]-4-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[1-(methylamino)-2-
nitroethenyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 470431-12-0 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 470431-13-1 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[1-amino-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-

yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 470431-14-2 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[1-(methylamino)-2-nitroethenyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 470431-15-3 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-12-0

CMF C40 H51 N11 O7


Relative stereochemistry.
 Double bond geometry unknown.



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 470431-16-4 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[1-amino-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 470431-13-1
CMF C38 H47 N11 O7

Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 77-92-9
CMF C6 H8 O7




RN 470431-17-5 CAPLUS
CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[1-(methylamino)-2-nitroethenyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-14-2
CMF C39 H49 N11 O7


Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 470431-18-6 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (1-oxopropoxy)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-32-4 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 1-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]ethyl ester, rel- (9CI) (CA INDEX NAME)


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-33-5 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxymethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A



PAGE 1-B




RN 470431-34-6 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-36-8 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

PAGE 1-A



PAGE 1-B



RN 470431-37-9 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(-)- (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

PAGE 1-A



PAGE 1-B




RN 470431-39-1 CAPLUS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(-) - (9CI) (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.

PAGE 1-A



PAGE 1-B





RN 470431-40-4 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.

PAGE 1-A








RN 470431-41-5 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 470431-42-6 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 470431-44-8 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470431-45-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B




RN 470431-46-0 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (benzoyloxy)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-47-1 CAPLUS


CN Cyclohexanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470431-48-2 CAPLUS
 CN Butanoic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-49-3 CAPLUS

CN Propanoic acid, 2-methyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyloxy]methyl ester, rel- (9CI) (CA INDEX NAME)]


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-50-6 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

oxopropyl]methyl-, (acetyloxy)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

—OAc


RN 470431-51-7 CAPLUS
 CN Pentanedioic acid, mono[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyloxy]methyl] ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-52-8 CAPLUS
 CN Cyclopropanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-53-9 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (1-oxopropoxy)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-54-0 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, butyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 470431-55-1 CAPLUS

CN Cyclopropanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470431-56-2 CAPLUS
 CN Butanoic acid, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-57-3 CAPLUS


CN Pentanoic acid, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA. INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-58-4 CAPLUS


CN Butanoic acid, 3,3-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-59-5 CAPLUS


CN Propanoic acid, 2-methyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 470431-60-8 CAPLUS


CN Cyclohexanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


CN Cyclopentanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A



PAGE 2-A




RN 470431-62-0 CAPLUS


CN Butanoic acid, 3-methyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470431-63-1 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]propyl]amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-64-2 CAPLUS


CN Carbonic acid, ethyl [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B





RN 470431-65-3 CAPLUS

CN Carbonic acid, [:[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl propyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



PAGE 1-A





RN 470431-66-4 CAPLUS
 CN Carbonic acid, cyclohexyl [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470431-67-5 CAPLUS
 CN Carbonic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-68-6 CAPLUS
 CN Carbonic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl 1-methylethyl ester, rel- (9CI)
 (CA INDEX NAME)


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-69-7 CAPLUS
 CN Carbonic acid, cyclopentyl [4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-70-0 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-74-4 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (2-oxo-5-phenyl-1,3-dioxol-4-yl)methyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-75-5 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-(4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [5-(1,1-dimethylethyl)-2-oxo-1,3-dioxol-4-yl]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-76-6 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 470431-77-7 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-(4-


pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-78-8 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-(4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (2-oxo-5-propyl-1,3-dioxol-4-yl)methyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B



RN 470431-79-9 CAPLUS


CN Carbamic acid, [3-[(1R,2R;4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-80-2 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [4-(acetyloxy)phenyl]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470431-81-3 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [4-(benzoyloxy)phenyl]methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 470431-82-4 CAPLUS

CN Butanoic acid, 3-methyl-, 4-[[[4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy)methyl]phenyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470431-83-5 CAPLUS
 CN Carbonic acid, ethyl 4-[[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470431-84-6 CAPLUS
 CN Butanoic acid, 3-methyl-, 2-chloro-4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 470431-85-7 CAPLUS

CN Butanoic acid, 3-methyl-, 4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]-2-methoxyphenyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-86-8 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, [4-[[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylanino]carbonyl]oxy)methyl]phenoxy)methyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

Bu-t


RN 470431-87-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 4-[[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy)methyl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470431-88-0 CAPLUS

CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470431-89-1 CAPLUS

CN Benzamide, 2-[(acetyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-90-4 CAPLUS

CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-4-[[4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-

1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-91-5 CAPLUS


CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 470431-92-6 CAPLUS
 CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470431-94-8 CAPLUS
 CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 470431-95-9 CAPLUS

CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470431-96-0 CAPLUS


CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470431-98-2 CAPLUS
 CN 2-Propenamide, 3-[2-(acetyloxy)phenyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




RN 470431-99-3 CAPLUS


CN Butanoic acid, 3-methyl-, 2-[3-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]-3-oxo-1-propenyl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 2-A




RN 470432-00-9 CAPLUS
 CN 2-Propenamide, 3-[2-(benzoyloxy)phenyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A





PAGE 2-A



RN 470432-01-0 CAPLUS


CN Carbonic acid, ethyl 2-[3-[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]-3-oxo-1-propenyl]phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 470432-02-1 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-2'-[3-(formylmethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-03-2 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-04-3 CAPLUS

CN Acetamide, 2-amino-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-05-4 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-06-5 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

INDEX NAME)


Relative stereochemistry.



RN 470432-08-7 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-10-1 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





PAGE 2-A



RN 470432-11-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 470432-12-3 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470432-13-4 CAPLUS
 CN Piperazine, 1-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-14-5 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-15-6 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-

isoquinolin]-4-yl]carbonyl]-4-[1-[(4-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-16-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-17-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-

isoquinolin]-4-yl]carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-18-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-19-0 CAPLUS

CN Piperazine, 1-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-20-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-
yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-
isoquinolin]-4-yl]carbonyl]-4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-

d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-21-4 CAPLUS

CN Piperazine; 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-methyl-3-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-22-5 CAPLUS

CN Piperazine, 1-(1-cyclohexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470432-23-6 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-24-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470432-25-8 CAPLUS
 CN Piperazine, 1-[1-(cyclobutylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
 [[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
 dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
 yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A





RN 470432-26-9 CAPLUS

CN Piperazine, 1-[1-(cyclopropylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470432-27-0 CAPLUS

CN Piperazine, 1-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
(CA INDEX NAME)



Relative stereochemistry.



RN 470432-28-1 CAPLUS


CN Piperazine, 1-[1-(cyclopentylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470432-29-2 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2,2-dimethylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-30-5 CAPLUS

CN Piperazine, 1-[1-(cyanomethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470432-31-6 CAPLUS

CN Piperazine, 1-[1-(2-cyanoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-32-7 CAPLUS

CN Piperazine, 1-[1-(3-cyanopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-33-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-fluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470432-34-9 CAPLUS
 CN Piperazine, 1-[1-(2-chloro-2-propenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
 [[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
 dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
 yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-35-0 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-
 yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-
 isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470432-36-1 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(4-thiazolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A





RN 470432-37-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 470432-38-3 CAPLUS
 CN Piperazine, 1-[1-(2-cyclopentylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
 [[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-
 dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-
 yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 470432-39-4 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-hexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(9CI) (CA INDEX NAME)



Relative stereochemistry.



RN 470432-40-7 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(1,3-dithiolan-2-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470432-41-8 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-42-9 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-43-0 CAPLUS


CN Piperazine, 1-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-44-1 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-45-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-46-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-47-4 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(methylthio)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-48-5 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-49-6 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-50-9 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-51-0 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(cyclobutylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470432-52-1 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(cyclopropylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-53-2 CAPLUS
 CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT	470432-54-3P	470432-55-4P	470432-56-5P
	470432-57-6P	470432-58-7P	470432-59-8P
	470432-60-1P	470432-61-2P	470432-62-3P
	470432-63-4P	470432-64-5P	470432-65-6P
	470432-66-7P	470432-67-8P	470432-68-9P
	470432-69-0P	470432-70-3P	470432-71-4P
	470432-72-5P	470432-73-6P	470432-75-8P
	470432-77-0P	470432-79-2P	470432-81-6P
	470432-83-8P	470432-85-0P	470432-87-2P
	470432-89-4P	470432-91-8P	470432-93-0P
	470432-95-2P	470432-97-4P	470432-99-6P
	470433-01-3P	470433-02-4P	470433-03-5P
	470433-04-6P	470433-05-7P	470433-06-8P
	470433-07-9P	470433-08-0P	470433-09-1P
	470433-10-4P	470433-11-5P	470433-12-6P
	470433-13-7P	470433-14-8P	470433-15-9P
	470433-16-0P	470433-17-1P	470433-18-2P
	470433-19-3P	470433-20-6P	470433-21-7P
	470433-22-8P	470433-23-9P	470433-24-0P
	470433-25-1P	470433-26-2P	470433-27-3P
	470433-28-4P	470433-29-5P	470433-30-8P
	470433-31-9P	470433-32-0P	470433-33-1P
	470433-34-2P	470433-35-3P	470433-36-4P
	470433-37-5P	470433-38-6P	470433-39-7P
	470433-40-0P	470433-41-1P	470433-42-2P
	470433-43-3P	470433-44-4P	470433-45-5P
	470433-46-6P	470433-47-7P	470433-48-8P
	470433-49-9P	470433-50-2P	470433-51-3P
	470433-52-4P	470433-53-5P	470433-54-6P
	470433-55-7P	470433-56-8P	470433-57-9P
	470433-58-0P	470433-59-1P	470433-60-4P
	470433-61-5P	470433-62-6P	470433-63-7P
	470433-64-8P	470433-65-9P	470433-66-0P
	470433-67-1P	470433-68-2P	470433-69-3P
	470433-70-6P	470433-71-7P	470433-72-8P
	470433-73-9P	470433-74-0P	470433-75-1P

470433-76-2P 470433-77-3P 470433-78-4P
 470433-79-5P 470433-80-8P 470433-81-9P
 470433-82-0P 470433-83-1P 470433-84-2P
 470433-85-3P 470433-86-4P 470433-87-5P
 470433-88-6P 470433-89-7P 470433-90-0P
 470433-91-1P 470433-92-2P 470433-93-3P
 470433-94-4P 470433-95-5P 470433-96-6P
 470433-97-7P 470433-98-8P 470433-99-9P
 470434-00-5P 470434-01-6P 470434-02-7P
 470434-03-8P 470434-04-9P 470434-05-0P
 470434-06-1P 470434-07-2P 470434-08-3P
 470434-09-4P 470434-10-7P 470434-11-8P
 470434-12-9P 470434-13-0P 470434-14-1P
 470434-15-2P 470434-16-3P 470434-17-4P
 470434-18-5P 470434-19-6P 470434-20-9P
 470434-21-0P 470434-22-1P 470434-23-2P
 470434-24-3P 470434-25-4P 470434-26-5P
 470434-27-6P 470434-28-7P 470434-29-8P
 470434-30-1P 470434-31-2P 470434-32-3P
 470434-33-4P 470434-34-5P 470434-35-6P
 470434-36-7P 470434-37-8P 470434-38-9P
 470434-39-0P 470434-40-3P 470434-41-4P
 470434-42-5P 470434-43-6P 470434-44-7P
 470434-45-8P 470434-46-9P 470434-47-0P
 470434-48-1P 470434-49-2P 470434-50-5P
 470434-51-6P 470434-52-7P 470434-53-8P
 470434-54-9P 470434-55-0P 470434-56-1P
 470434-57-2P 470434-58-3P 470434-59-4P
 470434-60-7P 470434-61-8P 470434-62-9P
 470434-63-0P 470434-64-1P 470434-65-2P
 470434-66-3P 470434-67-4P 470434-68-5P
 470434-69-6P 470434-70-9P 470434-71-0P
 470434-72-1P 470434-73-2P 470434-74-3P
 470434-75-4P 470434-76-5P 470434-77-6P
 470434-78-7P 470434-79-8P 470434-80-1P
 470434-81-2P 470434-82-3P 470434-83-4P
 470434-84-5P 470434-85-6P 470434-86-7P
 470434-87-8P 470434-88-9P 470434-89-0P
 470434-90-3P 470434-91-4P 470434-92-5P
 470434-93-6P 470434-94-7P 470434-95-8P
 470434-96-9P 470434-97-0P 470434-98-1P
 470434-99-2P 470435-00-8P 470435-01-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of spiroisoquinolines as small-conductance Ca^{2+} -activated K^{+}
 channel blockers and acetylcholine esterase inhibitors for treatment of
 diseases)

RN 470432-54-3 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-
 dimethoxy-4,5-dihydro-1H-benzodioxol-2-yl]carbonyl]-4-[1-
 (cyclopentylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX
 NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-55-4 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2,2-dimethylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-56-5 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(cyanomethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-57-6 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-cyanoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-58-7 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-cyanopropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-59-8 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-

dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-6-yl]carbonyl]-4-[1-(2-fluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-60-1 CAPLUS


CN Piperazine, 1-[[trans-2'- (3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-6-yl]carbonyl]-4-[1-(2-chloro-2-propenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-61-2 CAPLUS
 CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-62-3 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(4-thiazolylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470432-63-4 CAPLUS
 CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A





RN 470432-64-5 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-cyclopentylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470432-65-6 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-hexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-66-7 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(1,3-dithiolan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-67-8 CAPLUS
 CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-68-9 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470432-69-0 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470432-70-3 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-71-4 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-72-5 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470432-73-6 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(methylthio)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470432-75-8 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(2E)-2-butenedioate

(1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470432-74-7


CMF C34 H44 N8 O3 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-77-0 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470432-76-9


CMF C34 H44 N8 O4

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-79-2 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1


CRN 470432-78-1

CMF C34 H44 N8 O3 S

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-81-6 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-80-5

CMF C36 H44 F2 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-83-8 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-82-7

CMF C36 H45 F N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-85-0 CAPLUS

CN Piperazine, 1-[[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470432-84-9

CMF C36 H45 N9 O5

Relative stereochemistry.

o




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-87-2 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-86-1

CMF C36 H45 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-89-4 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-88-3

CMF C36 H46 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-91-8 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470432-90-7


CMF C34 H44 N8 O4

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-93-0 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


(9CI) (CA INDEX NAME)

CM 1

CRN 470432-92-9

CMF C35 H43 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-95-2 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-94-1

CMF C36 H52 N8 O3


Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470432-97-4 CAPLUS
CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-96-3
CMF C34 H48 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470432-99-6 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-methyl-3-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-98-5

CMF C34 H48 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470433-01-3 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-cyclohexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-00-2

CMF C35 H50 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 470433-02-4 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-03-5 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470433-04-6 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(cyclohexylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470433-05-7 CAPLUS
 CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[(1-methylethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-06-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(dipropylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-07-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[(2,2-dimethylpropyl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-08-0 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[(phenylmethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-09-1 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[(2,2-dimethylpropyl)methylamino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-

yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-10-4 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl(1-methylethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-11-5 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl(phenylmethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-12-6 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(cyclohexylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470433-13-7 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-(hexylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-14-8 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylpropylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-15-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(butylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-16-0 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylpentylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-17-1 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl(2-methylpropyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-

yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-18-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(ethylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-19-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-20-6 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-21-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-

methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-22-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-23-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-

methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-24-0 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-25-1 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-


furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470433-26-2 CAPLUS

CN Piperazine, 1-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-27-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-28-4 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-29-5 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-30-8 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-31-9 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-32-0 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-33-1 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-34-2 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-35-3 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-36-4 CAPLUS


CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-37-5 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470433-38-6 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-39-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-40-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-41-1 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-42-2 CAPLUS

CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-43-3 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-44-4 CAPLUS


CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-45-5 CAPLUS
 CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470433-46-6 CAPLUS
 CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-47-7 CAPLUS

CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-48-8 CAPLUS


CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-49-9 CAPLUS
 CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-(2-hydroxyethyl)spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470433-50-2 CAPLUS
 CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-(2-hydroxyethyl)spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-51-3 CAPLUS

CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-(2-hydroxyethyl)spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-52-4 CAPLUS


CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-(2-hydroxyethyl)spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-53-5 CAPLUS
 CN Piperazine, 1-[[trans-6',7'-diethoxy-3',4'-dihydro-2'-(2-hydroxyethyl)spiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-54-6 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-55-7 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.



RN 470433-56-8 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 [[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
 INDEX NAME)


Relative stereochemistry.



RN 470433-57-9 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-58-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470433-59-1 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'--[(dimethylamino)acetyl]-4-
 [[4-[1-(2-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470433-60-4 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 4-[[4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-61-5 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470433-62-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470433-63-7 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-64-8 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 4-[[4-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-65-9 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-66-0 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470433-67-1 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-methyl-2-butenyl)-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.




RN 470433-68-2 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-(cyclopentylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470433-69-3 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-70-6 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[(3,4-dimethylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733776-31-3 CAPLUS
 CN Piperazine, 1-[3,5-dibromo-4-[(diethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733776-32-4 CAPLUS
 CN Piperazine, 1-[3,5-dibromo-4-(1-pyrrolidinylmethyl)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733776-33-5 CAPLUS
 CN Piperazine, 1-[4-[(ethylmethylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

n-Pr


●2 HCl

RN 733776-34-6 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylmethylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl


RN 733776-35-7 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(ethylmethylamino)methyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733776-36-8 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylmethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A





● 2 HCl


RN 733776-37-9 CAPLUS
 CN Piperazine, 1-[4-[(ethylmethylamino)methyl]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733776-38-0 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylmethylamino)methyl]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl


RN 733776-39-1 CAPLUS
 CN Piperazine, 1-[4-[(ethylmethylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733776-40-4 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylmethylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

RN 733776-41-5 CAPLUS


CN Acetamide, 2-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733776-43-7 CAPLUS

CN Butanamide, 4-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 733776-44-8 CAPLUS
 CN 1-Pyrrolidinebutanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733776-46-0 CAPLUS
 CN 1-Piperidinebutanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

RN 733776-47-1 CAPLUS

CN Butanamide, 4-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 733776-48-2 CAPLUS

CN 1-Pyrrolidineacetamide, N-[[4-(dimethylamino)phenyl]methyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-49-3 CAPLUS
 CN 4-Morpholineacetamide, N-[[4-(dimethylamino)phenyl]methyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-50-6 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[[4-(dimethylamino)phenyl]methyl]-N-[4-
 [[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-52-8 CAPLUS
 CN 1-Pyrrolidinepropanamide, N-[[4-(dimethylamino)phenyl]methyl]-N-[4-[[4-[1-
 [(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-53-9 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[4-(dimethylamino)phenyl]methyl-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-54-0 CAPLUS
 CN 4-Morpholineacetamide, N-[[4-(dimethylamino)phenyl]methyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-55-1 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[[4-(dimethylamino)phenyl]methyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733776-56-2 CAPLUS
 CN 1-Pyrrolidinepropanamide, N-[[4-(dimethylamino)phenyl]methyl]-N-[4-[[4-[1-
 [(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-57-3 CAPLUS
 CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]-3-hydroxybenzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733776-58-4 CAPLUS
 CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]-3-hydroxybenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733776-59-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(4-morpholinylmethyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-60-8 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinylmethyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-61-9 CAPLUS

CN Piperazine, 1-[4-[3-(diethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733776-62-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 733776-63-1 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2-methylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● x HCl

RN 733776-64-2 CAPLUS
 CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]-3,5-dimethylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733776-65-3 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)propoxy]-3,5-dimethylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733776-66-4 CAPLUS
 CN Piperazine, 1-[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733776-67-5 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3,5-dimethylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

●x HCl


RN 733776-68-6 CAPLUS
 CN Piperazine, 1-[2-[3-(dimethylamino)propoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733776-69-7 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[2-[2-(1-pyrrolidinyl)ethoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733776-70-0 CAPLUS

CN Piperazine, 1-[2-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733776-71-1 CAPLUS

CN Acetamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[4-[1-[(2-propyl-


4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 733776-72-2 CAPLUS

CN Acetamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
n-Pr

RN 733776-73-3 CAPLUS


CN Acetamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733776-74-4 CAPLUS

CN Acetamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 733776-75-5 CAPLUS

CN Cyclopropanecarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-76-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-77-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733776-78-8 CAPLUS

CN Cyclopropanecarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-79-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733776-80-2 CAPLUS

CN 2-Butenamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

●x HCl


RN 733776-81-3 CAPLUS

CN 2-Butenamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A




PAGE 2-A

●x HCl

RN 733776-82-4 CAPLUS
 CN 2-Butenamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

F


●x HCl

RN 733776-83-5 CAPLUS
 CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733776-84-6 CAPLUS
 CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-
 [(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-85-7 CAPLUS
 CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733776-86-8 CAPLUS
 CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733776-87-9 CAPLUS

CN 2-Furancarboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733776-88-0 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]ethylamino]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733776-89-1 CAPLUS
 CN Piperazine, 1-[4-[(cyclopropylmethyl)[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl


RN 733776-90-4 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]propylamino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733776-91-5 CAPLUS

CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]ethylamino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 733776-92-6 CAPLUS

CN Piperazine, 1-[4-[(cyclopropylmethyl)[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733776-93-7 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl](2-methylpropyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733776-94-8 CAPLUS


CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]ethylamino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733776-95-9 CAPLUS

CN Piperazine, 1-[4-[(cyclopropylmethyl)[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-96-0 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]ethylamino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733776-97-1 CAPLUS
 CN Piperazine, 1-[4-[(cyclopropylmethyl)[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-98-2 CAPLUS
 CN Piperazine, 1-[4-[(cyclopropylmethyl)[2-(dimethylamino)ethyl]amino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733776-99-3 CAPLUS
 CN Piperazine, 1-[4-[(cyclopropylmethyl)[2-(dimethylamino)ethyl]amino]benzoyl
]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
 hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733777-00-9 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]ethylamino]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733777-01-0 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]methylamino]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733777-02-1 CAPLUS
 CN Piperazine, 1-[4-[(cyclopropylmethyl)[2-(dimethylamino)ethyl]amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733777-03-2 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]ethylamino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-04-3 CAPLUS


CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]methylamino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733777-05-4 CAPLUS

CN Piperazine, 1-[4-[(cyclopropylmethyl)[2-(dimethylamino)ethyl]amino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733777-06-5 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]ethylamino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733777-07-6 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]methylamino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-08-7 CAPLUS


CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]ethylamino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733777-09-8 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]methylamino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733777-10-1 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(methylamino)methyl]cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●2 HCl


RN 733777-11-2 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]ethylamino]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 733777-12-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(phenylmethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-13-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 733777-14-5 CAPLUS

CN Piperazine, 1-[[trans-4-[(cyclopentylamino)methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-15-6 CAPLUS

CN Piperazine, 1-[[[trans-4-[[bis(cyclopropylmethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-16-7 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[[trans-4-[[[2-methylpropyl]amino]methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733777-17-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(ethylamino)methyl]cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733777-18-9 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl](2-methylpropyl)amino]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 733777-19-0 CAPLUS
 CN Piperazine, 1-[4-[(cyclopropylmethyl)[2-(dimethylamino)ethyl]amino]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733777-20-3 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]methylamino]-3-methylbenzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


n-Pr

● 2 HCl

RN 733777-21-4 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]ethylamino]-3-methylbenzoyl]-4-

[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733777-22-5 CAPLUS
CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl](2-methylpropyl)amino]-3-methylbenzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl


RN 733777-23-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)



● 2 HCl

RN 733777-24-7 CAPLUS


CN Piperazine, 1-([1,4'-bipiperidin]-1'-ylcarbonyl)-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733777-25-8 CAPLUS


CN Piperazine, 1-[[4-(4-morpholinyl)-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733777-26-9 CAPLUS
 CN Piperazine, 1-[4-[[1-[(dimethylamino)methyl]cyclopropyl]methoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● x HCl

RN 733777-27-0 CAPLUS

CN Piperazine, 1-[4-[[cis-4-(dimethylamino)cyclohexyl]oxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 733777-28-1 CAPLUS

CN Piperazine, 1-[4-[[(2S)-2-(dimethylamino)-4-methylpentyl]oxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733777-29-2 CAPLUS
 CN Piperazine, 1-[4-[(3S)-3-(dimethylamino)butoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 733777-30-5 CAPLUS


CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-methylphenyl]-(9CI) (CA INDEX NAME)




RN 733777-31-6 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[2-methyl-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733777-32-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-methylphenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733777-33-8 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-methylphenyl]-, hydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A


●x HCl

RN 733777-34-9 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-methylphenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733777-35-0 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl] (phenylsulfonyl) amino]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-36-1 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[2-methyl-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733777-37-2 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[2-methyl-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733777-38-3 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[2-methyl-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733777-39-4 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl](phenylsulfonyl)amino]-3-methylbenzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733777-40-7 CAPLUS


CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[2-methyl-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-41-8 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-methylphenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733777-42-9 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-43-0 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl] (phenylsulfonyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733777-44-1 CAPLUS

CN Piperazine, 1-[[trans-4-[2-(dimethylamino)ethoxy]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride

(9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 733777-45-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[[(1S)-4-methyl-1-(methylamino)pentyl]oxy]benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733777-46-3 CAPLUS

CN Piperazine, 1-[4-[2,2-dimethyl-3-(methylamino)propoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733777-47-4 CAPLUS
 CN 2-Furancarboxamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733777-48-5 CAPLUS
 CN Piperazine, 1-[[[trans-4-[[[2-(diethylamino)ethyl](methylsulfonyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733777-49-6 CAPLUS

CN Acetamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-50-9 CAPLUS

CN Acetamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-51-0 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-52-1 CAPLUS

CN 2-Furancarboxamide, N-[2-(diethylamino)ethyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-53-2 CAPLUS

CN Propanamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-2,2-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-54-3 CAPLUS

CN Acetamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733777-55-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733777-56-5 CAPLUS

CN 2-Furancarboxamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

● x HCl


RN 733777-57-6 CAPLUS

CN 2-Furancarboxamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-

pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-3-methyl-N-[2-(1-piperidiny)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733777-58-7 CAPLUS

CN Acetamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733777-59-8 CAPLUS

CN Cyclopropanecarboxamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

●x HCl

RN 733777-60-1 CAPLUS

CN Acetamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.

RN 733777-62-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(dimethylamino)carbonyl][2-(1-pyrrolidinyl)ethyl]amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● x HCl

RN 733777-63-4 CAPLUS


CN Benzamide, N-[3-(dimethylamino)propyl]-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-4-fluoro-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



●x HCl

RN 733777-64-5 CAPLUS
 CN Piperazine, 1- [1- [(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4- [4- [2-(methylamino)ethoxy]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


● 2 HCl

RN 733777-65-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[1-[(methoxycarbonyl)methyl]cyclopropyl]methoxy]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733777-66-7 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(3S)-3-(methylamino)butoxy]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 733777-67-8 CAPLUS
 CN Piperazine, 1-[4-(2-aminoethoxy)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733777-68-9 CAPLUS
 CN Piperazine, 1-[4-(3-amino-2,2-dimethylpropoxy)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl


RN 733777-69-0 CAPLUS

CN Piperazine, 1-[4-[3-(methylamino)-1-propynyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)



RN 733777-70-3 CAPLUS


CN Piperazine, 1-[4-[3-(ethylamino)-1-propenyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733777-71-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(methylamino)-1-propynyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733777-72-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(ethylamino)-1-propenyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



● 2 HCl

RN 733777-73-6 CAPLUS


CN Piperazine, 1-[4-[3-(methylamino)-1-propynyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl

RN 733777-74-7 CAPLUS


CN Piperazine, 1-[4-[3-(ethylamino)-1-propenyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl


RN 733777-75-8 CAPLUS

CN Piperazine, 1-[4-[3-(ethylamino)propyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733777-76-9 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(ethylamino)propyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733777-77-0 CAPLUS

CN Piperazine, 1-[4-[3-(ethylamino)propyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride


(9CI) (CA INDEX NAME)



● 2 HCl

RN 733777-78-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(ethylamino)-1-propynyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733777-79-2 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-

yl]-4-[4-[3-(methylamino)-1-propenyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733777-80-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(methylamino)propyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 733777-81-6 CAPLUS

CN Piperazine, 1-[4-[(cyclopentylamino)methyl]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl


RN 733777-82-7 CAPLUS


CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[1-methylethyl]amino]methyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-83-8 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A






● x HCl

RN 733777-84-9 CAPLUS
 CN Piperazine, 1-[4-[(methylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)




● x HCl

RN 733777-86-1 CAPLUS
 CN Piperazine, 1-[4-[(propylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)




RN 733777-88-3 CAPLUS
 CN Piperazine, 1-[4-[[[(1-methylethyl)amino]methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)




RN 733777-90-7 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl


RN 733777-92-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(methylamino)methyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733777-94-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(propylamino)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 733777-96-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(1-methylethylamino)methyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733777-98-5 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(methylamino)methyl]benzoyl]-, hydrochloride (9CI)
 (CA INDEX NAME)




RN 733778-00-2 CAPLUS
 CN Piperazine, 1-[4-[(methylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)




RN 733778-02-4 CAPLUS

CN Piperazine, 1-[4-[(propylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)




RN 733778-04-6 CAPLUS

CN Piperazine, 1-[4-[[[(1-methylethyl)amino]methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)




RN 733778-06-8 CAPLUS
 CN Piperazine, 1-[4-[(cyclopentylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733778-07-9 CAPLUS


CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(propylamino)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 733778-08-0 CAPLUS

CN Piperazine, 1-[3-[2-(diethylamino)ethoxy]-4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-10-4 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-12-6 CAPLUS
 CN Piperazine, 1-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-14-8 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-[2-(1-pyrrolidinyl)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-16-0 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-[2-(1-piperidinyl)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-18-2 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-[2-(4-morpholinyl)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● 2 HCl

IT 733778-19-3P 733778-21-7P 733778-22-8P
 733778-23-9P 733778-24-0P 733778-25-1P
 733778-26-2P 733778-27-3P 733778-28-4P
 733778-29-5P 733778-30-8P 733778-31-9P
 733778-32-0P 733778-33-1P 733778-34-2P
 733778-36-4P 733778-37-5P 733778-38-6P
 733778-39-7P 733778-40-0P 733778-41-1P
 733778-42-2P 733778-43-3P 733778-44-4P
 733778-45-5P 733778-46-6P 733778-47-7P
 733778-48-8P 733778-49-9P 733778-50-2P
 733778-51-3P 733778-52-4P 733778-53-5P
 733778-54-6P 733778-55-7P 733778-56-8P
 733778-57-9P 733778-58-0P 733778-59-1P
 733778-60-4P 733778-61-5P 733778-62-6P
 733778-63-7P 733778-64-8P 733778-65-9P
 733778-66-0P 733778-67-1P 733778-68-2P
 733778-69-3P 733778-70-6P 733778-71-7P

733778-72-8P 733778-73-9P 733778-74-0P
733778-75-1P 733778-76-2P 733778-77-3P
733778-78-4P 733778-79-5P 733778-80-8P
733778-81-9P 733778-82-0P 733778-83-1P
733778-84-2P 733778-85-3P 733778-86-4P
733778-87-5P 733778-88-6P 733778-89-7P
733778-90-0P 733778-94-4P 733778-95-5P
733778-96-6P 733778-97-7P 733778-98-8P
733778-99-9P 733779-00-5P 733779-01-6P
733779-02-7P 733779-03-8P 733779-04-9P
733779-05-0P 733779-06-1P 733779-07-2P
733779-08-3P 733779-09-4P 733779-10-7P
733779-11-8P 733779-12-9P 733779-13-0P
733779-14-1P 733779-15-2P 733779-16-3P
733779-17-4P 733779-18-5P 733779-19-6P
733779-20-9P 733779-21-0P 733779-22-1P
733779-23-2P 733779-24-3P 733779-25-4P
733779-26-5P 733779-27-6P 733779-28-7P
733779-29-8P 733779-30-1P 733779-31-2P
733779-32-3P 733779-33-4P 733779-34-5P
733779-35-6P 733779-36-7P 733779-37-8P
733779-38-9P 733779-39-0P 733779-40-3P
733779-41-4P 733779-42-5P 733779-43-6P
733779-44-7P 733779-45-8P 733779-46-9P
733779-47-0P 733779-48-1P 733779-49-2P
733779-50-5P 733779-51-6P 733779-52-7P
733779-53-8P 733779-54-9P 733779-55-0P
733779-56-1P 733779-57-2P 733779-58-3P
733779-59-4P 733779-60-7P 733779-61-8P
733779-62-9P 733779-63-0P 733779-64-1P
733779-65-2P 733779-66-3P 733779-67-4P
733779-68-5P 733779-69-6P 733779-70-9P
733779-71-0P 733779-72-1P 733779-73-2P
733779-74-3P 733779-75-4P 733779-76-5P
733779-77-6P 733779-78-7P 733779-79-8P
733779-80-1P 733779-81-2P 733779-82-3P
733779-83-4P 733779-84-5P 733779-85-6P
733779-86-7P 733779-87-8P 733779-88-9P
733779-89-0P 733779-90-3P 733779-91-4P
733779-92-5P 733779-93-6P 733779-94-7P
733779-95-8P 733779-96-9P 733779-97-0P
733779-98-1P 733779-99-2P 733780-00-2P
733780-01-3P 733780-02-4P 733780-03-5P
733780-04-6P 733780-05-7P 733780-06-8P
733780-07-9P 733780-08-0P 733780-09-1P
733780-10-4P 733780-11-5P 733780-12-6P
733780-13-7P 733780-14-8P 733780-15-9P
733780-16-0P 733780-17-1P 733780-18-2P
733780-19-3P 733780-20-6P 733780-21-7P
733780-22-8P 733780-23-9P 733780-24-0P
733780-25-1P 733780-26-2P 733780-27-3P
733780-28-4P 733780-29-5P 733780-30-8P
733780-31-9P 733780-32-0P 733780-33-1P
733780-34-2P 733780-35-3P 733780-36-4P
733780-37-5P 733780-38-6P 733780-39-7P
733780-40-0P 733780-41-1P 733780-42-2P
733780-43-3P 733780-44-4P 733780-45-5P
733780-46-6P 733780-47-7P 733780-48-8P
733780-49-9P 733780-50-2P 733780-51-3P
733780-52-4P 733780-53-5P 733780-54-6P

733780-55-7P 733780-56-8P 733780-57-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as a small conductance potassium channel (SK channel) blocking agents)

RN 733778-19-3 CAPLUS

CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-3-[3-(dimethylamino)propoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-21-7 CAPLUS

CN Piperazine, 1-[3,4-bis[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-22-8 CAPLUS
 CN Piperazine, 1-[3,4-bis[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

●2 HCl


RN 733778-23-9 CAPLUS
 CN Piperazine, 1-[[4-(dimethylamino)-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 733778-24-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(ethylpropylamino)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733778-25-1 CAPLUS

CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]amino]phenyl]sulfonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733778-26-2 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]sulfonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 733778-27-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl]propylamino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A


● 2 HCl

RN 733778-28-4 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidiny]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733778-29-5 CAPLUS
 CN Piperazine, 1-[[1,4'-bipiperidin]-1'-yl(cyanoimino)methyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


F

RN 733778-30-8 CAPLUS
 CN Piperazine, 1-[4-[[[(cyanoimino) (dimethylamino)methyl]ethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733778-31-9 CAPLUS

CN Carbamimidic acid, N'-cyano-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, propyl ester (9CI) (CA INDEX NAME)




RN 733778-32-0 CAPLUS

CN Cyclohexanecarboxamide, N-[2-(diethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-ethyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl


RN 733778-33-1 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733778-34-2 CAPLUS
 CN Piperazine, 1-[[6-[[3-(dimethylamino)propyl]methylamino]-3-pyridazinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-36-4 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733778-37-5 CAPLUS


CN Carbamic acid, [3-[[2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]amino]-3-oxopropyl]methyl-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-38-6 CAPLUS

CN Piperazine, 1-[[trans-4-(cyclopentylmethylamino)cyclohexyl]carbonyl]-4-[1-
[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 733778-39-7 CAPLUS

CN Piperazine, 1-[[trans-4-(cyclopentylethylamino)cyclohexyl]carbonyl]-4-[1-
[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 733778-40-0 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[ethyl(1-methylethyl)amino]cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 733778-41-1 CAPLUS

CN Piperazine, 1-[[trans-4-(diethylamino)cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 733778-42-2 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl]ethylamino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl


RN 733778-43-3 CAPLUS

CN Acetamide, N-[2-(diethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]sulfonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733778-44-4 CAPLUS


CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]sulfonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733778-45-5 CAPLUS


CN Piperazine, 1-[[4-[[3-(dimethylamino)propyl]methylamino]phenyl]sulfonyl]-4-

[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 733778-46-6 CAPLUS

CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]phenyl]sulfonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 733778-47-7 CAPLUS

CN Piperazine, 1-[[4-[[2-(diethylamino)ethyl]ethylamino]phenyl]sulfonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 733778-48-8 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]sulfonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●2 HCl

RN 733778-49-9 CAPLUS
CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733778-50-2 CAPLUS
CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

n-Pr

● 2 HCl

RN 733778-51-3 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl

RN 733778-52-4 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 733778-53-5 CAPLUS

CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxy-2-hydroxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-54-6 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)-1,1-dimethylethyl]thio]benzoyl]-4-[1-
 [(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
 dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733778-55-7 CAPLUS
 CN Piperazine, 1-[4-[[3-(dimethylamino)-2,2-dimethylpropyl]thio]benzoyl]-4-[1-
 [(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
 dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733778-56-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxy-2-hydroxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●2 HCl

RN 733778-57-9 CAPLUS

CN Benzoic acid, 3-[[4-[4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733778-58-0 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(4-methyl-1-piperidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733778-59-1 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(hexahydro-1H-azepin-1-yl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733778-60-4 CAPLUS


CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidiny]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733778-61-5 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● 2 HCl

RN 733778-62-6 CAPLUS


CN Acetamide, N-[(3S)-1-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 733778-63-7 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(4-thiomorpholinyl)-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 733778-64-8 CAPLUS
 CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]amino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


● 2 HCl

RN 733778-65-9 CAPLUS
 CN Piperazine, 1-[[4-(1,1-dimethylethyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733778-66-0 CAPLUS
 CN Piperazine, 1-[[4-(4-butyl-1-piperazinyl)-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733778-67-1 CAPLUS
 CN Piperazine, 1-[[4-(2,5-dihydro-1H-pyrrol-1-yl)-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733778-68-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733778-69-3 CAPLUS


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CN Piperazine, 1-[(3,3-dimethyl[1,4'-bipiperidin]-1'-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl


RN 733778-70-6 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN	733778-71-7	CAPLUS
CN	Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(ethylmethylamino)-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)	




RN	733778-72-8	CAPLUS
CN	Piperazine, 1-[[4-(diethylamino)-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)	



●x HCl

RN 733778-73-9 CAPLUS


CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733778-74-0 CAPLUS


CN Piperazine, 1-[[4-[[2-(diethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-75-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

RN 733778-76-2 CAPLUS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]methylamino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733778-77-3 CAPLUS

CN Piperazine, 1-[[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733778-78-4 CAPLUS
CN Acetamide, N-[(3R)-1-[1-[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-3-pyrrolidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A


●x HCl

RN 733778-79-5 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[(2-methoxyethyl)methylamino]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-80-8 CAPLUS


CN Piperazine, 1-[[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[ethyl(2-methoxyethyl)amino]-1-piperidiny]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-81-9 CAPLUS


CN Piperazine, 1-[[trans-4-[[[(cyanoimino)(dimethylamino)methyl]methylamino]cylohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 733778-82-0 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-83-1 CAPLUS


CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-84-2 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]ethylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
n-Pr

●x HCl

RN 733778-85-3 CAPLUS
CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]ethylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
n-Pr

●x HCl

RN 733778-86-4 CAPLUS
CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733778-87-5 CAPLUS
 CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 733778-88-6 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733778-89-7 CAPLUS
 CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733778-90-0 CAPLUS
 CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733778-94-4 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733778-95-5 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]carbonyl]-
 4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
 hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



●x HCl

RN 733778-96-6 CAPLUS


CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]ethylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733778-97-7 CAPLUS


CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]ethylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733778-98-8 CAPLUS
 CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733778-99-9 CAPLUS
 CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733779-00-5 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733779-01-6 CAPLUS

CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733779-02-7 CAPLUS


CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl)methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733779-03-8 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl


RN 733779-04-9 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]amino]-5-pyrimidinyl]carbonyl]-
 4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
 hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




●x HCl

RN 733779-05-0 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]ethylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733779-06-1 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]ethylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733779-07-2 CAPLUS

CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733779-08-3 CAPLUS


CN Piperazine, 1-[[2-[[2-(diethylamino)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 733779-09-4 CAPLUS


CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 733779-10-7 CAPLUS

CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733779-11-8 CAPLUS


CN Piperazine, 1-[[2-[[3-(dimethylamino)propyl]methylamino]-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733779-12-9 CAPLUS

CN	Acetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)
----	---

PAGE 1-A




PAGE 2-A




●2 HCl

RN 733779-13-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733779-14-1 CAPLUS
 CN Cyclopropanecarboxamide, N-(1-methyl-4-piperidiny1)-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733779-15-2 CAPLUS
 CN 2-Furancarboxamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733779-16-3 CAPLUS
 CN 2-Furancarboxamide, N-(1-methyl-4-piperidinyl)-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733779-17-4 CAPLUS
 CN 2-Furancarboxamide, N-(1-methyl-4-piperidiny)-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733779-18-5 CAPLUS
 CN Piperazine, 1-[[trans-4-[[ethyl(2-hydroxyethyl)amino)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-19-6 CAPLUS

CN Piperazine, 1-[[trans-4-[(hexahydro-1(2H)-azocinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-20-9 CAPLUS


CN Piperazine, 1-[[trans-4-[(3,3-dimethyl-1-piperidinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-21-0 CAPLUS
 CN Piperazine, 1-[[trans-4-[(4-hydroxy-1-piperidinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733779-22-1 CAPLUS
 CN Piperazine, 1-[[trans-4-[(hexahydro-1H-azepin-1-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-23-2 CAPLUS

CN Piperazine, 1-[[trans-4-[[bis(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-24-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1-methylethyl)(phenylmethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-25-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733779-26-5 CAPLUS

CN Piperazine, 1-[[trans-4-[[[ethyl(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-27-6 CAPLUS

CN Piperazine, 1-[[trans-4-[[bis(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-28-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2-hydroxyethyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-29-8 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-30-1 CAPLUS

CN Piperazine, 1-[[trans-4-[(4-acetyl-1-piperazinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-31-2 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)ethylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-32-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-33-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-34-5 CAPLUS


CN Piperazine, 1-[[trans-4-[[4-(1-methylethyl)-1-piperazinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-35-6 CAPLUS
 CN Piperazine, 1-[[trans-4-[(1,3-dihydro-2H-isoindol-2-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-36-7 CAPLUS
 CN Piperazine, 1-[[trans-4-[[4-(2-ethoxyethyl)-1-piperazinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-37-8 CAPLUS
 CN Piperazine, 1-[[trans-4-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733779-38-9 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[ethyl(2-hydroxyethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-39-0 CAPLUS

CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(4-hydroxy-1-piperidinyl)methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-40-3 CAPLUS


CN Piperazine, 1-[[trans-4-[[bis(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-41-4 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(1-methylethyl)(phenylmethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733779-42-5 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733779-43-6 CAPLUS

CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[ethyl(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-44-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[bis(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-45-8 CAPLUS

CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[2-hydroxyethyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-46-9 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-47-0 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl) (2-methoxyethyl) amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-48-1 CAPLUS

CN Piperazine, 1-[[trans-4-[(1,3-dihydro-2H-isoindol-2-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-49-2 CAPLUS

CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[2-hydroxy-2-methylpropyl](1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-50-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[ethyl(2-hydroxyethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-51-6 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(hexahydro-1(2H)-azocinyl)methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-52-7 CAPLUS


CN Piperazine, 1-[[trans-4-[(3,3-dimethyl-1-piperidinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-53-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(4-hydroxy-1-piperidinyl)methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-54-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(hexahydro-1H-azepin-1-yl)methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-55-0 CAPLUS
 CN Piperazine, 1-[[trans-4-[[bis(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 733779-56-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733779-57-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[ethyl(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-58-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[bis(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-59-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(2-hydroxyethyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-60-7 CAPLUS

CN Piperazine, 1-acetyl-4-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-61-8 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-62-9 CAPLUS


CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733779-63-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[4-(1-methylethyl)-1-piperazinyl]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733779-64-1 CAPLUS
 CN Piperazine, 1-[[trans-4-[(1,3-dihydro-2H-isoindol-2-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-65-2 CAPLUS

CN Piperazine, 1-[[trans-4-[[4-(2-ethoxyethyl)-1-piperazinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-66-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-67-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(2-hydroxy-2-methylpropyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-68-5 CAPLUS

CN Piperazine, 1-[[trans-4-[(hexahydro-1(2H)-azocinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-69-6 CAPLUS

CN Piperazine, 1-[[trans-4-[(3,3-dimethyl-1-piperidinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-70-9 CAPLUS

CN Piperazine, 1-[[trans-4-[(4-hydroxy-1-piperidinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-71-0 CAPLUS

CN Piperazine, 1-[[trans-4-[(hexahydro-1H-azepin-1-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-72-1 CAPLUS

CN Piperazine, 1-[[trans-4-[[bis(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-73-2 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1-methylethyl)(phenylmethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-74-3 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 733779-75-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[ethyl(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-76-5 CAPLUS

CN Piperazine, 1-[[trans-4-[[bis(2-methoxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-77-6 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-78-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-79-8 CAPLUS

CN Piperazine, 1-[[[trans-4-[[[(1,1-dimethylethyl) (2-methoxyethyl) amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733779-80-1 CAPLUS


CN Piperazine, 1-[[[trans-4-[[[(2-hydroxy-2-methylpropyl) (1-methylethyl) amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733779-81-2 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)(2-hydroxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●x HCl

RN 733779-82-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(1-methylethyl)(phenylmethyl)amino]methyl]cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733779-83-4 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733779-84-5 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(1,1-dimethylethyl)ethylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



●x HCl

RN 733779-85-6 CAPLUS
 CN Piperazine, 1-[[trans-4-[[ethyl(2-hydroxyethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733779-86-7 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[(2-hydroxyethyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



●x HCl

RN 733779-87-8 CAPLUS
 CN Piperazine, 1-[[trans-4-[(1,3-dihydro-2H-isoindol-2-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



●x HCl

RN 733779-88-9 CAPLUS
 CN Benzoic acid, 3-[[4-[4-[[4-(1-piperidinyl)cyclohexyl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733779-89-0 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733779-90-3 CAPLUS
 CN Benzamide, 2,6-dichloro-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733779-91-4 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-2-methyl-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733779-92-5 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 733779-93-6 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl


RN 733779-94-7 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733779-95-8 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733779-96-9 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733779-97-0 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-
 (9CI) (CA INDEX NAME)



RN 733779-98-1 CAPLUS


CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733779-99-2 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733780-00-2 CAPLUS



CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733780-01-3 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)




RN 733780-02-4 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733780-03-5 CAPLUS
 CN 1-Naphthalenecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733780-04-6 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733780-05-7 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[4-(1-methylethyl)-1-piperazinyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733780-06-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(4-ethyl-1-piperazinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733780-07-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(4-methyl-1-piperazinyl)cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● x HCl

RN 733780-08-0 CAPLUS
 CN Piperazine, 1-[[trans-4-[cyclopentyl[2-(dimethylamino)ethyl]amino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



●x HCl


RN 733780-09-1 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl](2-methylpropyl)amino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733780-10-4 CAPLUS
 CN Piperazine, 1-[[trans-4-[(cyclopropylmethyl)[2-(dimethylamino)ethyl]amino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733780-11-5 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl]propylamino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733780-12-6 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl]ethylamino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 733780-13-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl]methylamino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 733780-14-8 CAPLUS

CN Propanamide, 2,2-dimethyl-N-[2-(1-piperidinyl)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733780-15-9 CAPLUS
 CN Acetamide, 2-methoxy-N-[2-(1-piperidinyl)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733780-16-0 CAPLUS
 CN 2-Furancarboxamide, N-[2-(1-piperidinyl)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





●2 HCl

RN 733780-17-1 CAPLUS
 CN Acetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-piperidinylethyl)]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733780-18-2 CAPLUS
 CN Acetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-methoxy-N-[2-(1-piperidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733780-19-3 CAPLUS
 CN 2-Butenamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-piperidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733780-20-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-piperidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733780-21-7 CAPLUS
 CN 2-Furancarboxamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-piperidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733780-22-8 CAPLUS
 CN Piperazine, 1-[[1,4'-bipiperidin]-1'-yl(cyanoimino)methyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733780-23-9 CAPLUS


CN Piperazine, 1-[(cyanoimino)[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733780-24-0 CAPLUS

CN Piperazine, 1-[(cyanoimino)[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733780-25-1 CAPLUS
 CN Piperazine, 1-[(cyanoimino)[4-(1-pyrrolidinyl)-1-piperidinylmethyl]-4-[1-
 [(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

|
F

RN 733780-26-2 CAPLUS
 CN Piperazine, 1-[(cyanoimino)[4-(1-pyrrolidinyl)-1-piperidinylmethyl]-4-[1-
 [(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl] - (9CI)
 (CA INDEX NAME)




- RN 733780-27-3 CAPLUS
CN Piperazine, 1-[[[1,4'-bipiperidin]-1'-yl(cyanoimino)methyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

- RN 733780-28-4 CAPLUS
CN Piperazine, 1-[4-[[[(cyanoamino)[[2-(dimethylamino)ethyl]imino]methyl]ethylamino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 733780-29-5 CAPLUS


CN Cyclohexanecarboxamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[2-(1-pyrrolidinyl)ethyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 733780-30-8 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 733780-31-9 CAPLUS

CN Cyclohexanecarboxamide, N-[2-(diethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733780-32-0 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-ethyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733780-33-1 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-(diethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 733780-34-2 CAPLUS

CN Cyclohexanecarboxamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[3-(1-pyrrolidinyl)propyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733780-35-3 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733780-36-4 CAPLUS
 CN Cyclohexanecarboxamide, N-[3-(dimethylamino)propyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 733780-37-5 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733780-38-6 CAPLUS
 CN Cyclohexanecarboxamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[3-(1-piperidinyl)propyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733780-39-7 CAPLUS
 CN Cyclohexanecarboxamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[[2R)-1-ethyl-2-pyrrolidinyl]methyl]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 733780-40-0 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-2,2-dimethyl-N-[5-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733780-41-1 CAPLUS


CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 733780-42-2 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl


RN 733780-43-3 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-2,2-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733780-44-4 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733780-45-5 CAPLUS


CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)

piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl


RN 733780-46-6 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-2,2-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733780-47-7 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 733780-48-8 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl


RN 733780-49-9 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-2,2-dimethyl-N-[5-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733780-50-2 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 733780-51-3 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●2 HCl

RN 733780-52-4 CAPLUS
 CN Carbamic acid, [3-[[2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]amino]-3-oxopropyl]methyl-, 1-methylethyl ester, hydrochloride (9CI) (CA INDEX NAME)



RN 733780-53-5 CAPLUS
 CN Carbamic acid, [3-[[2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]amino]-3-oxopropyl]methyl-, pentyl ester, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733780-54-6 CAPLUS
 CN Piperazine, 1-([1,4'-bipiperidin]-1'-ylcarbonyl)-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733780-55-7 CAPLUS
 CN Piperazine, 1-([1,4'-bipiperidin]-1'-ylcarbonyl)-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733780-56-8 CAPLUS
 CN Piperazine, 1-([1,4'-bipiperidin]-1'-ylcarbonyl)-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733780-57-9 CAPLUS
 CN Piperazine, 1-[[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]]- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 733780-58-0P 733780-59-1P 733780-60-4P
 733780-61-5P 733780-62-6P 733780-63-7P
 733780-64-8P 733780-65-9P 733780-66-0P
 733780-67-1P 733780-68-2P 733780-69-3P
 733780-70-6P 733780-71-7P 733780-72-8P
 733780-73-9P 733780-74-0P 733780-75-1P
 733780-76-2P 733780-77-3P 733780-78-4P
 733780-79-5P 733780-80-8P 733780-81-9P
 733780-82-0P 733780-83-1P 733780-84-2P
 733780-85-3P 733780-86-4P 733780-87-5P
 733780-88-6P 733780-89-7P 733780-90-0P
 733780-91-1P 733780-92-2P 733780-93-3P
 733780-94-4P 733780-95-5P 733780-96-6P
 733780-97-7P 733780-98-8P 733780-99-9P
 733781-00-5P 733781-01-6P 733781-02-7P
 733781-03-8P 733781-04-9P 733781-05-0P
 733781-06-1P 733781-07-2P 733781-08-3P

733781-09-4P 733781-10-7P 733781-11-8P
 733781-12-9P 733781-13-0P 733781-14-1P
 733781-15-2P 733781-16-3P 733781-17-4P
 733781-18-5P 733781-19-6P 733781-20-9P
 733781-21-0P 733781-22-1P 733781-23-2P
 733781-24-3P 733781-25-4P 733781-26-5P
 733781-27-6P 733781-28-7P 733781-29-8P
 733781-30-1P 733781-31-2P 733781-32-3P
 733781-33-4P 733781-34-5P 733781-35-6P
 733781-36-7P 733781-37-8P 733781-38-9P
 733781-39-0P 733781-40-3P 733781-41-4P
 733781-42-5P 733781-43-6P 733781-44-7P
 733781-45-8P 733781-46-9P 733781-47-0P
 733781-48-1P 733781-49-2P 733781-50-5P
 733781-51-6P 733781-52-7P 733781-53-8P
 733781-54-9P 733781-55-0P 733781-56-1P
 733781-57-2P 733781-58-3P 733781-59-4P
 733781-60-7P 733781-61-8P 733781-62-9P
 733781-63-0P 733781-64-1P 733781-65-2P
 733781-66-3P 733781-67-4P 733781-68-5P
 733781-69-6P 733781-70-9P 733781-71-0P
 733781-72-1P 733781-73-2P 733781-74-3P
 733781-75-4P 733781-76-5P 733781-77-6P
 733781-78-7P 733781-79-8P 733781-80-1P
 733781-81-2P 733781-82-3P 733781-83-4P
 733781-84-5P 733781-85-6P 733781-86-7P
 733781-87-8P 733781-88-9P 733781-89-0P
 733781-90-3P 733781-91-4P 733781-92-5P
 733781-93-6P 733781-94-7P 733781-95-8P
 733781-96-9P 733781-97-0P 733781-98-1P
 733781-99-2P 733782-00-8P 733782-01-9P
 733782-02-0P 733782-05-3P 733782-07-5P
 733782-08-6P 733782-09-7P 733782-10-0P
 733782-11-1P 733782-12-2P 733782-13-3P
 733782-14-4P 733782-15-5P 733782-16-6P
 733782-17-7P 733782-18-8P 733782-19-9P
 733782-20-2P 733782-21-3P 733782-22-4P
 733782-23-5P 733782-24-6P 733782-25-7P
 733782-26-8P 733782-27-9P 733782-28-0P
 733782-29-1P 733782-30-4P 733782-31-5P
 733782-32-6P 733782-33-7P 733782-34-8P
 733782-35-9P 733782-36-0P 733782-37-1P
 733782-38-2P 733782-39-3P 733785-81-4P
 733785-82-5P 733785-83-6P 733785-84-7P
 733785-85-8P 733785-86-9P 733785-87-0P
 733785-88-1P 733785-89-2P 733785-90-5P
 733785-91-6P 733785-92-7P 733785-93-8P
 733785-94-9P 733785-95-0P 733785-96-1P
 733785-97-2P 733785-98-3P 733785-99-4P
 733786-00-0P 733786-01-1P 733786-02-2P
 733786-03-3P 733786-04-4P 733786-05-5P
 733786-06-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of pyrazolopyrimidines as a small conductance potassium channel
 (SK channel) blocking agents)

RN 733780-58-0 CAPLUS

CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]- (9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 2-A


|
F

RN 733780-59-1 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733780-60-4 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-61-5 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-62-6 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-63-7 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-2-methyl-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● x HCl

RN 733780-64-8 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-65-9 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-2-methyl-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-66-0 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● x HCl

RN 733780-67-1 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-68-2 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-69-3 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-70-6 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-71-7 CAPLUS

CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A


●x HCl

RN 733780-72-8 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-73-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-74-0 CAPLUS
CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-75-1 CAPLUS
CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-76-2 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl](methylsulfonyl)amino]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-77-3 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-78-4 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733780-79-5 CAPLUS
 CN 2-Pyridinecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A


●x HCl

RN 733780-80-8 CAPLUS
 CN Carbamic acid, [3-[[2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]amino]-3-oxopropyl]methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 733780-81-9 CAPLUS
 CN Piperazine, 1-[4-[[[(cyanoamino)iminomethyl]ethylamino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 733780-82-0 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]amino]-3-pyridinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733780-83-1 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733780-84-2 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]amino]-3-pyridinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

●x HCl

RN 733780-85-3 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 733780-86-4 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733780-87-5 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]amino]-3-pyridinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733780-88-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733780-89-7 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-2-methyl-N-[5-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733780-90-0 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 733780-91-1 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-2-methyl-N-[5-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733780-92-2 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]ethylamino]-3-pyridazinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733780-93-3 CAPLUS
 CN Piperazine, 1-[[6-[[2-(diethylamino)ethyl]methylamino]-3-

pyridazinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733780-94-4 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]methylamino]-3-pyridazinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733780-95-5 CAPLUS
 CN Piperazine, 1-[[6-[[3-(dimethylamino)propyl]methylamino]-3-pyridazinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl


RN 733780-96-6 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]ethylamino]-3-pyridazinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733780-97-7 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]amino]-3-pyridazinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733780-98-8 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]ethylamino]-3-pyridazinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733780-99-9 CAPLUS
 CN Piperazine, 1-[[6-[[2-(diethylamino)ethyl]methylamino]-3-pyridazinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733781-00-5 CAPLUS
 CN Piperazine, 1-[[6-[[2-(dimethylamino)ethyl]methylamino]-3-pyridazinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733781-01-6 CAPLUS


CN Piperazine, 1-[[6-[[3-(dimethylamino)propyl]methylamino]-3-pyridazinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733781-02-7 CAPLUS

CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[(1-methylethyl)amino]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733781-03-8 CAPLUS
 CN Piperazine, 1-[[4-(2,5-dihydro-1H-pyrrol-1-yl)-1-piperidiny]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



|
F

● x HCl


RN 733781-04-9 CAPLUS
 CN Piperazine, 1-[[4-(diethylamino)-1-piperidinyl]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride
 (9CI) (CA INDEX NAME)




● x HCl

RN 733781-05-0 CAPLUS
 CN Piperazine, 1-[[4-(1,1-dimethylethyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl


RN 733781-06-1 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[(1-methylethyl)amino]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733781-07-2 CAPLUS
 CN Piperazine, 1-[[4-(1,1-dimethylethyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733781-08-3 CAPLUS

CN Piperazine, 1-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-1-piperidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl


RN 733781-09-4 CAPLUS

CN Piperazine, 1-[[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-10-7 CAPLUS
 CN Piperazine, 1-[(3,3-dimethyl[1,4'-bipiperidin]-1'-yl)carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733781-11-8 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733781-12-9 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-13-0 CAPLUS
 CN Piperazine, 1-[(3,3-dimethyl[1,4'-bipiperidin]-1'-yl)carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● x HCl

RN 733781-14-1 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A


●x HCl

RN 733781-15-2 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733781-16-3 CAPLUS
 CN Piperazine, 1-[(3,3-dimethyl[1,4'-bipiperidin]-1'-yl)carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-17-4 CAPLUS
 CN Piperazine, 1-[[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-18-5 CAPLUS
 CN Piperazine, 1-[(3,3-dimethyl[1,4'-bipiperidin]-1'-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-19-6 CAPLUS
 CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]methylamino]-1-piperidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733781-20-9 CAPLUS
 CN Piperazine, 1-[[4-[[ethyl(2-methoxyethyl)amino]-1-piperidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-21-0 CAPLUS
 CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 733781-22-1 CAPLUS


CN Piperazine, 1-[[4-[[ethyl(2-methoxyethyl)amino]-1-piperidinyl]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]]-piperazine, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 733781-23-2 CAPLUS

CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]]-piperazine, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-24-3 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[ethyl(2-methoxyethyl)amino]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733781-25-4 CAPLUS
 CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733781-26-5 CAPLUS


CN Piperazine, 1-[[4-[[2-(dimethylamino)ethyl]ethylamino]-1-piperidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733781-27-6 CAPLUS

CN Piperazine, 1-[[4-(diethylamino)-1-piperidinyl]carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733781-28-7 CAPLUS
 CN Piperazine, 1-[[4-[[2-(diethylamino)ethyl]amino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● x HCl

RN 733781-29-8 CAPLUS

CN Piperazine, 1-[[4-[[2-[bis(1-methylethyl)amino]ethyl]amino]-1-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl


RN 733781-30-1 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[[2-(1-piperidinyl)ethyl]amino]-1-piperidinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-31-2 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-32-3 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733781-33-4 CAPLUS
 CN 2-Butenamide, N- [2- (dimethylamino)ethyl] -N- [1- [[4- [1- [(2-fluoro-3-methylphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidiny]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-34-5 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733781-35-6 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733781-36-7 CAPLUS


CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733781-37-8 CAPLUS


CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 733781-38-9 CAPLUS
 CN Butanamide, N-[2-(dimethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-39-0 CAPLUS
 CN Acetamide, N-[2-(diethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-40-3 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(diethylamino)ethyl]-N-[1-[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● x HCl

RN 733781-41-4 CAPLUS

CN 2-Butenamide, N-[2-(diethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 733781-42-5 CAPLUS

CN 3-Furancarboxamide, N-[2-(diethylamino)ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733781-43-6 CAPLUS
 CN Acetamide, N-[2-[bis(1-methylethyl)amino]ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733781-44-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733781-45-8 CAPLUS
 CN 2-Butenamide, N-[2-[bis(1-methylethyl)amino]ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●x HCl

RN 733781-46-9 CAPLUS
 CN 3-Furancarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-N-[1-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-4-piperidinyl]-, hydrochloride (9CI) (CA INDEX NAME)

Page 1

=> dis his


(FILE 'HOME' ENTERED AT 12:14:02 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 12:14:10 ON 29 NOV 2005

L1	STR	
L2	25 S L1	
L3	2571 S L1 FUL	

=> d 13 que stat

L1	STR
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100



```

VAR G1=C/N
VAR G2=12/11
VAR G3=X/CN/N/O/S/14/H/C
VAR G4=H/N/X/O/S/N
NODE ATTRIBUTES:
NSPEC      IS R          AT 11
NSPEC      IS R          AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ELEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L3 2571 SEA FILE=REGISTRY SSS FUL L1

```
100.0% PROCESSED 181353 ITERATIONS                2571 ANSWERS
SEARCH TIME: 00.00.07
```

```
=> fil medl,biosis,embase,caplus;s l3
COST IN U.S. DOLLARS
```

SINCE FILE	TOTAL
ENTRY	SESSION
170.36	170.57

FILE 'MEDLINE' ENTERED AT 12:31:04 ON 29 NOV 2005

FILE 'BIOSIS' ENTERED AT 12:31:04 ON 29 NOV 2005
Copyright (c) 2005 The Thomson Corporation

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

FILE 'EMBASE' ENTERED AT 12:31:04 ON 29 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:31:04 ON 29 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L4	0	FILE MEDLINE
L5	3	FILE BIOSIS
L6	3	FILE EMBASE
L7	453	FILE CAPLUS

TOTAL FOR ALL FILES

L8	459	L3
----	-----	----

=> s peyman a?/au;s scheunemann k?/au;s gadek t?/au;s gourvest j?/au;s ruxer j?/au

L9	26	FILE MEDLINE
L10	79	FILE BIOSIS
L11	39	FILE EMBASE
L12	109	FILE CAPLUS

TOTAL FOR ALL FILES

L13	253	PEYMAN A?/AU
-----	-----	--------------

L14	11	FILE MEDLINE
L15	25	FILE BIOSIS
L16	10	FILE EMBASE
L17	47	FILE CAPLUS

TOTAL FOR ALL FILES

L18	93	SCHEUNEMANN K?/AU
-----	----	-------------------

L19	17	FILE MEDLINE
L20	76	FILE BIOSIS
L21	24	FILE EMBASE
L22	74	FILE CAPLUS

TOTAL FOR ALL FILES

L23	191	GADEK T?/AU
-----	-----	-------------

L24	8	FILE MEDLINE
L25	33	FILE BIOSIS
L26	8	FILE EMBASE
L27	47	FILE CAPLUS

TOTAL FOR ALL FILES

L28	96	GOURVEST J?/AU
-----	----	----------------

L29	6	FILE MEDLINE
L30	22	FILE BIOSIS
L31	20	FILE EMBASE
L32	31	FILE CAPLUS

TOTAL FOR ALL FILES

L33 79 RUXER J?/AU

=> s l13 and l18 and l23 and l28 and l33

L34 2 FILE MEDLINE

L35 4 FILE BIOSIS

L36 2 FILE EMBASE

L37 4 FILE CAPLUS

TOTAL FOR ALL FILES

L38 12 L13 AND L18 AND L23 AND L28 AND L33

=> dup rem l38

PROCESSING COMPLETED FOR L38

L39 6 DUP REM L38 (6 DUPLICATES REMOVED)

=> d 1-6 ibib abs;s (l13 or l18 or l23 or l28 or l33) and l8

L39 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:327350 BIOSIS

DOCUMENT NUMBER: PREV200400331069

TITLE: Thienylalanine derivatives as inhibitors of cell adhesion.

AUTHOR(S): Gadek, Thomas [Inventor, Reprint Author];
Gourvest, Jean-Francois [Inventor]; Peyman,
Anuschirvan [Inventor]; Ruxer, Jean-Marie
[Inventor]; Scheunemann, Karl-Heinz [Inventor]

CORPORATE SOURCE: Claye Souilly, France

ASSIGNEE: Aventis Pharma S.A. Deutschland GmbH Genentech,
Inc., Germany

PATENT INFORMATION: US 6762190 20040713

SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (July 13 2004) Vol. 1284, No. 2.
<http://www.uspto.gov/web/menu/patdata.html>. e-file.
ISSN: 0098-1133 (ISSN print).

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 29 Jul 2004

Last Updated on STN: 29 Jul 2004

AB The present invention relates to compounds of formula (I), in which A, B, X, Y, R1, R2, R3 and n have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

L39 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:290045 BIOSIS

DOCUMENT NUMBER: PREV200400290126



TITLE: Naphthyridine derivatives, processes for their preparation,
their use and pharmaceutical compositions comprising them.

AUTHOR(S): Peyman, Anuschirvan [Inventor, Reprint Author];

Scheunemann, Karl-Heinz [Inventor]; **Gadek, Thomas R** [Inventor]; **Gourvest, Jean-Francois** [Inventor]; **Ruxer, Jean-Marie** [Inventor]
 CORPORATE SOURCE: Kelkheim, Germany
 ASSIGNEE: Aventis Pharma Deutschland GmbH, Germany; Genentech Inc., Gainesville, VA, USA
 PATENT INFORMATION: US 6743800 20040601
 SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (June 1 2004) Vol. 1283, No. 1.
 http://www.uspto.gov/web/menu/patdata.html. e-file.
 ISSN: 0098-1133 (ISSN print).
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 ENTRY DATE: Entered STN: 16 Jun 2004
 Last Updated on STN: 16 Jun 2004
 AB ##STR1## The present invention relates to compounds of formula (1), in which H, G, Z, X, Y, r, s and t have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (1) are valuable, pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (1), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
 L39 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:450930 CAPLUS
 DOCUMENT NUMBER: 135:46196
 TITLE: Preparation of (tetrahydropyrimidinylcarbamoylalkyl)thienylalanine derivatives as inhibitors of cell adhesion
 INVENTOR(S): **Gadek, Thomas; Gourvest, Jean-Francois; Peyman, Anuschirwan; Ruxer, Jean-Marie; Scheunemann, Karl-Heinz**
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Genentech, Inc.
 SOURCE: Eur. Pat. Appl., 31 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1108721	A1	20010620	EP 1999-124971	19991215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2394767	AA	20010621	CA 2000-2394767	20001212
WO 2001044237	A1	20010621	WO 2000-EP12877	20001212
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US,				

UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 2001026742 A5 20010625 AU 2001-26742 20001212
 EP 1240161 A1 20020918 EP 2000-989987 20001212
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2003105080 A1 20030605 US 2002-169612 20020923
 US 6762190 B2 20040713
 PRIORITY APPLN. INFO.: EP 1999-124971 A 19991215
 WO 2000-EP12877 W 20001212
 OTHER SOURCE(S): MARPAT 135:46196
 GI



AB Title compds. (I) [wherein A and B = independently H, alkyl, cycloalkyl(alkyl), aryl(alkyl), halo, CN, CF₃, NO₂, CO₂H, alkoxy(alkyl), alkoxycarbonyl, (aryl)alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, alkoxyalkoxy, alkylaminocarbonyl, (di)alkylamino, alkylsulfonyl, or aminosulfonyl; or A and B together with the thiophene ring to which they are attached may form a fused ring system; X = alkanediyl, alkenediyl, or alkynediyl, where 1 C may be replaced by N, O, or S, etc.; Y = a bond, SO₂, CO, CO₂, SO₂NR₃', or CONR₃'; R₁ = (un)substituted alkyl, cycloalkyl(alkyl), or aryl(alkyl); R₂ = COR₄, CSR₄, SO₂R₄, POR₄R₄', or a heterocycle; R₃ and R₃' = independently H, alkyl, cycloalkyl(alkyl), or aryl(alkyl); R₄ and R₄' = independently OH, (aryl)alkoxy, (aryl)alkylcarbonyloxyalkoxy, or NR₅NR₅'; R₅ and R₅' = independently H, alkyl, cycloalkyl(alkyl), or aryl(alkyl); or R₅ and R₅' together with the N to which they are attached may form a heterocycle] were prepared as vitronectin receptor (VnR) antagonists. For example, coupling 5-[5-((2S)-2-amino-2-tert-butoxycarbonyl)thiophen-2-yl]pentanoic acid (6-step preparation given) and naphthalene-1-sulfonyl chloride to give the sulfonamide, followed by amidation with 1,4,5,6-tetrahydropyrimidin-2-ylamine and hydrolysis using TFA, gave (S)-II. II inhibited the binding of kistrin to human VnR $\alpha v\beta 3$ and the binding of human embryonic kidney 293 cells to human vitronectin with IC₅₀ values of 0.023 μ M and 0.42 μ M, resp. As cell adhesion inhibitors, I are suitable for the therapy and prophylaxis of illnesses which are based on or influenced by the interaction between vitronectin receptors and their ligands in

cell-cell or cell-matrix interaction processes, e.g. osteoporosis, angiogenesis, and proliferation of cells of the vascular smooth musculature (no data).

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:10662 CAPLUS

DOCUMENT NUMBER: 134:71600

TITLE: Naphthyridine derivatives, processes for their preparation, their use as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compositions comprising them

INVENTOR(S): Peyman, Anuschirwan; Scheunemann, Karl-Heinz; Gourvest, Jean-Francois; Ruxer, Jean-Marie; Gadek, Thomas R.

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany; Genentech, Inc.

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065207	A1	20010103	EP 1999-112636	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2376668	AA	20010111	CA 2000-2376668	20000626
WO 2001002398	A1	20010111	WO 2000-EP5920	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012129	A	20020507	BR 2000-12129	20000626
EP 1210348	A1	20020605	EP 2000-945825	20000626
EP 1210348	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200103856	T2	20020621	TR 2001-200103856	20000626
JP 2003503496	T2	20030128	JP 2001-507835	20000626
NZ 516058	A	20030131	NZ 2000-516058	20000626
EE 200100711	A	20030415	EE 2001-711	20000626
AU 775386	B2	20040729	AU 2000-59787	20000626
TW 593319	B	20040621	TW 2000-89117925	20000901
BG 106257	A	20021031	BG 2001-106257	20011220
HR 2001000946	A1	20030228	HR 2001-946	20011221
NO 2001006404	A	20020301	NO 2001-6404	20011228
ZA 2002000016	A	20030102	ZA 2002-16	20020102
US 6743800	B1	20040601	US 2002-30301	20020320
HK 1050003	A1	20050429	HK 2003-102163	20030325
US 2004198718	A1	20041007	US 2004-808496	20040324
PRIORITY APPLN. INFO.:			EP 1999-112636	A 19990702
			WO 2000-EP5920	W 20000626
			US 2002-30301	A3 20020320

OTHER SOURCE(S) : MARPAT 134:71600
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to compds. I. G is $-(CR1R2)_n-A-(CR1R2)_m-(CR1R3)_i-(CR1R2)_q-R4$. A is a direct bond, $-C(O)NR5-$, $-NR5C(O)-$, $-C(O)-$, $-NR5-$, $-O-$, $-S-$, $-S(O)-$, $-S(O)2-$, (C2-C4)alkynediyl, (C2-C4)alkenediyl, (C5-C14)arylene where in the arylene residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or a divalent residue of a 3-7-membered saturated or unsatd. ring which can contain 1-2 ring heteroatoms N, S and O and which can be monosubstituted or disubstituted by residues :O, :S and R3. B is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, F, Cl, Br, OH, CN, CF3, NO2, CO2H, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C5-C14)arylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C1-C6)alkylsulfonamino, (C5-C14)arylsulfonamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, aminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl(C1-C8)alkylsulfonyl, (C5-C14)aryl or (C5-C14)heteroaryl, where all residues B are independent of one another and can be identical or different. X is H, NR6R6', F, Cl, Br, OR6, SR6, hydroxy(C1-C6)alkyl-NH-, (hydroxy(C1-C6)alkyl)2N-, amino(C1-C6)alkyl-NH-, (amino(C1-C6)alkyl)2N-, hydroxy(C1-C6)alkyl-O-, hydroxy(C1-C6)alkyl-S- or -NH-C(O)-R6. Y is R5, F, Cl, Br, CN, NR6R6', OR6, SR6 or hydroxy(C1-C6)alkyl-NH-. Z is N or CH. R1 and R2 are H, F, Cl, CN, NO2, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6-S(O)p-R7, R6S(O)2NHR7, R6OC(O)NHR7 or R6R6'N-R7, where all residues R1 and R2 are independent of one another and can be identical or different. R3 is H, F, Cl, CN, NO2, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6R6'N-R7, R6C(O)-O-R7, R6C(O)R7, R6N(R6')C(O)OR7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, R6C(O)N(R5)R7, R6N(R6')C(O)N(R5)R7, R6N(R6')S(O)pN(R5)R7, R6S(O)pR7, R6SC(O)N(R5)R7, R6N(R6')C(O)R7 or R6N(R6')S(O)pR7, where alkyl can be monounsaturated or polyunsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by R6, F, Cl, Br, CN, CF3, R6R6'NR7, NO2, R6OC(O)R7, R6C(O)R7, R6N(R6')C(O)R7, R6N(R6')S(O)pR7 or R6-O-R7, and where all residues R3 are independent of one another and can be identical or different. R4 is $-C(O)R8$, $-C(S)R8$, $-S(O)pR8$, $-P(O)R8R8'$ or a residue of a 4-8-membered saturated or unsaturated heterocycle which contains 1-4 heteroatoms N, O and S. R5 is H, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl or (C5-C14)aryl(C1-C8)alkyl, where all residues R5 are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl(C1-C8)alkyl where aryl, heteroaryl, cycloalkyl and alkyl can be substituted 1-3 times by identical or different substituents F, Cl, Br, CN, CF3, NO2, CO2H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)arylcarbonyl, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C5-C14)arylsulfonamino, (C1-

C6) alkylsulfonylamino, (C1-C6) alkylamino, di((C1-C6) alkyl) amino, (C1-C6) alkylsulfonyl, (C1-C6) alkylaminosulfonyl, (C5-C14) arylaminosulfonyl, (C5-C14) aryl (C1-C8) alkylaminosulfonyl, (C5-C14) arylsulfonyl, (C5-C14) aryl (C1-C8) alkylsulfonyl, (C5-C14) aryl and (C5-C14) heteroaryl, and where all residues R6 and R6' are independent of one another and can be identical or different. R7 is (C1-C4) alkanediyl or a direct bond, where all residues R7 are independent of one another and can be identical or different. R8 and R8' are OH, (C1-C8) alkoxy, (C5-C14) aryl (C1-C8) alkoxy, (C5-C14) aryloxy, (C1-C8) alkylcarbonyloxy (C1-C4) alkoxy, (C5-C14) aryl (C1-C8) alkylcarbonyloxy (C1-C8) alkoxy, NR6R6', (di((C1-C8) alkyl) amino) carbonylmethyloxy, (di((C5-C14) aryl (C1-C8) alkyl) amino) carbonylmethyloxy, (C5-C14) arylamino, the residue of an amino acid, N-((C1-C4) alkyl) piperidin-4-yloxy, 2-methylsulfonylethoxy, 1,3-thiazol-2-ylmethyloxy, 3-pyridylmethyloxy, 2-(di((C1-C4) alkyl) amino) ethoxy or the residue Q-(CH₃)₃N⁺-CH₂-CH₂-O- in which Q- is a physiol. tolerable anion, where all residues R8 and R8' are independent of one another and can be identical or different. N is 0-5; m is 0-5; i is 0-1; q is 0-2; r is 0-2; s is 0-3; t is 0-8; p is 0-2, where all nos. p are independent of one another and can be identical or different. The claimed compds. also include stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure shown I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compns. comprising them. The process of preparation comprises reacting II (L1 = leaving group) with III or IV; B, G, X, Y, r, s and t are defined as above but wherein functional groups can also be present in the form of precursor groups or in protected form. For example, (2S)-2-benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester could be made from 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-1,8-naphthyridine and (S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester in DMF in the presence of NETiPr₂; the ester was then hydrolyzed by CF₃CO₂H to give the desired compound

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 5 OF 6 MEDLINE on STN DUPLICATE 1
 ACCESSION NUMBER: 2001402902 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 11454469
 TITLE: alpha(v)beta(3) Antagonists based on a central thiophene scaffold.
 AUTHOR: Peyman A; Scheunemann K; Will D W; Knolle J; Wehner V; Breipohl G; Stilz H U; Carniato D; Ruxer J; Gourvest J; Auberval M; Doucet B; Baron R; Gaillard M; Gadek T R; Bodary S
 CORPORATE SOURCE: Aventis Pharma Deutschland GmbH, D-65926, Frankfurt, Germany.. anusch.peyman@aventis.com
 SOURCE: Bioorganic & medicinal chemistry letters, (2001 Aug 6) 11 (15) 2011-5.

Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: England: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200110
 ENTRY DATE: Entered STN: 20011008
 Last Updated on STN: 20011008
 Entered Medline: 20011004

AB A series of novel, highly potent alpha(v)beta(3) antagonists based on a thiophene scaffold and containing an acylguanidine as an Arg-mimetic is described. A number of structural features, such as cyclic versus open guanidine and a variety of lipophilic side chains, carbamates, sulfonamides and beta-amino acids were explored with respect to inhibition of alpha(v)beta(3) mediated cell adhesion and selectivity versus alpha(IIb)beta(3) binding. In addition, compound 19 was found to be active in the TPTX model of osteoporosis.

L39 ANSWER 6 OF 6 MEDLINE on STN DUPLICATE 2
 ACCESSION NUMBER: 2000135661 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 10673106
 TITLE: RGD mimetics containing a central hydantoin scaffold: alpkha(v)beta3 vs alpha(IIb)beta3 selectivity requirements.
 AUTHOR: Peyman A; Wehner V; Knolle J; Stolz H U; Breipohl G; Scheunemann K H; Carniato D; Ruxer J M
 ; Gourvest J F; Gadek T R; Bodary S
 CORPORATE SOURCE: Hoechst Marion Roussel Deutschland GmbH, Frankfurt, Germany.. anusch.peyman@hmrag.com
 SOURCE: Bioorganic & medicinal chemistry letters, (2000 Jan 17) 10 (2) 179-82.
 Journal code: 9107377. ISSN: 0960-894X.
 PUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 200003
 ENTRY DATE: Entered STN: 20000320
 Last Updated on STN: 20000320
 Entered Medline: 20000307

AB The synthesis of a series of RGD mimetic alpha(v)beta3 antagonists containing a hydantoin scaffold is shown. The results demonstrate some of the structural requirements for the design of selective alpha(v)beta3 antagonists (vs alpha(IIb)beta3) in terms of the Arg-mimetic, the distance between N- and C-terminus and the lipophilic side chain.

L40 0 FILE MEDLINE
 L41 0 FILE BIOSIS
 L42 0 FILE EMBASE
 L43 4 FILE CAPLUS

TOTAL FOR ALL FILES

L44 4 (L13 OR L18 OR L23 OR L28 OR L33) AND L8

=> s l44 not l38

L45 0 FILE MEDLINE
 L46 0 FILE BIOSIS
 L47 0 FILE EMBASE
 L48 3 FILE CAPLUS

TOTAL FOR ALL FILES

L49 3 L44 NOT L38

=> d 1-3 ibib abs hitstr

L49 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171900 CAPLUS

DOCUMENT NUMBER: 136:216764

TITLE: Process for the preparation of 3-(6-piperidinylpurin-9-yl)propionates as vitronectin receptor antagonists

INVENTOR(S): Peyman, Anuschirwan; Schubert, Gerrit

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018384	A1	20020307	WO 2001-EP9985	20010829
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10042655	A1	20020314	DE 2000-10042655	20000831
AU 2001093791	A5	20020313	AU 2001-93791	20010829
EP 1315728	A1	20030604	EP 2001-974220	20010829
EP 1315728	B1	20041027		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507544	T2	20040311	JP 2002-523899	20010829
AT 280769	E	20041115	AT 2001-974220	20010829
ES 2232665	T3	20050601	ES 2001-1974220	20010829
US 2004248907	A1	20041209	US 2003-363450	20030401
PRIORITY APPLN. INFO.:			DE 2000-10042655	A 20000831
			WO 2001-EP9985	W 20010829
OTHER SOURCE(S):		CASREACT 136:216764; MARPAT 136:216764		
GI				




AB The present invention relates to a process for the preparation of vitronectin receptor antagonists I [wherein R = G1 or G2; R₁, R₂, R₃, and R₄ = independently H, F, Cl, CN, (un)substituted alkyl, cycloalkyl(alkyl), or aryl(alkyl), or R₆OR₇, R₆R₆'NR₇, R₆COR₇, R₆SO₂N(R₉)R₇, R₆CON(R₉)R₇, R₆CON(R₅)R₇, R₆N(R₉)CON(R₉)R₇, R₆N(R₉)SO₂N(R₉)R₇, R₆SO₂R₇, R₆SCON(R₉)R₇, R₆N(R₉)COR₇, R₆N(R₉)SO₂R₇, R₆N(R₉)R₇, or heterocyclyl; R₅ = OH, (aryl)alkoxy, alkylcarbonyloxyalkoxy, or cyclo(alkyl)alkoxy; R₆ and R₆' = independently (un)substituted alkyl, cycloalkyl(alkyl), aryl(alkyl), or heterocyclyl; R₇ = independently alkanediyl or a direct bond; R₉ = H or alkyl; and stereoisomers and salts thereof] by coupling a 9-chloropurine I [R = Cl] to a 4-substituted piperidine and comprises an efficient method for the preparation of I [R = Cl]. In contrast to prior art, the process according to the invention gives good yields in a lower number of steps and can be used advantageously for the syntheses on a relatively large scale. For example, Et (2S)-2-(naphthalene-1-sulfonylamino)-3-aminopropionate was aminated with 4,6-dichloro-5-nitropyrimidine in THF in the presence of TEA and then reduced to the amine using SnCl₂ in EtOH. Cyclocondensation with tri-Et orthoformate in N-methylpyrrolidone in the presence of EtSO₃H gave the 6-chloropurine. Reaction with 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-[1,8]naphthyridine in DMF and diisopropylethylamine at 70°C for 3 h afforded the piperidinylpurinylpropionate II.

IT 315212-31-8P, tert-Butyl (2S)-2-benzyloxycarbonylamino-3-[6-[4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl]purin-9-yl]propionate 402501-87-5P, Ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-[6-[4-(5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)piperidin-1-yl]purin-9-yl]propionate
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(target compound; process for preparation purinylpropionate vitronectin receptor antagonists starting from nitropyrimidines and

aminopropionates)
RN 315212-31-8 CAPLUS
CN 9H-Purine-9-propanoic acid, α -[[[(phenylmethoxy)carbonyl]amino]-6-[4-
[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-,
1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402501-87-5 CAPLUS
CN 9H-Purine-9-propanoic acid, α -[(1-naphthalenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, ethyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:10663 CAPLUS
 DOCUMENT NUMBER: 134:71601
 TITLE: Substituted purine derivatives, method of preparation
 and use as inhibitors of cell adhesion
 INVENTOR(S): Knolle, Jochen; Peyman, Anuschirwan;
 Gourvest, Jean-Francois; Ruxer,
 Jean-Marie; Gadek, Thomas R.
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany;
 Genentech, Inc.
 SOURCE: Eur. Pat. Appl., 41 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065208	A1	20010103	EP 1999-112637	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2376673	AA	20010111	CA 2000-2376673	20000626
WO 2001002399	A1	20010111	WO 2000-EP5921	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1196416	A1	20020417	EP 2000-940406	20000626
EP 1196416	B1	20040324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103858	T2	20020621	TR 2001-200103858	20000626
BR 2000012050	A	20021231	BR 2000-12050	20000626
JP 2003503497	T2	20030128	JP 2001-507836	20000626
EE 200100713	A	20030415	EE 2001-713	20000626
AT 262528	E	20040415	AT 2000-940406	20000626
AU 774382	B2	20040624	AU 2000-55349	20000626
NZ 516095	A	20040827	NZ 2000-516095	20000626
ES 2219353	T3	20041201	ES 2000-940406	20000626
BG 106229	A	20020830	BG 2001-106229	20011217
NO 2001006403	A	20020301	NO 2001-6403	20011228
ZA 2002000017	A	20030102	ZA 2002-17	20020102
US 6747016	B1	20040608	US 2002-30290	20020306
PRIORITY APPLN. INFO.:			EP 1999-112637	A 19990702
			WO 2000-EP5921	W 20000626
OTHER SOURCE(S):	MARPAT 134:71601			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to purine derivs. I. B is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl-(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl-(C1-C8)alkyl, F, Cl, Br, OH, CN, CF₃, NO₂, CO₂H, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C5-C14)arylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C1-C6)alkylsulfonylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, aminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl-(C1-C8)alkylsulfonyl, (C5-C14)aryl or (C5-C14)heteroaryl, where all residues B are independent of one another and can be identical or different, or B denotes an aromatic or nonarom. ring system that is fused to the 6-membered ring containing the groups G and Z. D is -C(O)-N(R6)-, -NR6-C(O)-, -NR6-C(O)-N(R6)-, -NR6-C(S)-N(R6)-, -C(S)-N(R6)- or -C(R6):N-N(R6)-, where the divalent residues representing D are bonded to the group E via the free bond on their right side. E is a residue from the series consisting of possibly substituted 2-pyrimidinyl, pyrrolyl, 2-imidazolyl, 2-imidazolin-2-yl, 2-pyridinyl many other N heterocycles, R6-C(:NR6)-NR6-, and R6R6'N-C(:NR6)-. G is N, CH or C((C1-C4)alkyl). X is H, -NR6R6', F, Cl, Br, -OR6, -SR6, hydroxy-(C1-C6)alkyl-NH-, (hydroxy-(C1-C6)alkyl)2N-, amino-(C1-C6)alkyl-NH-, (amino-(C1-C6)alkyl)2N-, hydroxy-(C1-C6)alkyl-O-, hydroxy-(C1-C6)alkyl-S- or -NH-C(O)-R6. Y has one of the meanings of R6 or is F, Cl, Br, CN, -NR6R6', -OR6, -SR6 or hydroxy-(C1-C6)alkyl-NH-. Z is N or CH. R1 is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl-(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl-(C1-C8)alkyl, where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of F, Cl, Br, CN, CF₃, NO₂, CO₂H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C8)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, (C1-C6)alkylaminosulfonyl, (C5-C14)arylaminosulfonyl, (C5-C14)aryl-(C1-C8)alkylaminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl-(C1-C8)alkylsulfonyl, (C5-C14)aryl and (C5-C14)heteroaryl. R2 is -C(O)R5, -C(S)R5, -S(O)pR5, -P(O)R5R5' or a residue of a 4-membered to 8-membered saturated or unsatd. heterocycle which contains 1-4 heteroatoms from the series consisting of N, O and S. R5 and R5' are OH, (C1-C8)alkoxy, (C5-C14)aryl-(C1-C8)alkoxy, (C1-C8)alkylcarbonyloxy-(C1-C4)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyloxy(C1-C8)alkoxy- or -NR6R6', where the residues R5' and R5' are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl where in the aryl residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or (C5-C14)aryl-(C1-C8)alkyl, where in the aryl moiety of the arylalkyl residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or R6 and R6' together with the N atom to which they are bonded form a 4-8-membered ring system which in addition to the N atom to which R6 and R6' are bonded can contain 1-3 ring heteroatoms N, O and S and which can be unsatd. or saturated, where all residues R6 and R6' are independent of one another and can be identical or different. R = 0-4; s = 0-4; v = 1-3; p = 1-2. The present invention also relates to stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure

shown in I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compns. comprising them. The process for the preparation comprises reacting II (L1 = leaving group; R15 = R1SO2 or an amino protecting group) with III or IV; B, D, E, G, X, R2 and s are as defined above but functional groups can also be present in the form of precursor groups or in protected form. For example, (2S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester was reacted with piperidine-4-carboxylic acid in the presence of N,O-bis(trimethylsilyl)acetamide to give 1-(9-((2S)-2-benzyloxycarbonylamino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid, which was reacted with 2-amino-1,4,5,6-tetrahydropyrimidine hydrochloride to give (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester, which was deprotected at N, N-sulfonated by various sulfonyl chlorides and hydrolyzed to give products such as (2S)-2-(naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid.

IT 315212-30-7P, 1-(9-((2S)-2-Benzyloxycarbonylamino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid
 315212-31-8P, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-32-9P, (2S)-2-Amino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-33-0P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-34-1P, (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-35-2P, (2S)-2-(4-tert-Butylbenzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-36-3P, (2S)-2-(n-Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-37-4P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid tert-butyl ester 315212-38-5P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(3-trifluoromethylbenzenesulfonylamino)propionic acid tert-butyl ester 315212-39-6P, (2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-40-9P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-trifluoromethanesulfonylamino)propionic acid tert-butyl ester 315212-41-0P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(2,2,2-trifluoroethanesulfonylamino)propionic acid tert-butyl ester 315212-42-1P, 1-(9-((2S)-2-Amino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid 315212-43-2P,


1-(9-((2S)-2-tert-Butoxycarbonyl-2-(2-methylpropane-1-sulfonylamino)ethyl)purin-6-yl)piperidine-4-carboxylic acid **315212-44-3P**, (2S)-2-(2-Methylpropane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester **315212-45-4P**, 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(toluene-4-sulfonylamino)ethyl)purin-6-yl)piperidine-4-carboxylic acid **315212-46-5P**, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)-2-(toluene-4-sulfonylamino)propionic acid tert-butyl ester **315212-47-6P**, 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(2,4,6-trimethylbenzenesulfonylamino)ethyl)purin-6-yl)piperidine-4-carboxylic acid **315212-48-7P**, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)-2-(2,4,6-trimethylbenzenesulfonylamino)propionic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; substituted purine derivs., method of preparation and use as inhibitors of cell adhesion)

RN 315212-30-7 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)- α -[[phenylmethoxy)carbonyl]amino]-, α -(1,1-dimethylethyl) ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-31-8 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[phenylmethoxy)carbonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-32-9 CAPLUS

CN 9H-Purine-9-propanoic acid, α-amino-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-33-0 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(1-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-34-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(2-naphthalenylsulfonyl)amino]-6-[4-[[[1,4,5,6-tetrahydro-2-pyrimidinyl]amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-35-2 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-6-[4-[[[1,4,5,6-tetrahydro-2-pyrimidinyl]amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-36-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(propylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-37-4 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-38-5 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]- α -[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-39-6 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[[(phenylmethyl)sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-40-9 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[(trifluoromethyl)sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-41-0 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[(2,2,2-trifluoroethyl)sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-42-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α-amino-6-(4-carboxy-1-piperidinyl)-, α-(1,1-dimethylethyl) ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-43-2 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)-α-[(2-methylpropyl)sulfonyl]amino]-, α-(1,1-dimethylethyl) ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-44-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[(2-methylpropyl)sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-45-4 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)-α-[[[(4-methylphenyl)sulfonyl]amino]-, α-(1,1-dimethylethyl) ester, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-46-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[4-methylphenyl)sulfonyl]amino]-6-[4-[[[1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-47-6 CAPLUS


CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)-α-[[[2,4,6-trimethylphenyl)sulfonyl]amino]-, α-(1,1-dimethylethyl) ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315212-48-7 CAPLUS
 CN 9H-Purine-9-propanoic acid, 6-[4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]-α-[(2,4,6-trimethylphenyl)sulfonyl]amino-, 1,1-dimethylethyl ester, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 315212-18-1P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyle)piperidin-1-yl)purin-9-yl)propionic acid 315212-19-2P, (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyle)piperidin-1-yl)purin-9-yl)propionic acid 315212-20-5P, (2S)-2-(4-tert-Butylbenzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyle)piperidin-1-yl)purin-9-yl)propionic acid 315212-21-6P, (2S)-2-(Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyle)piperidin-1-yl)purin-9-yl)propionic acid 315212-22-7P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyle)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid 315212-23-8P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyle)piperidin-1-yl)purin-9-yl)-2-(3-

trifluoromethylbenzenesulfonylamino)propionic acid **315212-24-9P**,
 (2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)propionic acid **315212-25-0P**,
 (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)-2-trifluoromethanesulfonylamino)propionic acid **315212-26-1P**,
 (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)-2-(2,2,2-trifluoroethanesulfonylamino)propionic acid **315212-27-2P**,
 (2S)-2-(2-Methylpropane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)propionic acid **315212-28-3P**,
 (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)-2-(toluene-4-sulfonylamino)propionic acid **315212-29-4P**,
 (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)piperidin-1-yl)purin-9-yl)-2-(2,4,6-trimethylbenzenesulfonylamino)propionic acid


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(substituted purine derivs., method of preparation and use as inhibitors of cell adhesion)

RN 315212-18-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[(1-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-19-2 CAPLUS


CN 9H-Purine-9-propanoic acid, α -[(2-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 315212-20-5 CAPLUS
 CN 9H-Purine-9-propanoic acid, α-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-6-[4-[[1,4,5,6-tetrahydro-2-pyrimidinyl]amino]carbonyl]-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315212-21-6 CAPLUS
 CN 9H-Purine-9-propanoic acid, α-[(propylsulfonyl)amino]-6-[4-[[1,4,5,6-tetrahydro-2-pyrimidinyl]amino]carbonyl]-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-22-7 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]]-α-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-23-8 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]]-α-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-24-9 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[(phenylmethyl) sulfonyl] amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl) amino] carbonyl]-1-piperidinyl]-, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-25-0 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl) amino] carbonyl]-1-piperidinyl]-α-[[[(trifluoromethyl) sulfonyl] amino]-, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-26-1 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[(2,2,2-trifluoroethyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-27-2 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[(2-methylpropyl)sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-28-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[4-methylphenyl)sulfonyl]amino]-6-[4-[[[1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-29-4 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[2,4,6-trimethylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:641626 CAPLUS

DOCUMENT NUMBER: 133:344177

TITLE: Vitronectin receptor antagonists: purine-based peptidomimetics

AUTHOR(S): Peyman, Anusch; Gourvest, Jean-Francois; Gadek, Thomas R.; Knolle, Jochen

CORPORATE SOURCE: Aventis Pharma, Medicinal Chemistry G838, Frankfurt, 65926, Germany

SOURCE: Angewandte Chemie, International Edition (2000), 39(16), 2874-2877

CODEN: ACIEF5; ISSN: 1433-7851

PUBLISHER: Wiley-VCH Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors introduce the purine scaffold in the design and synthesis of selective antagonists of $\alpha v \beta 3$ (vitronectin receptor) and present structure-activity relationship within this series.


IT 304859-59-4P 304859-60-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(vitronectin receptor antagonists)

RN 304859-59-4 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(4,5-dihydro-1H-imidazol-2-yl)amino]methyl]-1-piperidinyl]- α -[[[(phenylmethoxy)carbonyl]amino]-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 304859-60-7 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[4,5-dihydro-1H-imidazol-2-yl]amino]methyl]-1-piperidinyl]-α-[[[phenylmethoxy]carbonyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil caplus;s 13/p
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
191.47	362.04

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
------------	-------

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CA SUBSCRIBER PRICE	ENTRY -3.65	SESSION -3.65
---------------------	----------------	------------------

FILE 'CAPLUS' ENTERED AT 12:33:13 ON 29 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2005 VOL 143 ISS 23
 FILE LAST UPDATED: 28 Nov 2005 (20051128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L50 366 L3/P

=> s l50 and pharm? comp?

546229 PHARM?

11016462 COMP?

31297 PHARM? COMP?

(PHARM?(W)COMP?)

L51 14 L50 AND PHARM? COMP?

=> d 1-14 ibib abs hitstr

L51 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:612301 CAPLUS

DOCUMENT NUMBER: 143:153230

TITLE: Preparation of substituted purines and other bicyclic heterocycles as p-38 kinase inhibitors

INVENTOR(S): Dong, Qing; Wang, Jianqiang; Lan, Jiong; Lang, Hengyuan

PATENT ASSIGNEE(S): Triad Therapeutics, Inc., USA; Novartis Pharma AG

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063766	A2	20050714	WO 2004-US43682	20041223
WO 2005063766	A3	20050909		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-532529P

P 20031223



US 2004-575113P

P 20040528

OTHER SOURCE(S):

MARPAT 143:153230

GI



AB The present invention discloses preparation of bicyclic heterocyclic compds., such as I [R¹ = halo, alkyl, cycloalkyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, NR₄R₅, OR₄; R² = alkyl, cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, CN, NR₄R₅, OR₄, etc.; R³ = H, alkyl, cycloalkyl, OR₄, heteroaryl, heterocycle; R₄, R₅ = H, alkyl, cycloalkyl; n = 0-2; Y = C(:O)NH, NHC(:O), NHC(:O)NH, SO₂NH, NHSO₂, CO; X¹ = single bond, alkylene, O, S, SO₂, CO, CONH; A = bicyclic heterocycle; X² = single bond, alkylene, O, S, NH, alkylamino, SO₂, CO, CONH; D = monocyclic or bicyclic aromatic or nonarom. ring containing up to four heteroatoms], or a pharmaceutically acceptable derivs. thereof, for their therapeutic use as p38 kinase, including p38 α and p38 β kinase, inhibitors. Thus, N-cyclopropyl-3-hydrazino-4-methyl-benzamide (also prepared) was reacted with aminomalononitrile p-toluene sulfonate to afford 3-(5-amino-4-cyanoimidazol-1-yl)-N-cyclopropyl-4-methyl-benzamide, which on reaction with phenylmagnesium bromide, provided 3-(5-amino-4-benzoyl-imidazol-1-yl)-N-cyclopropyl-4-methyl-benzamide (II). A mixture of benzamide derivative II, formamide and acetic acid was heated in the microwave to afford purine derivative III. **Pharmaceutical compns.** containing I are also provided. Methods of treatment, prevention or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders are also provided.

IT 858358-46-0P 858358-48-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted purines and other bicyclic heterocycles as p-38

kinase inhibitors for the treatment of inflammatory disease, autoimmune disease etc.)


RN 858358-46-0 CAPLUS

CN Benzoic acid, 4-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 858358-48-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[4-(hydroxymethyl)phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)



IT 858358-07-3P 858358-08-4P 858358-09-5P
 858358-10-8P 858358-11-9P 858358-13-1P
 858358-14-2P 858358-15-3P 858358-16-4P
 858358-17-5P 858358-18-6P 858358-19-7P
 858358-21-1P 858358-22-2P 858358-23-3P
 858358-24-4P 858358-25-5P 858358-26-6P
 858358-27-7P 858358-28-8P 858358-29-9P
 858358-30-2P 858358-31-3P 858358-32-4P
 858358-33-5P 858358-34-6P 858358-35-7P
 858358-36-8P 858358-37-9P 858358-38-0P
 858358-39-1P 858358-41-5P 858358-42-6P
 858358-43-7P 858358-44-8P 858358-45-9P
 858358-47-1P 858358-49-3P 858358-50-6P
 858358-51-7P 858358-52-8P 858358-53-9P
 858358-57-3P 858358-58-4P 858358-59-5P
 858358-60-8P 858358-61-9P 858358-69-7P
 858358-70-0P 858358-71-1P 858358-73-3P
 858358-79-9P 858358-89-1P 858358-91-5P


858358-97-1P 858359-03-2P 858359-07-6P
 858359-09-8P 858359-11-2P 858359-12-3P
 858359-13-4P 858359-15-6P 858359-16-7P
 858359-17-8P 858359-18-9P 858359-19-0P
 858359-20-3P 858359-21-4P 858359-32-7P
 858359-33-8P 858359-34-9P 858359-35-0P
 858359-37-2P 858359-38-3P 858359-39-4P
 858359-40-7P 858359-41-8P 858359-42-9P
 858359-43-0P 858359-44-1P 858359-45-2P
 858359-46-3P 858359-47-4P 858359-48-5P
 858359-50-9P 858359-51-0P 858359-52-1P
 858359-55-4P 859511-90-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted purines and other bicyclic heterocycles as p-38 kinase inhibitors for the treatment of inflammatory disease, autoimmune disease etc.)


RN 858358-07-3 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-(6-phenyl-9H-purin-9-yl)- (9CI) (CA INDEX NAME)




RN 858358-08-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(3-fluorophenyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-09-5 CAPLUS

CN Benzamide, 3-[6-(3-chlorophenyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-10-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-(8-methyl-6-phenyl-9H-purin-9-yl)-(9CI) (CA INDEX NAME)




RN 858358-11-9 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-(methylthio)phenyl]-9H-purin-9-yl]-(9CI) (CA INDEX NAME)




RN 858358-13-1 CAPLUS

CN Benzamide, 3-[6-[3-[(cyclopentylamino)carbonyl]phenyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl-(9CI) (CA INDEX NAME)




RN 858358-14-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[3-[(cyclopropylamino)carbonyl]phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-15-3 CAPLUS

CN Benzamide, 3-[6-(1,3-benzodioxol-5-yl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-16-4 CAPLUS

CN Benzamide, N-cyclopropyl-3-[9-[3-[(cyclopropylamino)carbonyl]phenyl]-9H-purin-6-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-17-5 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-(9-phenyl-9H-purin-6-yl)- (9CI) (CA INDEX NAME)




RN 858358-18-6 CAPLUS

CN Benzamide, 3-(6-cyclohexyl-9H-purin-9-yl)-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-19-7 CAPLUS

CN Benzamide, 3-(6-cyclopentyl-9H-purin-9-yl)-N-cyclopropyl-4-methyl- (9CI)
(CA INDEX NAME)




RN 858358-21-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2-fluoro-3-methoxyphenyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-22-2 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[2-(trifluoromethyl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-23-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(4-methoxyphenyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-24-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(3-methylphenyl)-9H-purin-9-yl]-
(9CI) (CA INDEX NAME)




RN 858358-25-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(3-methoxyphenyl)-9H-purin-9-yl]-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-26-6 CAPLUS

CN Benzamide, 3-[6-[3-(aminocarbonyl)phenyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-27-7 CAPLUS

CN Benzamide, 3-[6-(4-cyanophenyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-28-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-methylphenyl)-9H-purin-9-yl]-
(9CI) (CA INDEX NAME)




RN 858358-29-9 CAPLUS

CN Benzamide, 3-[6-[2-(aminocarbonyl)phenyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-30-2 CAPLUS

CN Benzamide, 3-[6-[4-(aminocarbonyl)phenyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-31-3 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(6-methoxy-3-pyridinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-32-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[3-[(methylsulfonyl)amino]phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-33-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(4-fluorophenyl)-9H-purin-9-yl]-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-34-6 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(5-pyrimidinyl)-9H-purin-9-yl]-
(9CI) (CA INDEX NAME)




RN 858358-35-7 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-methylphenyl)-9H-purin-9-yl]-
(9CI) (CA INDEX NAME)




RN 858358-36-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(3-pyridinyl)-9H-purin-9-yl]- (9CI)
(CA INDEX NAME)




RN 858358-37-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2-fluorophenyl)-9H-purin-9-yl]-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-38-0 CAPLUS

CN Benzamide, 3,3'-(9H-purine-6,9-diyl)bis[N-cyclopropyl-4-methyl- (9CI) (CA
INDEX NAME)




RN 858358-39-1 CAPLUS

CN Benzamide, 3-[6-(3-cyanophenyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-41-5 CAPLUS

CN Benzamide, 3-[6-(2-cyanophenyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-42-6 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2,4-difluorophenyl)-9H-purin-9-yl]-4-methyl-
(9CI) (CA INDEX NAME)




RN 858358-43-7 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[3-(1H-1,2,4-triazol-3-yl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-44-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2,3-dihydro-1,4-benzodioxin-6-yl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-45-9 CAPLUS

CN Benzamide, 3-[6-(2-chlorophenyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-47-1 CAPLUS

CN Benzoic acid, 3-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 858358-49-3 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-[(methylsulfonyl)amino]phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-50-6 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2,3-difluorophenyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-51-7 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[3-(methylsulfonyl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-52-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-(methylsulfonyl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-53-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[3-(hydroxymethyl)phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-57-3 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-methyl-1-piperidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-58-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(3-methyl-1-piperidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-59-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(hexahydro-1(2H)-azocinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-60-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(1-pyrrolidinyl)-9H-purin-9-yl]-
(9CI) (CA INDEX NAME)




RN 858358-61-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(hexahydro-1H-azepin-1-yl)-9H-purin-9-yl]-4-
methyl- (9CI) (CA INDEX NAME)




RN 858358-69-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-
methylphenyl]-9H-purin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858358-70-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 858358-71-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)




RN 858358-73-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)




RN 858358-79-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2-ethyl-1-piperidinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-89-1 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-methyl-1-pyrrolidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-91-5 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(tetrahydro-1,4-oxazepin-4(5H)-yl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858358-97-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-03-2 CAPLUS


CN Benzamide, N-cyclopropyl-3-[6-(3-fluoro-1-piperidinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-07-6 CAPLUS


CN Benzamide, N-cyclopropyl-3-[6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858359-09-8 CAPLUS


CN Benzamide, 3-[6-[3-(acetylamino)-1-pyrrolidinyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-11-2 CAPLUS



CN 2-Pyrrolidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858359-12-3 CAPLUS


CN Benzamide, 3-[6-(7-azabicyclo[2.2.1]hept-7-yl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)



RN 858359-13-4 CAPLUS


CN Benzamide, N-cyclopropyl-3-[6-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]-9H-purin-9-yl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 858359-15-6 CAPLUS


CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(1-piperidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)



RN 858359-16-7 CAPLUS


CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-morpholinyl)-9H-purin-9-yl]-

(9CI) (CA INDEX NAME)




RN 858359-17-8 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(4-ethyl-1-piperazinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-18-9 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-methyl-1-piperidiny1)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-19-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-(2,6-dimethyl-4-morpholinyl)-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-20-3 CAPLUS

CN Benzamide, 3-[6-(4-acetyl-1-piperazinyl)-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-21-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(4-methyl-1-piperazinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-32-7 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[2-[(dimethylamino)methyl]-1-piperidinyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-33-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)




RN 858359-34-9 CAPLUS

CN Benzamide, 3-[6-[3-(acetymethylamino)-1-pyrrolidinyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-35-0 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[(6-phenyl-9H-purin-9-yl)methyl]- (9CI) (CA INDEX NAME)




RN 858359-37-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-(6-cyclopropyl-9H-purin-9-yl)-4-methyl- (9CI)
(CA INDEX NAME)




RN 858359-38-3 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(tetrahydro-2H-pyran-4-yl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-39-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-(4-morpholinylmethyl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-40-7 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[4-[(dimethylamino)methyl]phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-41-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-[(methylamino)methyl]phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-42-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[4-[(cyclopropylamino)carbonyl]phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-43-0 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-(1,3,4-oxadiazol-2-yl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-44-1 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-45-2 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[4-(5-ethyl-1,3,4-oxadiazol-2-yl)phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-46-3 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[3-(1,3,4-oxadiazol-2-yl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-47-4 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)




RN 858359-48-5 CAPLUS

CN Benzamide, N-cyclopropyl-3-[6-[3-(5-ethyl-1,3,4-oxadiazol-2-yl)phenyl]-9H-purin-9-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858359-50-9 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-pyridinyl)-9H-purin-9-yl]- (9CI)
(CA INDEX NAME)




RN 858359-51-0 CAPLUS


CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-pyrimidinyl)-9H-purin-9-yl]-
(9CI) (CA INDEX NAME)




RN 858359-52-1 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-[6-(2-thiazolyl)-9H-purin-9-yl]- (9CI)
 (CA INDEX NAME)



RN 858359-55-4 CAPLUS
 CN Benzamide, N-cyclopropyl-3-[6-(2-methoxyphenyl)-9H-purin-9-yl]-4-methyl-
 (9CI) (CA INDEX NAME)



RN 859511-90-3 CAPLUS
 CN Benzamide, N-cyclopropyl-4-methyl-3-[6-[2-(4-morpholinyl)phenyl]-9H-purin-
 9-yl]- (9CI) (CA INDEX NAME)




IT 858359-60-1P 858359-61-2P 858359-62-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted purines and other bicyclic heterocycles as p-38 kinase inhibitors for the treatment of inflammatory disease, autoimmune disease etc.)


RN 858359-60-1 CAPLUS

CN Benzoic acid, 4-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)




RN 858359-61-2 CAPLUS

CN Benzoic acid, 4-[9-[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]-9H-purin-6-yl]-, hydrazide (9CI) (CA INDEX NAME)



RN 858359-62-3 CAPLUS

CN Benzamide, 3-[6-[4-(bromomethyl)phenyl]-9H-purin-9-yl]-N-cyclopropyl-4-methyl- (9CI) (CA INDEX NAME)



L51 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1079848 CAPLUS

DOCUMENT NUMBER: 142:56277

TITLE: Preparation of 3-guanidinocarbonyl heterocyclic derivatives as NHE (sodium/hydrogen exchanger) inhibitors, and their **pharmaceutical compositions** used as cytoprotective agents

INVENTOR(S): Carry, Jean Christophe; Mignani, Serge; Evers, Michel; Doerflinger, Gilles; Genevois, Borella Arielle; Le, Brun Alain; Martin, Jean Paul; Desmazeau, Pascal; Kleemann, Heinz Werner

PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.

SOURCE: Fr. Demande, 59 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856062	A1	20041217	FR 2003-7080	20030612
FR 2856062	B1	20051111		
WO 2004111048	A1	20041223	WO 2004-EP5764	20040528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005014758 A1 20050120 US 2004-865454 20040610

PRIORITY APPLN. INFO.: FR 2003-7080 A 20030612


US 2003-497281P P 20030822

OTHER SOURCE(S): MARPAT 142:56277

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [wherein X, Y, Z, V = independently CR2 or N, with the proviso that one or two of them = N; R2 = H, halo, cyclo/perfluoro/sulfonyl/hydroxy/dialkylamino/alkyl, OH and derivs., etc.; R1 = (un)substituted hetero/aryl, cyclo/polyfluoro/aryl/heteroaryl/alkyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, benzothiazolyl, benzimidazolyl, indolyl, 7-aza-indolyl, pyrrolo[2,3-d]pyrimidinyl; their racemics, enantiomers, diastereomers and their mixts., their tautomers and pharmaceutically acceptable salts], in particular containing pyrrolo[2,3-b]pyridine core, were prepared as NHE (sodium/hydrogen exchanger) inhibitors, in particular NHE-1 inhibitors. For example, II•HCl was prepared, in 4 steps, by amination of 4-Chloro-2-methylquinoline with Me 1H-pyrrolo[2,3-b]pyridine-3-carboxylate (preparation given), ester hydrolysis, reaction with SOCl2, and substitution of the acyl chloride with guanidine hydrochloride. Selected I exhibited IC50 < 100 µM in a FLIPR (fluorescent imaging plate reader) test. Thus, I and their pharmaceutical formulations are useful for as cytoprotective agents.
- IT 808138-45-6P, N-[[1-(7-Methylpyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]guanidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (NHE inhibitor; preparation of 3-guanidinocarbonyl heterocyclic derivs., in particular containing pyrrolo[2,3-b]pyridine core, as cytoprotective agents via condensation)
- RN 808138-45-6 CAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-(aminoiminomethyl)-1-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:718539 CAPLUS

DOCUMENT NUMBER: 141:243568

TITLE: Preparation of 1-[(3-pyridinyl)carbonyl]pyrrolidine derivatives as immunosuppressants

INVENTOR(S): Baxter, Andrew; King, Sarah; Pimm, Austen; Reuberson,

James
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074287	A1	20040902	WO 2004-SE215	20040218
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:



SE 2003-457

A 20030219

OTHER SOURCE(S):

MARPAT 141:243568

GI




AB The title compds. [I; A = 4-6 membered saturated ring; R1 = H, alkyl, halo, NR4R5, X(alkyl); X = O, S, NR4; R2 = H, alkyl; R3 = (un)substituted Ph, 5-6 membered heteroaryl with one or more N atoms, (un)saturated bicyclic

system containing one or more heteroatoms, 5-6 membered heteroaryl containing one or more heteroatoms; R4, R5 = H, alkyl, hydroxyalkyl] and their pharmaceutically acceptable salts, were prepared E.g., a multi-step synthesis of II, was given. The compds. I were tested for inhibition of PMA/ionomycin-stimulated peripheral blood mononuclear cell proliferation (data were given for representative compds. I). Processes for the preparation of the compds. I together with **pharmaceutical compns.** containing them and their use in therapy in particular in effecting immunosuppression are also described.

IT 749908-38-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1-[(3-pyridinyl)carbonyl]pyrrolidine derivs. as immunosuppressants)

RN 749908-38-1 CAPLUS
 CN Pyrrolidine, 1-[[5-chloro-6-[4-(9-methyl-9H-purin-6-yl)-1-piperazinyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:696368 CAPLUS
 DOCUMENT NUMBER: 141:225546
 TITLE: Preparation of heteroaryl substituted pyrroles useful as inhibitors of protein kinases
 INVENTOR(S): Aronov, Alex; Hale, Michael R.; Maltais, Francois; Tang, Qing
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072063	A1	20040826	WO 2004-US3026	20040203
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515132	AA	20040826	CA 2004-2515132	20040203
PRIORITY APPLN. INFO.:			US 2003-445962P	P 20030207
			US 2003-463847P	P 20030418
			WO 2004-US3026	W 20040203
OTHER SOURCE(S):		MARPAT 141:225546		
GI				



AB The title compds. [I; A = N, CR_x; U = a bond, O, S, NR, etc.; R = H, alkyl; or two R on the same N atom are taken together with the N atom attached thereto to form 4-8 membered (un)saturated or aryl ring having 1-4 heteroatoms selected from N, O or S; R₄ = R, CN, NO₂, halo, NR₂, SR, OR; R₃ = H, (un)substituted alkyl, COR, CO₂R, SO₂R; R₂ = (CH₂)_yX, (CH₂)_yCHX₂, etc. (wherein y = 0-6; X = CN, R, Ar, OR, OAr, etc.); R₁ = CN, R, Ar, etc.; Ar = (un)substituted 5-7 membered (un)saturated monocyclic ring having 0-4 heteroatoms or 8-10 membered (un)saturated bicyclic ring having 0-4 heteroatoms; Rx = R, halo, CN, NO₂, etc.; Q = a bond, O, S, NR, etc.; with proviso] that are inhibitors of protein kinase, particularly inhibitors of ERK2, GSK3, PKA, CDK2 protein kinases, mammalian protein kinases involved in proliferative and neurodegenerative disorders, were prepared. Thus, amidation 4-(6-phenylaminopyrimidin-4-yl)-1H-pyrrole-2-carboxylic acid with (S)-3-chlorophenylglycinol hydrochloride afforded II. The invention also provides **pharmaceutical compns.** comprising the compds. I and methods of utilizing those compns. in the treatment of various disorders.

IT 746673-68-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl substituted pyrroles useful as inhibitors of protein kinases)

RN 746673-68-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L51 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:680002 CAPLUS

DOCUMENT NUMBER: 141:206968

TITLE: Process for preparation of new purine derivatives, their application as drugs, **pharmaceutical compositions** containing them, and new uses for them

INVENTOR(S): Bordon, Pallier Florence; Haesslein, Jean Luc

PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.

SOURCE: Fr. Demande, 91 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2851248	A1	20040820	FR 2003-1915	20030218
FR 2851248	B1	20050408		
CA 2515610	AA	20040902	CA 2004-2515610	20040213
WO 2004073595	A2	20040902	WO 2004-FR330	20040213
WO 2004073595	A3	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				

GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1597258 A2 20051123 EP 2004-710901 20040213
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRIORITY APPLN. INFO.: FR 2003-1915 A 20030218
 WO 2004-FR330 W 20040213
 OTHER SOURCE(S): CASREACT 141:206968; MARPAT 141:206968
 GI



I




II

AB The invention has as an aim new products I [Y = N, O, S, CHR₃, :CR₃; the dotted lines = single or double bond; R, R₁ = H, halo, OH, alkyl, alkoxy, CN, NO₂, NR₄R₅, CF₃, CF₃O, aryl, heteroaryl, S(O)_nNR₄R₅; n = 0 - 2; R₃ = H, halo, alkyl, CN, NO₂, NR₄R₅, CF₃, aryl; R₂ = R₄, OR₄, SR₄ or NR₄R₅; R₄ = H, alkyl, cycloalkyl, aryl; either R₄ and R₅ is selected among the values of R₄ or heterocyclic containing N, O and S, all optionally substituted], these products being in all the isomer forms - racemates, enantiomers or diastereomers - and pharmaceutically acceptable salts, for use as drugs. Thus, trans-N-[6-(5,6-dichloro-1H-benzimidazol-1-yl)9H-purin-2-yl]-1,4-cyclohexanediamine (II·HCl) was prepared, from 2,6-dichloropurine via amination with 5,6-dichloro-1H-benzimidazole in BuOH followed by fusion with trans-1,4-diaminocyclohexane. The protein kinase inhibitory activity of II·HCl was determined [IC₅₀ = 1.3 μM vs CIV-CDK; 98% inhibition SRC kinase @ 20 μM; 93% inhibition CDK1 @ 20 μM; 98% inhibition ZAP kinase @ 20 μM; 93% inhibition casein kinase II @ 20 μM; 100% inhibition AKT kinase @ 20 μM; IC₅₀ = 2 μM vs FAK kinase; IC₅₀ = 0.84 μM vs JNK3 kinase].


IT 741261-56-3P 741261-58-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and amination of, by cyclohexanediamine; preparation of new purine derivs. with protein kinase inhibitory activity)

RN 741261-56-3 CAPLUS
 CN 9H-Purine, 2-chloro-6-[6-(phenylmethoxy)-1H-benzimidazol-1-yl]-9-[[2-(trimethylsilyl)ethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 741261-58-5 CAPLUS

CN 9H-Purine, 2-chloro-6-[5-(phenylmethoxy)-1H-benzimidazol-1-yl]-9-[[2-(trimethylsilyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:493703 CAPLUS

DOCUMENT NUMBER: 141:54356

TITLE: Preparation of 1,3-dihydroimidazole fused-ring compounds as dipeptidylpeptidase IV (DPP-IV) inhibitors

INVENTOR(S): Kira, Kazunobu; Clark, Richard; Yoshikawa, Seiji; Uehara, Taisuke

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050656	A1	20040617	WO 2003-JP15402	20031202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,				

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2507763 AA 20040617 CA 2003-2507763 20031202
 EP 1568699 A1 20050831 EP 2003-812368 20031202
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003016991 A 20051025 BR 2003-16991 20031202
 PRIORITY APPLN. INFO.: JP 2002-352186 A 20021204
 WO 2003-JP15402 W 20031202
 OTHER SOURCE(S): MARPAT 141:54356
 GI




AB Title compds. I [wherein T1 = (un)substituted 1-2 nitrogen containing cyclic ring; X1 = (un)substituted alkyl, alkenyl, (hetero)allyl, etc.; X3 = O, S, (un)substituted amino; Z1 = N or CR3; Z2, Z3 = independently N, CR1, CO, NR2; R1-R3, X2 = H, (un)substituted heterocyclic ring or (un)substituted alkylene; and their salts or hydrates thereof] were prepared as dipeptidylpeptidase IV (DPP-IV) inhibitors. For example, II•CF3CO2H was prepared in 6-steps synthesis starting from 3,7-dihydro-3-methyl-1H-purine-2,6-dione. I showed DPP-IV inhibition with the IC50 value of 0.0029-89.5 μ M. Thus, I and their **pharmaceutical compns.** are useful as DPP-IV inhibitors for the treatment of diabetes mellitus, obesity, hyperlipemia, and etc. (no data).

IT 121370-57-8P 121370-98-7P 705300-59-0P
 705300-70-5P 705300-81-8P 705300-82-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 7,9-dihdropurine and 2,3-dihydroimidazo[4,5-c]pyridine derivs. as DPP-IV inhibitors)


RN 121370-57-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(9-methyl-9H-purin-6-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 121370-98-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-chloro-9-methyl-9H-purin-6-yl)-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705300-59-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2,8-dichloro-9-methyl-9H-purin-6-yl)-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705300-70-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(8-chloro-9-methyl-9H-purin-6-yl)-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 705300-81-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[9-[(2-cyanophenyl)methyl]-9H-purin-6-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 705300-82-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[8-chloro-9-[(2-cyanophenyl)methyl]-9H-purin-6-yl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:307614 CAPLUS

DOCUMENT NUMBER: 140:332509

TITLE: **Pharmaceutical compositions**
containing spiroisoquinolines as small-conductance
calcium-activated potassium channel (SK channel)
blockers and acetylcholine esterase inhibitors

INVENTOR(S): Takamuro, Iwao; Honma, Koichi; Ishida, Akihiko;
Taniguchi, Hiroyuki; Onoda, Yuichi

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 334 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004115450	A2	20040415	JP 2002-282311	20020927
PRIORITY APPLN. INFO.:			JP 2002-282311	20020927
OTHER SOURCE(S):	MARPAT	140:332509		

GI



I

AB Title compns., useful for treatment of digestive tract function failure, central nervous disorders, myotonic dystrophy, etc., contain

spiroisoquinolines I [ring A may be substituted; R10 = H, ZR1; R1 = H, (un)substituted lower alkyl, (un)substituted lower alkenyl; Y, Z = CH2, CO; R2 H, (un)substituted heterocyclyl; B = N, CH; R3 = (un)substituted NH2, (un)substituted N-containing aliphatic heterocyclyl] or their pharmacol. acceptable salts as active ingredients. Thus, (1R*,2R*(S*),4R*)-2'-[3-(methylamino)propionyl]-3',4'-dihydro-6',7'-dimethoxy-2-(2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolyl)-4-[4-[1-(4-pyridylmethyl)-1H-pyrazolol-[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl-spiro[cyclohexane-1,1'(2'H)isoquinoline] difumarate inhibited binding of 125I-apamin to SK channel in guinea pigs with IC50 value of 0.05 μ M.

IT 470428-23-0P 470428-56-9P 470428-95-6P
470430-29-6P 470430-33-2P 470430-37-6P
470438-20-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of spiroisoquinolines as small-conductance Ca2+-activated K+ channel blockers and acetylcholine esterase inhibitors for treatment of diseases)

RN 470428-23-0 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(9-methyl-9H-purin-6-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel-, (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470428-56-9 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-4-[[4-(9-butyl-9H-purin-6-yl)-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470428-95-6 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl)methyl-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-29-6 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(9-methyl-9H-purin-6-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-33-2 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-(9-butyl-9H-purin-6-yl)-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470430-37-6 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 470438-20-1 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470430-37-6

CMF C45 H60 N8 O6

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



L51 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:2886 CAPLUS

DOCUMENT NUMBER: 140:77157

TITLE: Preparation of novel purine- or pyrrolo[2,3-d]pyrimidine-2-carbonitriles for treating diseases associated with cysteine protease activity

INVENTOR(S): Bailey, Andrew; Pairaudeau, Garry; Patel, Anil; Thom, Stephen

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000843	A1	20031231	WO 2003-SE1079	20030623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1532148	A1	20050525	EP 2003-761002	20030623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

JP 2005533804	T2	20051110	JP 2004-515329	20030623
US 2005203107	A1	20050915	US 2004-518815	20041220
PRIORITY APPLN. INFO.:			SE 2002-1980	A 20020624
			WO 2003-SE1079	W 20030623

OTHER SOURCE(S): MARPAT 140:77157
GI



AB The title compds. [I; X = N, NH, CH, CH₂; Y = N, CH, CO, CH₂, CNR₂R₃ (wherein R₂, R₃ = H, alkyl, cycloalkyl); R = (un)substituted (hetero)aryl, H, alkyl, cycloalkyl, etc.; R₁ = Z(CH₂)_pR₇ (wherein p = 0-2; Z = O, NR₈; R₈ = H, alkyl, cycloalkyl; R₇ = (un)substituted 5-6 membered saturated ring containing one or more O, S or N atoms, aryl or heteroaryl), NR₉R₁₀ (R₉, R₁₀ = H, alkyl, etc.; or NR₉R₁₀ = (un)substituted 5-6 membered saturated ring optionally containing a further O, S or N atom)] which are reversible inhibitors of cysteine proteases S, K, F, L and B (no data), and therefore useful for treating diseases associated with cysteine protease activity

(especially

diseases associated with Cathepsin S), were prepared Thus, a 4-step synthesis of 1-[9-(4-chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide (starting from 4-chloroaniline and 5-amino-4,6-dichloro-2-propylthiopyrimidine), was given. **Pharmaceutical composition** comprising the compound I is claimed.


IT 640285-25-2P 640285-26-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of purine- or pyrrolo[2,3-d]pyrimidine-2-carbonitriles for treating diseases associated with cysteine protease activity)


RN 640285-25-2 CAPLUS

CN 9H-Purine, 9-(2-chlorophenyl)-6-(4-morpholinyl)-2-(propylthio)- (9CI) (CA INDEX NAME)



RN 640285-26-3 CAPLUS

CN 9H-Purine, 9-(2-chlorophenyl)-6-(4-morpholinyl)-2-(propylsulfonyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:950987 CAPLUS
 DOCUMENT NUMBER: 140:4840
 TITLE: Preparation of arylalkylamines as calcium receptor modulators for treatment of hyperparathyroidism and osteoporosis
 INVENTOR(S): Kelly, Michael G.; Xu, Shimin; Xi, Ning; Miller, Philip; Kincaid, John F.; Ghiron, Chiara; Coulter, Thomas
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 300 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099776	A1	20031204	WO 2003-US16401	20030523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004082625	A1	20040429	US 2003-444946	20030522
US 6908935	B2	20050621		
CA 2486399	AA	20031204	CA 2003-2486399	20030523
EP 1509497	A1	20050302	EP 2003-729111	20030523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005527625	T2	20050915	JP 2004-507434	20030523
US 2005143426	A1	20050630	US 2005-61084	20050218
PRIORITY APPLN. INFO.:				
			US 2002-383050P	P 20020523
			US 2003-441065P	P 20030117
			US 2003-444946	A 20030522
			WO 2003-US16401	W 20030523

OTHER SOURCE(S) : MARPAT 140:4840
GI



AB Title compds. I [wherein R1, R6 = independently (un)substituted aryl, heterocyclyl, cycloalkyl; R2 = (halo)alkyl; R3, R4 = independently H, (halo)alkyl; R5 = independently (un)substituted alkyl, or alkoxy, halo, CO2H, CN, NRdSO1-2Rd, NRdCONRdRd, NRdSO1-2NRdRd, NRdCORD; Rd = independently H or (un)substituted (ar)alkyl, aryl, heterocyclyl(alkyl); p = 0-4; with provisos; and pharmaceutically acceptable salts thereof] were prepared as calcium receptor modulators to reduce or inhibit parathyroid hormone (PTH) secretion. For example, 4-amino-3-bromobenzaldehyde was alkylated with MeOH in the presence of NaBH4 to give 2-bromo-4-hydroxymethylaniline (89%). Palladium catalyzed coupling with 4-methoxybenzeneboronic acid provided 4-hydroxymethyl-2-(4-methoxyphenyl)aniline (89%), which was O-protected with tri-isopropylsilyl chloride. Amidation with acetic anhydride, deprotection using tetrabutylammonium fluoride in THF, and reduction with MnO2 in acetone afforded 6-acetamido-3-(4-methoxyphenyl)benzaldehyde. Reaction of the aldehyde with (R)- α -methylbenzylamine gave the title benzylamine II. Invention compds. were assayed and exhibited activity against the human parathyroid cell Ca2+ receptor (hPCaR) transfected into HEK 293 cells with EC50 \leq 10 μ M. Thus, I and their **pharmaceutical compns.** are useful for the treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism.

IT 628713-53-1P, (1R)-1-(4-Methylphenyl)-N-[[3-(9-methyl-9H-purin-6-yl)phenyl]methyl]ethanamine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hPCaR modulator; preparation of arylalkylamines as hPCaR modulators for treatment of bone disorders and hyperparathyroidism)

RN 628713-53-1 CAPLUS

CN Benzenemethanamine, α ,4-dimethyl-N-[[3-(9-methyl-9H-purin-6-yl)phenyl]methyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:837045 CAPLUS

DOCUMENT NUMBER: 139:337995

TITLE: Preparation of benzamides as histone deacetylase inhibitors

INVENTOR(S): Stokes, Elaine Sophie Elizabeth; Roberts, Craig Anthony; Waring, Michael James

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087057	A1	20031023	WO 2003-GB1442	20030402
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2480356	AA	20031023	CA 2003-2480356	20030402
BR 2003008875	A	20050104	BR 2003-8875	20030402
EP 1495002	A1	20050112	EP 2003-712442	20030402
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005171103	A1	20050804	US 2003-509941	20030402
JP 2005533011	T2	20051104	JP 2003-584013	20030402
NO 2004004444	A	20041228	NO 2004-4444	20041019
PRIORITY APPLN. INFO.:			GB 2002-7863	A 20020405
			GB 2002-29930	A 20021221
			WO 2003-GB1442	W 20030402

OTHER SOURCE(S) : MARPAT 139:337995
GI



AB The title compds. [I; ring A = heterocycllyl; m = 0-4; R1 = OH, halo, CF3, CN, etc.; R2 = halo; n = 0-2; R3 = NH2, OH; R4 = OH, halo, CF3, CN, etc.; p = 0-4; or pharmaceutically-acceptable salts or in-vivo-hydrolysable esters or amides thereof], useful in the treatment of diseases or medical conditions mediated by histone deacetylase such as cancer, were prepared Thus, deprotection of N-(2-tert-butoxycarbonylamino-phenyl)-4-(pyridin-4-yl)benzamide (preparation given) with 4M HCl solution in dioxane afforded 46% I.HCl [A = pyridin-4-yl; R2 = H; R3 = NH2; R4 = H]. The compds. I showed IC50 of < 50.0 μ M in in vitro enzyme assay of pooled histone deacetylases. **Pharmaceutical composition** comprising the compound I is claimed.


IT 617702-34-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamides as histone deacetylase inhibitors)

RN 617702-34-8 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-(9-methyl-9H-purin-6-yl)- (9CI) (CA INDEX NAME)




IT 617703-29-4P 617703-38-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzamides as histone deacetylase inhibitors)


RN 617703-29-4 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-(9-methyl-9H-purin-6-yl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 617703-38-5 CAPLUS

CN Carbamic acid, [2-[[4-(9-methyl-9H-purin-6-yl)benzoyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:10663 CAPLUS

DOCUMENT NUMBER: 134:71601

TITLE: Substituted purine derivatives, method of preparation and use as inhibitors of cell adhesion

INVENTOR(S): Knolle, Jochen; Peyman, Anuschirwan; Gourvest,

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PATENT ASSIGNEE(S): Jean-Francois; Ruxer, Jean-Marie; Gadek, Thomas R.
 Aventis Pharma Deutschland G.m.b.H., Germany;
 Genentech, Inc.
 SOURCE: Eur. Pat. Appl., 41 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065208	A1	20010103	EP 1999-112637	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2376673	AA	20010111	CA 2000-2376673	20000626
WO 2001002399	A1	20010111	WO 2000-EP5921	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1196416	A1	20020417	EP 2000-940406	20000626
EP 1196416	B1	20040324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103858	T2	20020621	TR 2001-200103858	20000626
BR 2000012050	A	20021231	BR 2000-12050	20000626
JP 2003503497	T2	20030128	JP 2001-507836	20000626
EE 200100713	A	20030415	EE 2001-713	20000626
AT 262528	E	20040415	AT 2000-940406	20000626
AU 774382	B2	20040624	AU 2000-55349	20000626
NZ 516095	A	20040827	NZ 2000-516095	20000626
ES 2219353	T3	20041201	ES 2000-940406	20000626
BG 106229	A	20020830	BG 2001-106229	20011217
NO 2001006403	A	20020301	NO 2001-6403	20011228
ZA 2002000017	A	20030102	ZA 2002-17	20020102
US 6747016	B1	20040608	US 2002-30290	20020306
PRIORITY APPLN. INFO.:			EP 1999-112637	A 19990702
			WO 2000-EP5921	W 20000626
OTHER SOURCE(S):			MARPAT 134:71601	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to purine derivs. I. B is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl-(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl-(C1-C8)alkyl, F, Cl, Br, OH, CN, CF₃, NO₂, CO₂H, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C5-C14)arylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C1-C6)alkylsulfonylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, aminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl-(C1-C8)alkylsulfonyl, (C5-C14)aryl or

(C5-C14)heteroaryl, where all residues B are independent of one another and can be identical or different, or B denotes an aromatic or nonarom. ring system that is fused to the 6-membered ring containing the groups G and Z. D is -C(O)-N(R6)-, -NR6-C(O)-, -NR6-C(O)-N(R6)-, -NR6-C(S)-N(R6)-, -C(S)-N(R6)- or -C(R6):N-N(R6)-, where the divalent residues representing D are bonded to the group E via the free bond on their right side. E is a residue from the series consisting of possibly substituted 2-pyrimidinyl, pyrrolyl, 2-imidazolyl, 2-imidazolin-2-yl, 2-pyridinyl many other N heterocycles, R6-C(:NR6)-NR6-, and R6R6'N-C(:NR6)-. G is N, CH or C((C1-C4)alkyl). X is H, -NR6R6', F, Cl, Br, -OR6, -SR6, hydroxy-(C1-C6)alkyl-NH-, (hydroxy-(C1-C6)alkyl)2N-, amino-(C1-C6)alkyl-NH-, (amino-(C1-C6)alkyl)2N-, hydroxy-(C1-C6)alkyl-O-, hydroxy-(C1-C6)alkyl-S- or -NH-C(O)-R6. Y has one of the meanings of R6 or is F, Cl, Br, CN, -NR6R6', -OR6, -SR6 or hydroxy-(C1-C6)alkyl-NH-. Z is N or CH. R1 is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl-(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl-(C1-C8)alkyl, where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of F, Cl, Br, CN, CF3, NO2, CO2H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy-(C1-C8)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy-(C1-C6)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyl, (C1-C6)alkylsulfonylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, (C1-C6)alkylaminosulfonyl, (C5-C14)arylaminosulfonyl, (C5-C14)aryl-(C1-C8)alkylaminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl-(C1-C8)alkylsulfonyl, (C5-C14)aryl and (C5-C14)heteroaryl. R2 is -C(O)R5, -C(S)R5, -S(O)pR5, -P(O)R5R5' or a residue of a 4-membered to 8-membered saturated or unsatd. heterocycle which contains 1-4 heteroatoms from the series consisting of N, O and S. R5 and R5' are OH, (C1-C8)alkoxy, (C5-C14)aryl-(C1-C8)alkoxy, (C1-C8)alkylcarbonyloxy-(C1-C4)alkoxy, (C5-C14)aryl-(C1-C8)alkylcarbonyloxy-(C1-C8)alkoxy- or -NR6R6', where the residues R5' and R5' are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl-(C1-C8)alkyl, (C5-C14)aryl where in the aryl residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or (C5-C14)aryl-(C1-C8)alkyl, where in the aryl moiety of the arylalkyl residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or R6 and R6' together with the N atom to which they are bonded form a 4-8-membered ring system which in addition to the N atom to which R6 and R6' are bonded can contain 1-3 ring heteroatoms N, O and S and which can be unsatd. or saturated, where all residues R6 and R6' are independent of one another and can be identical or different. R = 0-4; s = 0-4; v = 1-3; p = 1-2. The present invention also relates to stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure shown in I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of I, their use, in particular as active ingredients in pharmaceuticals, and **pharmaceutical compns.** comprising them. The process for the preparation comprises

reacting II (L1 = leaving group; R15 = R1SO₂ or an amino protecting group) with III or IV; B, D, E, G, X, R2 and s are as defined above but functional groups can also be present in the form of precursor groups or in protected form. For example, (2S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester was reacted with piperidine-4-carboxylic acid in the presence of N,O-bis(trimethylsilyl)acetamide to give 1-(9-((2S)-2-benzyloxycarbonylamino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid, which was reacted with 2-amino-1,4,5,6-tetrahydropyrimidine hydrochloride to give (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester, which was deprotected at N, N-sulfonated by various sulfonyl chlorides and hydrolyzed to give products such as (2S)-2-(naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid.

IT 315212-30-7P, 1-(9-((2S)-2-Benzyloxycarbonylamino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid
 315212-31-8P, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-32-9P, (2S)-2-Amino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-33-0P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-34-1P, (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-35-2P, (2S)-2-(4-tert-Butylbenzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-36-3P, (2S)-2-(n-Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-37-4P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid tert-butyl ester 315212-38-5P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(3-trifluoromethylbenzenesulfonylamino)propionic acid tert-butyl ester 315212-39-6P, (2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-40-9P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-trifluoromethanesulfonylamino)propionic acid tert-butyl ester 315212-41-0P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(2,2,2-trifluoroethanesulfonylamino)propionic acid tert-butyl ester 315212-42-1P, 1-(9-((2S)-2-Amino-2-tert-butoxycarbonylethyl)purin-6-yl)piperidine-4-carboxylic acid 315212-43-2P, 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(2-methylpropane-1-sulfonylamino)ethyl)purin-6-yl)piperidine-4-carboxylic acid 315212-44-3P, (2S)-2-(2-Methylpropane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315212-45-4P, 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(toluene-4-sulfonylamino)ethyl)purin-6-yl)piperidine-4-carboxylic acid 315212-46-5P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(toluene-4-sulfonylamino)propionic acid tert-butyl ester 315212-47-6P, 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(2,4,6-trimethylbenzenesulfonylamino)ethyl)purin-6-yl)piperidine-4-carboxylic acid 315212-48-7P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)piperidin-1-yl)purin-9-yl)-2-(2,4,6-

trimethylbenzenesulfonylamino)propionic acid tert-butyl ester


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; substituted purine derivs., method of preparation and use as inhibitors of cell adhesion)

RN 315212-30-7 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)- α -[[[(phenylmethoxy)carbonyl]amino]-, α -(1,1-dimethylethyl) ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-31-8 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[[(phenylmethoxy)carbonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-32-9 CAPLUS

CN 9H-Purine-9-propanoic acid, α -amino-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-33-0 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(1-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-34-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(2-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-35-2 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-6-[4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-36-3 CAPLUS


CN 9H-Purine-9-propanoic acid, α -[(propylsulfonyl)amino]-6-[4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 315212-37-4 CAPLUS
 CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315212-38-5 CAPLUS
 CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-39-6 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[(phenylmethyl) sulfonyl] amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl) amino] carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-40-9 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl) amino] carbonyl]-1-piperidinyl]-α-[[[(trifluoromethyl) sulfonyl] amino]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-41-0 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[2,2,2-trifluoroethyl)sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-42-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α-amino-6-(4-carboxy-1-piperidinyl)-, α-(1,1-dimethylethyl) ester, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-43-2 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)-α-[(2-methylpropyl)sulfonyl]amino]-, α-(1,1-dimethylethyl) ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-44-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(2-methylpropyl)sulfonyl]amino]-6-[4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-45-4 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)- α -[[4-methylphenyl)sulfonyl]amino]-, α -(1,1-dimethylethyl) ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-46-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[4-methylphenyl)sulfonyl]amino]-6-[4-[[1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, 1,1-dimethylethyl ester, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-47-6 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-(4-carboxy-1-piperidinyl)-α-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]-, α-(1,1-dimethylethyl) ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-48-7 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[(2,4,6-trimethylphenyl)sulfonyl]amino]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 315212-18-1P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)propionic acid 315212-19-2P, (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)propionic acid 315212-20-5P, (2S)-2-(4-tert-Butylbenzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)propionic acid 315212-21-6P, (2S)-2-(Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)propionic acid 315212-22-7P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid 315212-23-8P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)-2-(3-trifluoromethylbenzenesulfonylamino)propionic acid 315212-24-9P, (2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)propionic acid 315212-25-0P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)-2-trifluoromethanesulfonylamino)propionic acid 315212-26-1P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)-2-(2,2,2-trifluoroethanesulfonylamino)propionic acid 315212-27-2P, (2S)-2-(2-Methylpropane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)propionic acid 315212-28-3P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)-2-(toluene-4-sulfonylamino)propionic acid 315212-29-4P, (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoylethyl)carbamoyl)piperidin-1-yl)purin-9-yl)-2-(2,4,6-trimethylbenzenesulfonylamino)propionic acid

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(substituted purine derivs., method of preparation and use as inhibitors of cell adhesion)

RN 315212-18-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α -[[(1-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 315212-19-2 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(2-naphthalenylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-20-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (αS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-21-6 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(propylsulfonyl)amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-22-7 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-23-8 CAPLUS

CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315212-24-9 CAPLUS


CN 9H-Purine-9-propanoic acid, α-[[[(phenylmethyl)sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 315212-25-0 CAPLUS
 CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[(trifluoromethyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 315212-26-1 CAPLUS
 CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[(2,2,2-trifluoroethyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 315212-27-2 CAPLUS
 CN 9H-Purine-9-propanoic acid, α-[[[(2-methylpropyl)sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]]], (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 315212-28-3 CAPLUS
 CN 9H-Purine-9-propanoic acid, α-[[[(4-methylphenyl)sulfonyl]amino]-6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidiny]]], (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315212-29-4 CAPLUS
 CN 9H-Purine-9-propanoic acid, 6-[4-[[[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]carbonyl]-1-piperidinyl]-α-[[[2,4,6-trimethylphenyl)sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:10662 CAPLUS
 DOCUMENT NUMBER: 134:71600
 TITLE: Naphthyridine derivatives, processes for their preparation, their use as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compositions comprising them
 INVENTOR(S): Peyman, Anuschirwan; Scheunemann, Karl-Heinz;

Gourvest, Jean-Francois; Ruxer, Jean-Marie; Gadek, Thomas R.
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany;
 Genentech, Inc.
 SOURCE: Eur. Pat. Appl., 36 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1065207	A1	20010103	EP 1999-112636	19990702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2376668	AA	20010111	CA 2000-2376668	20000626
WO 2001002398	A1	20010111	WO 2000-EP5920	20000626
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012129	A	20020507	BR 2000-12129	20000626
EP 1210348	A1	20020605	EP 2000-945825	20000626
EP 1210348	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200103856	T2	20020621	TR 2001-200103856	20000626
JP 2003503496	T2	20030128	JP 2001-507835	20000626
NZ 516058	A	20030131	NZ 2000-516058	20000626
EE 200100711	A	20030415	EE 2001-711	20000626
AU 775386	B2	20040729	AU 2000-59787	20000626
TW 593319	B	20040621	TW 2000-89117925	20000901
BG 106257	A	20021031	BG 2001-106257	20011220
HR 2001000946	A1	20030228	HR 2001-946	20011221
NO 2001006404	A	20020301	NO 2001-6404	20011228
ZA 2002000016	A	20030102	ZA 2002-16	20020102
US 6743800	B1	20040601	US 2002-30301	20020320
HK 1050003	A1	20050429	HK 2003-102163	20030325
US 2004198718	A1	20041007	US 2004-808496	20040324
PRIORITY APPLN. INFO.:			EP 1999-112636	A 19990702
			WO 2000-EP5920	W 20000626
			US 2002-30301	A3 20020320

OTHER SOURCE(S): MARPAT 134:71600
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to compds. I. G is -(CR1R2)n-A-(CR1R2)m-(CR1R3)i-(CR1R2)q-R4. A is a direct bond, -C(O)NR5-, -NR5C(O)-, -C(O)-, -NR5-, -O-, -S-, -S(O)-, -S(O)2-, (C2-C4)alkynediyl, (C2-C4)alkenediyl, (C5-C14)arylene where in the arylene residue 1-5 ring C atoms can be replaced by heteroatoms N, O and S, or a divalent residue of a 3-7-membered saturated or unsatd. ring which can contain 1-2 ring heteroatoms

N, S and O and which can be monosubstituted or disubstituted by residues :O, :S and R3. B is (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, F, Cl, Br, OH, CN, CF3, NO2, CO2H, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C5-C14)arylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C1-C6)alkylsulfonylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, aminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl(C1-C8)alkylsulfonyl, (C5-C14)aryl or (C5-C14)heteroaryl, where all residues B are independent of one another and can be identical or different. X is H, NR6R6', F, Cl, Br, OR6, SR6, hydroxy(C1-C6)alkyl-NH-, (hydroxy(C1-C6)alkyl)2N-, amino(C1-C6)alkyl-NH-, (amino(C1-C6)alkyl)2N-, hydroxy(C1-C6)alkyl-O-, hydroxy(C1-C6)alkyl-S- or -NH-C(O)-R6. Y is R5, F, Cl, Br, CN, NR6R6', OR6, SR6 or hydroxy(C1-C6)alkyl-NH-. Z is N or CH. R1 and R2 are H, F, Cl, CN, NO2, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6-S(O)p-R7, R6S(O)2NHR7, R6OC(O)NHR7 or R6R6'N-R7, where all residues R1 and R2 are independent of one another and can be identical or different. R3 is H, F, Cl, CN, NO2, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl, (C5-C14)heteroaryl(C1-C8)alkyl, R6-O-R7, R6R6'N-R7, R6C(O)R7, R6OC(O)R7, R6N(R6')C(O)OR7, R6S(O)pN(R5)R7, R6OC(O)N(R5)R7, R6C(O)N(R5)R7, R6N(R6')C(O)N(R5)R7, R6N(R6')S(O)pN(R5)R7, R6S(O)pR7, R6SC(O)N(R5)R7, R6N(R6')C(O)R7 or R6N(R6')S(O)pR7, where alkyl can be monounsaturated or polyunsaturated and where alkyl, cycloalkyl, aryl, and heteroaryl can be monosubstituted or polysubstituted by R6, F, Cl, Br, CN, CF3, R6R6'NR7, NO2, R6OC(O)R7, R6C(O)R7, R6N(R6')C(O)R7, R6N(R6')S(O)pR7 or R6-O-R7, and where all residues R3 are independent of one another and can be identical or different. R4 is -C(O)R8, -C(S)R8, -S(O)pR8, -P(O)R8R8' or a residue of a 4-8-membered saturated or unsaturated heterocycle which contains 1-4 heteroatoms N, O and S. R5 is H, (C1-C10)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl or (C5-C14)aryl(C1-C8)alkyl, where all residues R5 are independent of one another and can be identical or different. R6 and R6' are H, (C1-C18)alkyl, (C3-C14)cycloalkyl, (C3-C14)cycloalkyl(C1-C8)alkyl, (C5-C14)aryl, (C5-C14)aryl(C1-C8)alkyl, (C5-C14)heteroaryl or (C5-C14)heteroaryl(C1-C8)alkyl where aryl, heteroaryl, cycloalkyl and alkyl can be substituted 1-3 times by identical or different substituents F, Cl, Br, CN, CF3, NO2, CO2H, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkylaminocarbonyl, (C1-C6)alkoxy(C1-C6)alkoxy, (C5-C14)arylcarbonyl, (C5-C14)aryl(C1-C8)alkylcarbonyl, (C1-C6)alkanoylamino, (C5-C14)arylsulfonylamino, (C1-C6)alkylsulfonylamino, (C1-C6)alkylamino, di((C1-C6)alkyl)amino, (C1-C6)alkylsulfonyl, (C1-C6)alkylaminosulfonyl, (C5-C14)arylaminosulfonyl, (C5-C14)aryl(C1-C8)alkylaminosulfonyl, (C5-C14)arylsulfonyl, (C5-C14)aryl(C1-C8)alkylsulfonyl, (C5-C14)aryl and (C5-C14)heteroaryl, and where all residues R6 and R6' are independent of one another and can be identical or different. R7 is (C1-C4)alkanediyl or a direct bond, where all residues R7 are independent of one another and can be identical or different. R8 and R8' are OH, (C1-C8)alkoxy, (C5-C14)aryl(C1-C8)alkoxy, (C5-C14)aryloxy, (C1-C8)alkylcarbonyloxy(C1-C4)alkoxy, (C5-C14)aryl(C1-C8)alkylcarbonyloxy(C1-C8)alkoxy, NR6R6', di((C1-C8)alkyl)amino)carbonylmethyloxy, di((C5-C14)aryl(C1-C8)alkyl)amino)carbonylmethyloxy, (C5-C14)arylmino, the residue of an amino acid, N-((C1-C4)alkyl)piperidin-4-yloxy, 2-methylsulfonylethoxy, 1,3-thiazol-2-ylmethyloxy, 3-pyridylmethyloxy, 2-(di((C1-

C4)alkyl)amino)ethoxy or the residue Q-(CH₃)₃N⁺-CH₂-CH₂-O- in which Q- is a physiol. tolerable anion, where all residues R₈ and R₈' are independent of one another and can be identical or different. N is 0-5; m is 0-5; i is 0-1; q is 0-2; r is 0-2; s is 0-3; t is 0-8; p is 0-2, where all nos. p are independent of one another and can be identical or different. The claimed compds. also include stereoisomeric forms and mixts. thereof in all ratios, and their physiol. tolerable salts and their prodrugs; where, instead of the purine structure shown I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present. I are valuable pharmacol. active compds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of I, their use, in particular as active ingredients in pharmaceuticals, and **pharmaceutical compns.** comprising them. The process of preparation comprises reacting II (L₁ = leaving group) with III or IV; B, G, X, Y, r, s and t are defined as above but wherein functional groups can also be present in the form of precursor groups or in protected form. For example, (2S)-2-benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-Bu ester could be made from 7-(piperidin-4-yl)-1,2,3,4-tetrahydro-1,8-naphthyridine and (S)-2-benzyloxycarbonylamino-3-(6-chloropurin-9-yl)propionic acid tert-Bu ester in DMF in the presence of NEt₃Pr₂; the ester was then hydrolyzed by CF₃CO₂H to give the desired compound

IT 315240-30-3P, (2S)-2-Benzyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315240-32-5P, (2S)-2-Amino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester 315240-34-7P, (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid tert-butyl ester


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; naphthyridine derivs., processes for preparation, uses as vitronectin receptor antagonists and inhibitors of cell adhesion, and **pharmaceutical compns.** comprising them)

RN 315240-30-3 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[(phenylmethoxy)carbonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-32-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α-amino-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-34-7 CAPLUS


CN 9H-Purine-9-propanoic acid, α-[(phenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, 1,1-dimethylethyl ester, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 315240-14-3P, (2S)-2-Benzoyloxycarbonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
 315240-16-5P, (2S)-2-Benzenesulfonylamino-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
 315240-18-7P, (2S)-2-(4-Chlorobenzenesulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
 315240-20-1P, (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
 315240-22-3P, (2S)-3-(6-(4-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)-2-(4-trifluoromethylbenzenesulfonylamino)propionic acid
 315240-24-5P, (2S)-2-(Butane-1-sulfonylamino)-3-(6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)purin-9-yl)propionic acid
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (naphthyridine derivs., processes for preparation, uses as vitronectin receptor antagonists and inhibitors of cell adhesion, and pharmaceutical compns. comprising them)
 RN 315240-14-3 CAPLUS
 CN 9H-Purine-9-propanoic acid, α -[[[(phenylmethoxy)carbonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-], (α S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-16-5 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(phenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidiny]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-18-7 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[[[4-chlorophenyl)sulfonyl]amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidiny]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-20-1 CAPLUS

CN 9H-Purine-9-propanoic acid, α-[(1-naphthalenylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 315240-22-3 CAPLUS


CN 9H-Purine-9-propanoic acid, 6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-α-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 315240-24-5 CAPLUS
 CN 9H-Purine-9-propanoic acid, α-[(butylsulfonyl)amino]-6-[4-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)-1-piperidinyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2000:493544 CAPLUS
 DOCUMENT NUMBER: 133:129892
 TITLE: High affinity enzyme inhibitors and therapeutic uses thereof
 INVENTOR(S): Shokat, Kevan M.
 PATENT ASSIGNEE(S): Princeton University, USA
 SOURCE: PCT Int. Appl., 169 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042042	A2	20000720	WO 2000-US551	20000111
WO 2000042042	A3	20001102		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2369895	AA	20000720	CA 2000-2369895	20000111
EP 1140938	A2	20011010	EP 2000-904268	20000111
EP 1140938	B1	20030827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6383790	B1	20020507	US 2000-480993	20000111
JP 2002534524	T2	20021015	JP 2000-593609	20000111
EP 1321467	A2	20030625	EP 2003-5036	20000111
EP 1321467	A3	20031008		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 248170	E	20030915	AT 2000-904268	20000111
ES 2206191	T3	20040516	ES 2000-904268	20000111
AU 779008	B2	20041223	AU 2000-26053	20000111
US 2003073218	A1	20030417	US 2002-44967	20020529
PRIORITY APPLN. INFO.:				
			US 1999-115340P	P 19990111
			US 1999-145422P	P 19990723
			EP 2000-904268	A3 20000111
			US 2000-480993	A1 20000111
			WO 2000-US551	W 20000111
AB	The invention provides general methods for discovering mutant inhibitors for any class of enzymes as well as the specific inhibitors so identified. More specifically, the invention provides general methods for discovering specific inhibitors for multi-substrate enzymes. Examples of such multi-substrate enzymes include, but are not limited to, kinases and transferases. The mutant inhibitors identified by the methods of the invention can be used to highly selectively disrupt cell functions such as oncogenic transformation. In one particular example, the invention provides an Src protein kinase inhibitor, pharmaceutical compns. thereof and methods of disrupting transformation in a cell that expresses the target v-src comprising contacting the cell with the protein kinase inhibitor.			
IT	206978-69-0P 206978-71-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (high affinity enzyme inhibitors and therapeutic uses)			
RN	206978-69-0 CAPLUS			
CN	9H-Purine, 9- [5-O- [hydroxy [[hydroxy (phosphonooxy) phosphinyl] oxy] phosphinyl] -β-D-ribofuranosyl] -6- (1-pyrrolidinyl) - (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 206978-71-4 CAPLUS

CN 9H-Purine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-6-(1-piperidinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L51 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1982:200111 CAPLUS

DOCUMENT NUMBER: 96:200111

TITLE: 1,4;3,6-Dianhydrohexitol nitrates substituted by purine bases and their **pharmaceutical compositions**

INVENTOR(S): Klessing, Klaus; Chatterjee, Shyam Sunder

PATENT ASSIGNEE(S): Dr. Wilmar Schwabe G.m.b.H., Fed. Rep. Ger.

SOURCE: Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 44928	A1	19820203	EP 1981-104476	19810611
EP 44928	B1	19850313		
R: AT, BE, CH, FR, GB, IT, NL, SE				
DE 3028273	A1	19820225	DE 1980-3028273	19800725
DE 3028273	C2	19891214		

AT 12117	E	19850315	AT 1981-104476	19810611
ES 503486	A1	19820516	ES 1981-503486	19810629
CA 1190544	A1	19850716	CA 1981-381368	19810708
US 4479951	A	19841030	US 1981-285406	19810720
JP 57064700	A2	19820419	JP 1981-116321	19810724
JP 02047476	B4	19901019		
US 4622324	A	19861111	US 1984-642140	19840817
PRIORITY APPLN. INFO.:			DE 1980-3028273	A 19800725
			EP 1981-104476	A 19810611
			US 1981-285406	A3 19810720
OTHER SOURCE(S):	CASREACT 96:200111			
GI				




AB The title compds. I (R = aminopurinyl, theophyllinyl) were prepared Thus 1,4:3,6-dianhydro-D-glucitol was mesylated and treated with adenine Na salt, followed by esterification with HNO₃, to give II. At 25 µg/mL II increased blood flow in the isolated guinea pig heart by 92.13%. II had a ED₅₀ against noradrenaline-induced spasms of 1.35 + 10⁻⁷ mol/L.

IT 81621-22-9P 81621-25-2P 81621-28-5P
81621-31-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and esterification of, with nitric acid)

RN 81621-22-9 CAPLUS


CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(1-pyrrolidinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 81621-25-2 CAPLUS
CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(1-piperidinyl)-9H-purin-9-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 81621-28-5 CAPLUS
CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(4-morpholinyl)-9H-purin-9-yl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81621-31-0 CAPLUS

CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(4-methyl-1-piperazinyl)-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 81621-23-0P 81621-26-3P 81621-29-6P
81621-32-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and pharmacol. activity of)

RN 81621-23-0 CAPLUS


CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(1-pyrrolidinyl)-9H-purin-9-yl]-, 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 81621-26-3 CAPLUS
 CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(1-piperidinyl)-9H-purin-9-yl]-,
 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 81621-29-6 CAPLUS
 CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(4-morpholinyl)-9H-purin-9-yl]-,
 5-nitrate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81621-32-1 CAPLUS

CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(4-methyl-1-piperazinyl)-9H-purin-9-yl]-, 5-nitrate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 81621-24-1P 81621-27-4P 81621-30-9P


81621-33-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 81621-24-1 CAPLUS

CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(1-pyrrolidinyl)-9H-purin-9-yl]-, 5-nitrate, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 81621-27-4 CAPLUS
 CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(1-piperidinyl)-9H-purin-9-yl]-, 5-nitrate, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 81621-30-9 CAPLUS
 CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(4-morpholinyl)-9H-purin-9-yl]-, 5-nitrate, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 81621-33-2 CAPLUS
 CN L-Iditol, 1,4:3,6-dianhydro-2-deoxy-2-[6-(4-methyl-1-piperazinyl)-9H-purin-9-yl]-, 5-nitrate, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

73.39

435.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-10.22	-13.87

FILE 'REGISTRY' ENTERED AT 12:33:57 ON 29 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1
 DICTIONARY FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.


```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> => d 154 que stat
 L52 STR



C @11

VAR G2=12/11

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

VAR G4=H/N/X/O/S/N

NODE ATTRIBUTES:

NSPEC IS R AT 11
 NSPEC IS R AT 12
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L54 3742 SEA FILE=REGISTRY SSS FUL L52

100.0% PROCESSED 12770 ITERATIONS

3742 ANSWERS

SEARCH TIME: 00.00.01

=> fil medl,biosis,embase,caplus;s l54

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
161.76	597.19

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-13.87

CA SUBSCRIBER PRICE

FILE 'MEDLINE' ENTERED AT 12:35:14 ON 29 NOV 2005

FILE 'BIOSIS' ENTERED AT 12:35:14 ON 29 NOV 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:35:14 ON 29 NOV 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 12:35:14 ON 29 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L55 0 FILE MEDLINE

L56 0 FILE BIOSIS

L57 0 FILE EMBASE

L58 95 FILE CAPLUS

TOTAL FOR ALL FILES

L59 95 L54

=> s (l13 or l18 or l23 or l28 or l33) and l59

L60 0 FILE MEDLINE

L61 0 FILE BIOSIS

L62 0 FILE EMBASE

L63 0 FILE CAPLUS

TOTAL FOR ALL FILES

L64 0 (L13 OR L18 OR L23 OR L28 OR L33) AND L59

=> fil caplus;s l54/p

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	227.52	824.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.87

FILE 'CAPLUS' ENTERED AT 12:35:55 ON 29 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2005 VOL 143 ISS 23
 FILE LAST UPDATED: 28 Nov 2005 (20051128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

L65 70 L54/P



=> s l65 and pharm? comp?
 546229 PHARM?
 11016462 COMP?
 31297 PHARM? COMP?
 (PHARM?(W)COMP?)
 L66 5 L65 AND PHARM? COMP?

=> d 1-5 ibib abs hitstr

L66 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:612301 CAPLUS
 DOCUMENT NUMBER: 143:153230
 TITLE: Preparation of substituted purines and other bicyclic heterocycles as p-38 kinase inhibitors
 INVENTOR(S): Dong, Qing; Wang, Jianqiang; Lan, Jiong; Lang, Hengyuan
 PATENT ASSIGNEE(S): Triad Therapeutics, Inc., USA; Novartis Pharma AG
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 2005063766 A2 20050714 WO 2004-US43682 20041223
 WO 2005063766 A3 20050909
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2003-532529P P 20031223
 US 2004-575113P P 20040528
 OTHER SOURCE(S): MARPAT 143:153230
 GI



AB The present invention discloses preparation of bicyclic heterocyclic compds., such as I [R¹ = halo, alkyl, cycloalkyl, alkynyl, haloalkyl, alkoxy, haloalkoxy, NR₄R₅, OR₄; R² = alkyl, cycloalkyl, halo, trifluoromethyl, trifluoromethoxy, CN, NR₄R₅, OR₄, etc.; R³ = H, alkyl, cycloalkyl, OR₄, heteroaryl, heterocycle; R₄, R₅ = H, alkyl, cycloalkyl; n = 0-2; Y = C(:O)NH, NHC(:O), NHC(:O)NH, SO₂NH, NHSO₂, CO; X¹ = single bond, alkylene, O, S, SO₂, CO, CONH; A = bicyclic heterocycle; X² = single bond, alkylene, O, S, NH, alkylamino, SO₂, CO, CONH; D = monocyclic or bicyclic aromatic or nonarom. ring containing up to four heteroatoms], or a pharmaceutically acceptable derivs. thereof, for their therapeutic use as p38 kinase, including p38 α and p38 β kinase, inhibitors. Thus, N-cyclopropyl-3-hydrazino-4-methyl-benzamide (also prepared) was reacted with aminomalononitrile p-toluene sulfonate to afford 3-(5-amino-4-cyanoimidazol-1-yl)-N-cyclopropyl-4-methyl-benzamide, which on reaction with phenylmagnesium bromide, provided 3-(5-amino-4-benzoyl-imidazol-1-yl)-N-cyclopropyl-4-methyl-benzamide (II). A mixture of benzamide derivative II, formamide and acetic acid was heated in the microwave to afford purine derivative III. **Pharmaceutical compns.** containing I are also provided. Methods of treatment, prevention or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders are also provided.


IT 53645-78-6P 858357-97-8P 858357-98-9P
858357-99-0P 858358-00-6P 858358-01-7P
858358-02-8P 858358-03-9P 858358-04-0P
858358-06-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted purines and other bicyclic heterocycles as p-38 kinase inhibitors for the treatment of inflammatory disease, autoimmune disease etc.)


RN 53645-78-6 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1,4-diphenyl- (9CI) (CA INDEX NAME)




RN 858357-97-8 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-(4-phenyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)- (9CI) (CA INDEX NAME)



RN 858357-98-9 CAPLUS


CN Benzamide, N-cyclopropyl-3-[4-(2-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858357-99-0 CAPLUS


CN Benzamide, N-cyclopropyl-4-methyl-3-[4-[4-(methylsulfonyl)phenyl]-1H-

pyrazolo[3,4-d]pyrimidin-1-yl]- (9CI) (CA INDEX NAME)




RN 858358-00-6 CAPLUS

CN Benzamide, N-cyclopropyl-3-[4-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858358-01-7 CAPLUS


CN Benzamide, N-cyclopropyl-3-[4-(3-iodophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858358-02-8 CAPLUS


CN Benzamide, N-cyclopropyl-4-methyl-3-[4-[3-[(4-methyl-1-

piperazinyl)methyl]phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl] - (9CI) (CA INDEX NAME)




RN 858358-03-9 CAPLUS

CN Benzamide, N-cyclopropyl-3-[4-(3-ethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 858358-04-0 CAPLUS

CN Benzamide, N-cyclopropyl-3-[4-(3-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 858358-06-2 CAPLUS

CN Benzamide, N-cyclopropyl-4-methyl-3-[4-[3-(1H-1,2,4-triazol-3-yl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1059356 CAPLUS

DOCUMENT NUMBER: 142:38272

TITLE: 4-Amino-substituted derivatives of
pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine
and their preparation, **pharmaceutical**
compositions, and use as antitumor and
antileukemic agents

INVENTOR(S): Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga;

Manetti, Fabrizio; Schenone, Silvia; Carraro, Fabio

PATENT ASSIGNEE(S): Universita Degli Studi di Siena, Italy

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106340	A2	20041209	WO 2004-IT303	20040526
WO 2004106340	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: IT 2003-RM263 A 20030528
IT 2003-RM264 A 20030528

OTHER SOURCE(S): MARPAT 142:38272

GI



AB 4-Amino-substituted pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivs., particularly I [X = CH or N; R = H, alkylthio, aminoalkylthio; R1 = NH-cyclopropyl, NHPr, NHBu, NEt2, NHCH2CH2OEt, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, NH-cyclohexyl, hexahydroazepin-1-yl, NHCH2Ph, NHCH2CH2Ph (others unclaimed); R2 = H, C6H4R3; R3 = H, halo, alkyl; R4 = CH2CH(R5)C6H4R3 or CH:CHC6H4R3; R5 = Cl, Br, OH], are described. I are inhibitors of cell proliferation in A431, 8701-BC, and leukemia cell lines, and are thus potential antitumor and antileukemic agents. Approx. 50 compds. I were tested in bioassays, and preparatory data for most of the compds. is given. For instance, Et 5-amino-1-(2-hydroxy-2-phenylethyl)-1H-pyrazole-4-carboxylate was thioacylated with benzoyl isothiocyanate (93%), cyclized with aqueous NaOH (80%), S-methylated with MeI (72%), and chlorinated at both the ring and sidechain with POCl3 and DMF (Vilsmeier complex) (65%), to give the chloride intermediate II. Reaction of II with PhCH2NH2 in PhMe at room temperature for 24 h gave 81% invention compound III. This compound inhibited

Src phosphorylation with almost the same efficacy as PP2. In regard to antiproliferative activity toward A431 cells, 11 compds. including III had IC50 values comparable to or better than PP2. Compds. I showed no cytotoxicity toward tested cell lines at 10 nM to 10 μ M when evaluated by trypan blue exclusion.

IT 679805-32-4P, 4-(Piperidin-1-yl)-1-(2-chloro-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine 679805-33-5P, 4-(Morpholin-4-yl)-1-(2-chloro-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine 679805-38-0P, 4-(Piperidin-1-yl)-1-(2-chloro-2-phenylethyl)-6-(ethylthio)-1H-pyrazolo[3,4-d]pyrimidine 679805-39-1P, 4-(Morpholin-4-yl)-1-(2-chloro-2-phenylethyl)-6-(ethylthio)-1H-pyrazolo[3,4-d]pyrimidine 679805-41-5P, 4-(Morpholin-4-yl)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidine 679805-43-7P, 4-(Piperidin-1-yl)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine 679805-44-8P, 4-(Morpholin-4-yl)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine 679805-46-0P, 4-(Hexahydroazepin-1-yl)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine


691390-36-0P, 4-(Pyrrolidin-1-yl)-1-(2-chloro-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine 691390-38-2P, 4-(Hexahydroazepin-1-yl)-1-(2-chloro-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine 716378-87-9P, 4-(Pyrrolidin-1-yl)-1-(2-chloro-2-phenylethyl)-6-(ethylthio)-1H-pyrazolo[3,4-d]pyrimidine 716378-91-5P, 4-(Pyrrolidin-1-yl)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine 716378-92-6P, 4-(Morpholin-4-yl)-6-(ethylthio)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine 716378-94-8P, 4-(Piperidin-1-yl)-6-(methylthio)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine 716378-95-9P, 4-(Morpholin-4-yl)-6-(methylthio)-1-(2-phenylvinyl)-1H-pyrazolo[3,4-d]pyrimidine 805326-13-0P, 4-(Piperidin-1-yl)-1-(2-hydroxy-2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidine 805326-28-7P, 1-(2-Bromo-2-phenylethyl)-4-(pyrrolidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine 805326-29-8P, 1-(2-Bromo-2-phenylethyl)-4-(piperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine 805326-30-1P, 1-(2-Bromo-2-phenylethyl)-4-(morpholin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine 805326-31-2P, 1-(2-Bromo-2-phenylethyl)-4-(hexahydroazepin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of amino-substituted pyrazolopyrimidine and pyrrolopyrimidine derivs. as antitumor and antileukemic agents)


RN 679805-32-4 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-6-(methylthio)-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 679805-33-5 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-6-(methylthio)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 679805-38-0 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-6-(ethylthio)-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 679805-39-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-6-(ethylthio)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 679805-41-5 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine-1-ethanol, 4-(4-morpholinyl)-α-phenyl- (9CI) (CA INDEX NAME)




RN 679805-43-7 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-phenylethenyl)-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 679805-44-8 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(4-morpholinyl)-1-(2-phenylethenyl)- (9CI)
 (CA INDEX NAME)



RN 679805-46-0 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(hexahydro-1H-azepin-1-yl)-1-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 691390-36-0 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-6-(methylthio)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 691390-38-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-4-(hexahydro-1H-azepin-1-yl)-6-(methylthio)- (9CI) (CA INDEX NAME)




RN 716378-87-9 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-6-(ethylthio)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 716378-91-5 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-phenylethenyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 716378-92-6 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 6-(ethylthio)-4-(4-morpholinyl)-1-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 716378-94-8 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-1-(2-phenylethenyl)-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 716378-95-9 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-4-(4-morpholinyl)-1-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 805326-13-0 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine-1-ethanol, α-phenyl-4-(1-piperidinyl)-
 (9CI) (CA INDEX NAME)




RN 805326-28-7 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-bromo-2-phenylethyl)-4-(1-pyrrolidinyl)-
 (9CI) (CA INDEX NAME)




RN 805326-29-8 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-bromo-2-phenylethyl)-4-(1-piperidinyl)-
 (9CI) (CA INDEX NAME)



RN 805326-30-1 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-bromo-2-phenylethyl)-4-(4-morpholinyl)-
(9CI) (CA INDEX NAME)



RN 805326-31-2 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-bromo-2-phenylethyl)-4-(hexahydro-1H-
azepin-1-yl)- (9CI) (CA INDEX NAME)




L66 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1059355 CAPLUS
DOCUMENT NUMBER: 142:38271
TITLE: 4-Amine-substituted derivatives of
pyrazolo[3,4-d]pyrimidine and their preparation,
pharmaceutical compositions, and use
as antitumor agents
INVENTOR(S): Bondavalli, Francesco; Botta, Maurizio; Manetti,
Fabrizio; Donnini, Sandra; Schenone, Silvia; Ziche,
Marina

PATENT ASSIGNEE(S): Universita Degli Studi di Siena, Italy
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004106339	A2	20041209	WO 2004-IT302	20040526
WO 2004106339	A3	20050217		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IT 2003-RM263 A 20030528
 IT 2003-RM264 A 20030528

GI




AB Title compds. I [R1 = cyclopropylamino, NHPr, pyrrolidin-1-yl, NHBu, NEt2, morpholin-4-yl, NHCH2CH2OEt, piperidin-1-yl, cyclohexylamino, hexahydroazepin-1-yl, NHCH2Ph, NHCH2CH2Ph; R2 = CH2CH(Cl)Ph] and I [R1 = cyclopropylamino; R2 = CH:CHPh] are described. The compds. are active as antitumor agents. In particular, I are inhibitors of tyrosine kinase activity linked to receptors involved in endothelial cell growth, such as VEGFR, FGFR, and EGFR. For example, cyclocondensation of 2-(2-hydroxy-2-phenylethyl)-3-amino-2H-pyrazole-4-carboxylic acid Et ester with formamide at 190° gave 1-(2-hydroxy-2-phenylethyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, which underwent chlorination of the hydroxy group and the ring carbonyl by POCl3 and DMF (Vilsmeier complex) to give the chloride intermediate II. Aminolysis of II with various amines in PhMe at room temperature for 36 h gave title compds. I [R2 = CH2CH(Cl)Ph] in 55-90% yield with high regioselectivity, i.e., no substitution of the sidechain chloride was observed. The compds. generally showed no toxic side effects on 3 tumor cell lines at 10 µM, but inhibited proliferation of two cell lines: A431 with a high d. of EGF receptors, and PAEC transfected with VEGFR2 receptors. In particular, I

[R1 = NHCH2Ph, R2 = CH2CH(Cl)Ph], one of 3 preferred compds., gave approx. 125% inhibition of PAEC proliferation compared to SU5614, a known VEGF receptor antagonist.

IT 805227-51-4P, 1-(2-Chloro-2-phenylethyl)-4-(pyrrolidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine 805227-54-7P, 1-(2-Chloro-2-phenylethyl)-4-(morpholin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine 805227-56-9P, 1-(2-Chloro-2-phenylethyl)-4-(piperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine 805227-58-1P, 1-(2-Chloro-2-phenylethyl)-4-(hexahydroazepin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of amine-substituted derivs. of pyrazolopyrimidine as antitumor agents)


RN 805227-51-4 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 805227-54-7 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 805227-56-9 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)





RN 805227-58-1 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-chloro-2-phenylethyl)-4-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)




L66 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:633436 CAPLUS
 DOCUMENT NUMBER: 141:174191
 TITLE: Preparation of pyrazolopyrimidines as a small conductance potassium channel (SK channel) blocking agents
 INVENTOR(S): Takamuro, Iwao; Sekine, Yasuo; Tsuboi, Yasunori; Nogi, Kouji; Taniguchi, Hiroyuki
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 306 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064721	A2	20040805	WO 2004-JP617	20040123
WO 2004064721	A3	20040923		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI, NI, NO				
JP 2005162726	A2	20050623	JP 2004-14376	20040122




Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733774-83-9 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(ethylamino)methyl]benzoyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 733774-87-3 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(methylamino)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 733774-88-4 CAPLUS
 CN Piperazine, 1-[(trans-4-(aminocyclohexyl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 733774-96-4 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl]amino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●3 HCl

RN 733775-29-6 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(propylamino)cyclohexyl]carbonyl]-, dihydrochloride (9CI)
(CA INDEX NAME)


Relative stereochemistry.



●2 HCl


RN 733778-35-3 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)



RN 733782-46-2 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(ethylamino)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 733782-48-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 733770-06-4P 733770-07-5P 733770-08-6P
 733770-09-7P 733770-11-1P 733770-12-2P
 733770-13-3P 733770-14-4P 733770-15-5P
 733770-16-6P 733770-17-7P 733770-18-8P
 733770-19-9P 733770-20-2P 733770-21-3P
 733770-22-4P 733770-23-5P 733770-24-6P
 733770-25-7P 733770-26-8P 733770-27-9P
 733770-29-1P 733770-30-4P 733770-31-5P
 733770-33-7P 733770-34-8P 733770-35-9P
 733770-36-0P 733770-37-1P 733770-38-2P
 733770-40-6P 733770-42-8P 733770-44-0P
 733770-46-2P 733770-48-4P 733770-49-5P
 733770-50-8P 733770-51-9P 733770-52-0P
 733770-53-1P 733770-54-2P 733770-55-3P
 733770-56-4P 733770-57-5P 733770-58-6P
 733770-59-7P 733770-60-0P 733770-61-1P
 733770-62-2P 733770-63-3P 733770-64-4P
 733770-65-5P 733770-66-6P 733770-67-7P
 733770-68-8P 733770-69-9P 733770-70-2P
 733770-71-3P 733770-72-4P 733770-73-5P
 733770-74-6P 733770-75-7P 733770-76-8P
 733770-77-9P 733770-78-0P 733770-79-1P
 733770-80-4P 733770-81-5P 733770-82-6P
 733770-83-7P 733770-84-8P 733770-85-9P
 733770-86-0P 733770-87-1P 733770-88-2P
 733770-89-3P 733770-90-6P 733770-91-7P
 733770-92-8P 733770-93-9P 733770-94-0P
 733770-95-1P 733770-96-2P 733770-97-3P
 733770-98-4P 733770-99-5P 733771-00-1P
 733771-01-2P 733771-02-3P 733771-03-4P
 733771-04-5P 733771-06-7P 733771-08-9P
 733771-10-3P 733771-12-5P 733771-14-7P
 733771-16-9P 733771-18-1P 733771-20-5P
 733771-22-7P 733771-24-9P 733771-26-1P
 733771-28-3P 733771-30-7P 733771-31-8P
 733771-32-9P 733771-33-0P 733771-34-1P
 733771-35-2P 733771-37-4P 733771-39-6P

733771-41-0P 733771-43-2P 733771-45-4P
 733771-47-6P 733771-49-8P 733771-51-2P
 733771-53-4P 733771-55-6P 733771-57-8P
 733771-59-0P 733771-60-3P 733771-61-4P
 733771-62-5P 733771-63-6P 733771-64-7P
 733771-65-8P 733771-66-9P 733771-67-0P
 733771-68-1P 733771-69-2P 733771-70-5P
 733771-71-6P 733771-72-7P 733771-73-8P
 733771-74-9P 733771-75-0P 733771-76-1P
 733771-77-2P 733771-78-3P 733771-79-4P
 733771-80-7P 733771-81-8P 733771-82-9P
 733771-83-0P 733771-84-1P 733771-85-2P
 733771-87-4P 733771-88-5P 733771-89-6P
 733771-90-9P 733771-91-0P 733771-92-1P
 733771-93-2P 733771-94-3P 733771-95-4P
 733771-96-5P 733771-97-6P 733771-98-7P
 733771-99-8P 733772-00-4P 733772-01-5P
 733772-02-6P 733772-03-7P 733772-04-8P
 733772-05-9P 733772-06-0P 733772-07-1P
 733772-08-2P 733772-09-3P 733772-10-6P
 733772-11-7P 733772-12-8P 733772-13-9P
 733772-14-0P 733772-15-1P 733772-16-2P
 733772-17-3P 733772-18-4P 733772-19-5P
 733772-20-8P 733772-21-9P 733772-22-0P
 733772-23-1P 733772-24-2P 733772-25-3P
 733772-26-4P 733772-27-5P 733772-28-6P
 733772-29-7P 733772-30-0P 733772-31-1P
 733772-32-2P 733772-33-3P 733772-34-4P
 733772-35-5P 733772-36-6P 733772-37-7P
 733772-38-8P 733772-39-9P 733772-40-2P
 733772-41-3P 733772-42-4P 733772-43-5P
 733772-44-6P 733772-45-7P 733772-46-8P
 733772-47-9P 733772-48-0P 733772-49-1P
 733772-50-4P 733772-51-5P 733772-52-6P
 733772-53-7P 733772-54-8P 733772-55-9P
 733772-56-0P 733772-57-1P 733772-58-2P
 733772-59-3P 733772-60-6P 733772-61-7P
 733772-62-8P 733772-63-9P 733772-64-0P
 733772-65-1P 733772-66-2P 733772-67-3P
 733772-68-4P 733772-69-5P 733772-70-8P
 733772-71-9P 733772-72-0P 733772-73-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolopyrimidines as a small conductance potassium channel
 (SK channel) blocking agents)


RN 733770-06-4 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733770-07-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl] - (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733770-08-6 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733770-09-7 CAPLUS

CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-11-1 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733770-10-0


CMF C34 H45 N9 O3




CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 733770-12-2 CAPLUS
CN Carbamic acid, [2-(dimethylamino)ethyl] [4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)




RN 733770-13-3 CAPLUS
CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-14-4 CAPLUS

CN Butanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-15-5 CAPLUS


CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 733770-16-6 CAPLUS
 CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2,2-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-17-7 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-18-8 CAPLUS

CN Acetamide, N- [2- (dimethylamino)ethyl] -N- [4- [[4- [1- [(3-ethoxyphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] -1-piperazinyl]carbonyl]phenyl] -2-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-19-9 CAPLUS

CN 2-Butenamide, N- [2- (dimethylamino)ethyl] -N- [4- [[4- [1- [(3-ethoxyphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] -1-piperazinyl]carbonyl]phenyl] -3-methyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-20-2 CAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733770-21-3 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733770-22-4 CAPLUS


CN Butanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-3,3-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 733770-23-5 CAPLUS
 CN Cyclopentanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






●x HCl

RN 733770-24-6 CAPLUS


CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl][(methoxymethyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazine, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733770-25-7 CAPLUS

CN Piperazine, 1-[4-[[[2-(dimethylamino)ethyl][(methoxymethyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazine, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-26-8 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl][[(2-methylpropyl)amino]thioxomethyl]amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-27-9 CAPLUS

CN Propanamide, 3-(diethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-29-1 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-30-4 CAPLUS

CN Pentanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-31-5 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 733770-33-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 733770-34-8 CAPLUS


CN Piperazine, 1-[4-[[[butylamino]carbonyl]-2-(dimethylamino)ethyl]amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)




RN 733770-35-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733770-36-0 CAPLUS
 CN Acetamide, 2-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 733770-37-1 CAPLUS


CN Propanamide, 3-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-38-2 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733770-40-6 CAPLUS
 CN Propanamide, 3-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 733770-42-8 CAPLUS


CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-44-0 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-propyl-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl


RN 733770-46-2 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-propyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 733770-48-4 CAPLUS
 CN Propanamide, 3-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-propyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-49-5 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-(2-ethoxyethyl)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-50-8 CAPLUS

CN Propanamide, 3-(diethylamino)-N-(2-ethoxyethyl)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-51-9 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-(2-ethoxyethyl)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-52-0 CAPLUS

CN Acetamide, 2-(diethylamino)-N-(2-ethoxyethyl)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-53-1 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733770-54-2 CAPLUS

CN Propanamide, 3-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 733770-55-3 CAPLUS


CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 733770-56-4 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 733770-57-5 CAPLUS

CN Pentanamide, N-[2-(dimethylamino)ethyl]-N-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 733770-58-6 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 733770-59-7 CAPLUS

CN Piperazine, 1-[4-[[[(dimethylamino)carbonyl][2-(dimethylamino)ethyl]amino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-60-0 CAPLUS


CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)



RN 733770-61-1 CAPLUS
 CN Piperazine, 1-[4-[[[(butylamino)carbonyl][2-(dimethylamino)ethyl]amino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)




RN 733770-62-2 CAPLUS
 CN Piperazine, 1-[3-[(dimethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)




RN 733770-63-3 CAPLUS

CN Piperazine, 1-[3-[(butylmethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-64-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[[2-methoxyethyl](1-methylethyl)amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 733770-65-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 733770-66-6 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-(1-pyrrolidinylmethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 733770-67-7 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-(1-piperidinylmethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 733770-68-8 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]propylamino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)






RN 733770-69-9 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl](2-methylpropyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-70-2 CAPLUS

CN Piperazine, 1-[4-[(cyclohexylmethyl)[2-(dimethylamino)ethyl]amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN	733770-71-3	CAPLUS
CN	Piperazine, 1-[4-[[[2-(dimethylamino)ethyl]methylamino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)	




RN 733770-72-4 CAPLUS

CN Piperazine, 1-[4-[[[2-(dimethylamino)ethyl]propylamino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-73-5 CAPLUS


CN Piperazine, 1-[4-[[[2-(dimethylamino)ethyl](2-methylpropyl)amino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733770-74-6 CAPLUS
 CN Piperazine, 1-[4-[[[(cyclohexylmethyl)[2-(dimethylamino)ethyl]amino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


PAGE 1-A






RN 733770-75-7 CAPLUS

CN Piperazine, 1-[4-[(diethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-76-8 CAPLUS

CN Piperazine, 1-[4-[(butylmethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-77-9 CAPLUS

CN Piperazine, 1-[4-[(butylethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl] - (9CI) (CA INDEX NAME)




RN 733770-78-0 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(2-methoxyethyl)(1-methylethyl)amino]methyl]benzoyl] - (9CI) (CA INDEX NAME)



RN 733770-79-1 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[ethyl(phenylmethyl)amino]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 733770-80-4 CAPLUS

CN Piperazine, 1-[4-[(cyclohexylmethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733770-81-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(1-pyrrolidinylmethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733770-82-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(1-piperidinylmethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733770-83-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733770-84-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[2-methoxyethyl)methylamino]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 733770-85-9 CAPLUS

CN Carbamic acid, [2-[[2-(dimethylamino)ethyl][4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 733770-86-0 CAPLUS

CN Piperazine, 1-[3-[[2-(diethylamino)ethyl](methanesulfonyl)amino]-4-methoxybenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-87-1 CAPLUS

CN Piperazine, 1-[[6-[(dimethylamino)methyl]-3-pyridinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733770-88-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[(ethylmethylamino)methyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733770-89-3 CAPLUS


CN Piperazine, 1-[[6-[(diethylamino)methyl]-3-pyridinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733770-90-6 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-(1-pyrrolidinylmethyl)-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733770-91-7 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-(1-piperidinylmethyl)-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733770-92-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[(4-methyl-1-piperazinyl)methyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733770-93-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[[[(2-methoxyethyl)(1-methylethyl)amino]methyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

●x HCl


RN 733770-94-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[[methyl(1-methylethyl)amino]methyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733770-95-1 CAPLUS


CN Piperazine, 1-[[6-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-3-pyridinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733770-96-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(1-propyl-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 733770-97-3 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(1-methylethyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)



RN 733770-98-4 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(4-pyridinyl)-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 733770-99-5 CAPLUS

CN Piperazine, 1-[4-(dimethylamino)-1-oxobutyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733771-00-1 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(1-methylethyl)-4-piperidiny]acetyl]- (9CI) (CA INDEX NAME)




RN 733771-01-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733771-02-3 CAPLUS

CN Piperazine, 1-[[trans-4-[(dimethylamino)methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733771-03-4 CAPLUS

CN Piperazine, 1-[[trans-4-(dimethylamino)cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733771-04-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(4-morpholinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733771-06-7 CAPLUS

CN Carbamic acid, [[4-[[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl][2-(dimethylamino)ethyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-05-6


CMF C34 H44 Cl N9 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-08-9 CAPLUS
CN Carbamic acid, [2-(dimethylamino)ethyl] [[4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-07-8
CMF C34 H46 N10 O3

PAGE 1-A




PAGE 2-A

Me

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-10-3 CAPLUS
CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-09-0
CMF C35 H48 N10 O3

PAGE 1-A



PAGE 2-A


Et

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-12-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-11-4

CMF C35 H47 N9 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 733771-14-7 CAPLUS


CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-13-6

CMF C35 H48 N10 O4

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-16-9 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl] [[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 733771-15-8
CMF C36 H49 N9 O4



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 733771-18-1 CAPLUS
CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-17-0
CMF C35 H44 F3 N9 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-20-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl] [[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-19-2

CMF C35 H46 F N9 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 733771-22-7 CAPLUS


CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 733771-21-6

CMF C34 H48 N10 O3 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 733771-24-9 CAPLUS


CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-23-8

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CMF C33 H46 N10 O3 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 733771-26-1 CAPLUS


CN Carbamic acid, [2-(dimethylamino)ethyl] [[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 733771-25-0

CMF C36 H50 N10 O3

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-28-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1


CRN 733771-27-2
CMF C36 H50 N10 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 733771-30-7 CAPLUS
CN Carbamic acid, [2-(dimethylamino)ethyl][[4-[[4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]-, 3-(dimethylamino)propyl ester, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-29-4
CMF C33 H47 N11 O3 S




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-31-8 CAPLUS


CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733771-32-9 CAPLUS
 CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-33-0 CAPLUS
 CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-34-1 CAPLUS

CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733771-35-2 CAPLUS

CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-37-4 CAPLUS
 CN Propanamide, N-[4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-36-3

CMF C32 H40 Cl N9 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 733771-39-6 CAPLUS


CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-38-5

CMF C33 H44 N10 O2

PAGE 1-A



PAGE 2-A


Et

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-41-0 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-40-9

CMF C32 H42 N10 O2

PAGE 1-A



PAGE 2-A


Me

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-43-2 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-42-1
 CMF C34 H46 N10 O2

PAGE 1-A




PAGE 2-A




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-45-4 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)
 CM 1
 CRN 733771-44-3
 CMF C33 H42 F N9 O2



CM 2
 CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 733771-47-6 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)
 CM 1
 CRN 733771-46-5

CMF C33 H44 N10 O3

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-49-8 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-48-7

CMF C33 H43 N9 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-51-2 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-50-1

CMF C33 H40 F3 N9 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-53-4 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-52-3

CMF C34 H46 N10 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-55-6 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-54-5

CMF C31 H43 N11 O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-57-8 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-56-7

CMF C31 H42 N10 O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-59-0 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 733771-58-9

CMF C32 H44 N10 O2 S




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 733771-60-3 CAPLUS

CN Piperazine, 1-[3-[4-[2-(dimethylamino)ethoxy]phenyl]-1-oxo-2-propenyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-61-4 CAPLUS
 CN Piperazine, 1-[3-[4-[3-(dimethylamino)propoxy]phenyl]-1-oxo-2-propenyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-62-5 CAPLUS
 CN Piperazine, 1-[1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl]-1-oxo-2-propenyl]-

(9CI) (CA INDEX NAME)



RN 733771-63-6 CAPLUS


CN Piperazine, 1-[3-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-64-7 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[2-(1-piperidinyl)ethoxy]benzoyl- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733771-65-8 CAPLUS
 CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-66-9 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(4-methyl-1-piperazinyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733771-67-0 CAPLUS
 CN Benzamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[2-(1-piperidinyl)ethyl]-, hydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733771-68-1 CAPLUS
 CN Benzamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733771-69-2 CAPLUS
 CN Benzamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733771-70-5 CAPLUS


CN Benzamide, N-[2-(diethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733771-71-6 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-[4-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 733771-72-7 CAPLUS

CN 1,2-Ethanediamine, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]-N,N',N'-trimethyl- (9CI)
(CA INDEX NAME)




RN 733771-73-8 CAPLUS

CN 1,2-Ethanediamine, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]-N',N'-diethyl-N-methyl- (9CI)
(CA INDEX NAME)




RN 733771-74-9 CAPLUS

CN Ethanamine, 2-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 733771-75-0 CAPLUS


CN Phenol, 2-[(diethylamino)methyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 733771-76-1 CAPLUS
 CN Phenol, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-2-methoxy-6-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 733771-77-2 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[2-[2-(4-morpholinyl)ethoxy]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)




RN 733771-78-3 CAPLUS
 CN Piperazine, 1-[2-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)




RN 733771-79-4 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-methoxy-4-[2-(4-morpholinyl)ethoxy]benzoyl]-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 733771-80-7 CAPLUS
 CN Piperazine, 1-[4-(dimethylamino)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-81-8 CAPLUS

CN Piperazine, 1-[3-(dimethylamino)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-82-9 CAPLUS

CN Piperazine, 1-[[4-(dimethylamino)phenyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-83-0 CAPLUS

CN Piperazine, 1-[[6-(dimethylamino)-2-naphthalenyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-84-1 CAPLUS

CN Piperazine, 1-[3-[4-(dimethylamino)phenyl]-1-oxo-2-propenyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-85-2 CAPLUS

CN Piperazine, 1-[4-[(2-ethoxyethyl)amino]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-87-4 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(2-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 733771-88-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 733771-89-6 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[[2-methoxyethyl)methylamino]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 733771-90-9 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-(4-morpholinylmethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 733771-91-0 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(4-morpholinylmethyl)benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733771-92-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-[1-(4-pyrimidinyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733771-93-2 CAPLUS
 CN 4-Morpholineacetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733771-94-3 CAPLUS
 CN 4-Morpholinepropanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733771-95-4 CAPLUS
 CN 4-Morpholinepropanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-propyl-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733771-96-5 CAPLUS
 CN Benzamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[2-(4-morpholinyl)ethyl]-, hydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733771-97-6 CAPLUS
 CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-98-7 CAPLUS

CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733771-99-8 CAPLUS

CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733772-00-4 CAPLUS

CN Piperazine, 1-[4-[(dimethylamino)methyl]benzoyl]-4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733772-01-5 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-[4-[4-methoxy-3-[2-(4-morpholinyl)ethoxy]phenyl)methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 733772-02-6 CAPLUS

CN Ethanol, 2-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 733772-03-7 CAPLUS

CN Urea, N'-butyl-N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733772-04-8 CAPLUS

CN Benzenamine, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 733772-05-9 CAPLUS

CN Ethanol, 2-[[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]methylamino]- (9CI) (CA INDEX NAME)



RN 733772-06-0 CAPLUS


CN Propanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 733772-07-1 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-08-2 CAPLUS


CN Pentanamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 733772-09-3 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]phenyl]-2-methoxy-
 (9CI) (CA INDEX NAME)




RN 733772-10-6 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-[4-[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 733772-11-7 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-[4-[[3-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-12-8 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-[4-[[3-[2-(4-morpholinyl)ethoxy]phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 733772-13-9 CAPLUS

CN Benzenamine, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 733772-14-0 CAPLUS

CN Benzenamine, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 733772-15-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-[4-[[4-(4-morpholinyl)phenyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 733772-16-2 CAPLUS

CN Phenol, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-2-methoxy-6-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 733772-17-3 CAPLUS

CN Phenol, 2-[(dimethylamino)methyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]methyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 733772-18-4 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 733772-19-5 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 733772-20-8 CAPLUS


CN Benzamide, N-[3-(dimethylamino)propyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 733772-21-9 CAPLUS

CN Benzamide, 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-22-0 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[[4-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 733772-23-1 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-methyl-4-[[4-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 733772-24-2 CAPLUS


CN Benzamide, N-[3-(dimethylamino)propyl]-4-[[4-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 733772-25-3 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[[4-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-26-4 CAPLUS
 CN 1-Pyrrolidineacetamide, N-(cyclohexylmethyl)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733772-27-5 CAPLUS
 CN Propanamide, N-(cyclohexylmethyl)-3-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733772-28-6 CAPLUS

CN 1-Pyrrolidinepropanamide, N-(cyclohexylmethyl)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733772-29-7 CAPLUS
 CN Propanamide, N-(cyclohexylmethyl)-3-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl


RN 733772-30-0 CAPLUS
 CN Acetamide, 2-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 733772-31-1 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






●x HCl

RN 733772-32-2 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 733772-33-3 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl


RN 733772-34-4 CAPLUS
 CN Propanamide, 3-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 733772-35-5 CAPLUS

CN Acetamide, N-(cyclohexylmethyl)-2-(dimethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN	733772-36-6	CAPLUS
CN	Acetamide, N-(cyclohexylmethyl)-2-(diethylamino)-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2 - A



●x HCl

RN 733772-37-7 CAPLUS
CN Piperazine, 1-[3-bromo-4-[(dimethylamino)methyl]benzoyl]-4-[1-[(3-


ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl

RN 733772-38-8 CAPLUS

CN Piperazine, 1-[3-bromo-4-[(diethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)




● 2 HCl


RN 733772-39-9 CAPLUS

CN Piperazine, 1-[3-bromo-4-(1-pyrrolidinylmethyl)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●2 HCl


RN 733772-40-2 CAPLUS
 CN Piperazine, 1-[4-[(dimethylamino)methyl]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733772-41-3 CAPLUS


CN Piperazine, 1-[[1-[(dimethylamino)acetyl]-4-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733772-42-4 CAPLUS

CN Piperazine, 1-[[1-[3-(dimethylamino)-1-oxopropyl]-4-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733772-43-5 CAPLUS

CN Piperazine, 1-[[1-[[3-(diethylamino)-1-oxopropyl]-4-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 733772-44-6 CAPLUS

CN Piperazine, 1-[[1-[(dimethylamino)acetyl]-4-piperidinyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl


RN 733772-45-7 CAPLUS

CN Piperazine, 1-[[1-[(diethylamino)acetyl]-4-piperidinyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733772-46-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(1-pyrrolidinylacetyl)-4-piperidinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733772-47-9 CAPLUS
 CN Piperazine, 1-[[1-[3-(dimethylamino)-1-oxopropyl]-4-piperidinyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733772-48-0 CAPLUS
 CN Piperazine, 1-[[1-[3-(diethylamino)-1-oxopropyl]-4-piperidinyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733772-49-1 CAPLUS
 CN Piperazine, 1-[3-[1-[(dimethylamino)acetyl]-4-piperidinyl]-1-oxopropyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-50-4 CAPLUS
 CN Piperazine, 1-[3-[1-[(diethylamino)acetyl]-4-piperidinyl]-1-oxopropyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-51-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-[1-(1-pyrrolidinylacetyl)-4-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733772-52-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-[1-[1-oxo-3-(1-pyrrolidinyl)propyl]-4-piperidinyl]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 733772-53-7 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733772-54-8 CAPLUS

CN Acetamide, 2-(diethylamino)-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733772-55-9 CAPLUS


CN 1-Pyrrolidineacetamide, N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733772-56-0 CAPLUS

CN Piperazine, 1-[[4-[(diethylamino)methyl]phenyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 733772-57-1 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-pyrrolidinylmethyl)phenyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733772-58-2 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-piperidinylmethyl)phenyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●2 HCl

RN 733772-59-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-[[methyl(1-methylethyl)amino]methyl]phenyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 733772-60-6 CAPLUS
 CN Piperazine, 1-[4-[2-(dimethylamino)ethyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 733772-61-7 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-(ethylmethylamino)ethyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● 2 HCl

RN 733772-62-8 CAPLUS
 CN Piperazine, 1-[4-[2-(diethylamino)ethyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 733772-63-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-

yl]-4-[4-[2-(1-pyrrolidinyl)ethyl]benzoyl]-, dihydrochloride (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 733772-64-0 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-(1-piperidiny)ethyl]benzoyl]-, dihydrochloride (9CI) (CA
INDEX NAME)

PAGE 1-A.




PAGE 2-A




● 2 HCl

RN 733772-65-1 CAPLUS
CN Piperazine, 1-[4-[(2,5-dimethyl-1-pyrrolidinyl)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733772-66-2 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733772-67-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]methyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A


●x HCl

RN 733772-68-4 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(4-hydroxy-1-piperidinyl)methyl]benzoyl]-, hydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733772-69-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733772-70-8 CAPLUS
 CN Carbamic acid, [[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl)methyl]methyl-,
 2-(diethylamino)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733772-71-9 CAPLUS
 CN Carbamic acid, [[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]methyl]methyl-, 2-(1-pyrrolidinyl)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733772-72-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-methyl-4-(1-pyrrolidinylmethyl)benzoyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 733772-73-1 CAPLUS
 CN Propanamide, 3-(dimethylamino)-N-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A

● 2 HCl

IT 733772-74-2P 733772-75-3P 733772-76-4P
733772-77-5P 733772-78-6P 733772-79-7P
733772-80-0P 733772-82-2P 733772-84-4P
733772-86-6P 733772-87-7P 733772-88-8P
733772-89-9P 733772-92-4P 733772-95-7P
733772-98-0P 733772-99-1P 733773-02-9P
733773-04-1P 733773-06-3P 733773-08-5P
733773-10-9P 733773-12-1P 733773-14-3P
733773-16-5P 733773-18-7P 733773-20-1P
733773-22-3P 733773-24-5P 733773-26-7P
733773-28-9P 733773-30-3P 733773-32-5P
733773-34-7P 733773-36-9P 733773-38-1P
733773-40-5P 733773-42-7P 733773-44-9P
733773-46-1P 733773-48-3P 733773-50-7P
733773-52-9P 733773-53-0P 733773-55-2P
733773-57-4P 733773-59-6P 733773-60-9P
733773-61-0P 733773-62-1P 733773-63-2P
733773-64-3P 733773-65-4P 733773-67-6P
733773-68-7P 733773-69-8P 733773-70-1P
733773-71-2P 733773-72-3P 733773-73-4P
733773-74-5P 733773-75-6P 733773-76-7P
733773-77-8P 733773-78-9P 733773-79-0P
733773-80-3P 733773-81-4P 733773-82-5P
733773-83-6P 733773-84-7P 733773-85-8P
733773-86-9P 733773-87-0P 733773-88-1P
733773-89-2P 733773-90-5P 733773-91-6P
733773-92-7P 733773-93-8P 733773-94-9P
733773-95-0P 733773-96-1P 733773-97-2P
733773-98-3P 733773-99-4P 733774-00-0P
733774-01-1P 733774-02-2P 733774-03-3P


733774-04-4P 733774-05-5P 733774-06-6P
 733774-07-7P 733774-08-8P 733774-09-9P
 733774-10-2P 733774-11-3P 733774-12-4P
 733774-13-5P 733774-14-6P 733774-15-7P
 733774-16-8P 733774-17-9P 733774-18-0P
 733774-19-1P 733774-20-4P 733774-21-5P
 733774-22-6P 733774-23-7P 733774-24-8P
 733774-25-9P 733774-26-0P 733774-27-1P
 733774-28-2P 733774-29-3P 733774-30-6P
 733774-31-7P 733774-32-8P 733774-33-9P
 733774-34-0P 733774-35-1P 733774-36-2P
 733774-37-3P 733774-38-4P 733774-39-5P
 733774-40-8P 733774-41-9P 733774-42-0P
 733774-43-1P 733774-44-2P 733774-45-3P
 733774-46-4P 733774-47-5P 733774-48-6P
 733774-49-7P 733774-50-0P 733774-51-1P
 733774-52-2P 733774-53-3P 733774-54-4P
 733774-55-5P 733774-56-6P 733774-57-7P
 733774-58-8P 733774-59-9P 733774-60-2P
 733774-61-3P 733774-62-4P 733774-63-5P
 733774-64-6P 733774-65-7P 733774-66-8P
 733774-67-9P 733774-68-0P 733774-69-1P
 733774-70-4P 733774-71-5P 733774-72-6P
 733774-73-7P 733774-74-8P 733774-75-9P
 733774-76-0P 733774-77-1P 733774-78-2P
 733774-79-3P 733774-80-6P 733774-81-7P
 733774-82-8P 733774-85-1P 733774-86-2P
 733774-90-8P 733774-92-0P 733774-94-2P
 733774-97-5P 733774-99-7P 733775-01-4P
 733775-03-6P 733775-05-8P 733775-07-0P
 733775-09-2P 733775-10-5P 733775-11-6P
 733775-12-7P 733775-13-8P 733775-14-9P
 733775-15-0P 733775-16-1P 733775-17-2P
 733775-18-3P 733775-19-4P 733775-20-7P
 733775-21-8P 733775-22-9P 733775-23-0P
 733775-24-1P 733775-25-2P 733775-26-3P
 733775-27-4P 733775-28-5P 733775-30-9P
 733775-31-0P 733775-32-1P 733775-33-2P
 733775-34-3P 733775-35-4P 733775-36-5P
 733775-37-6P 733775-38-7P 733775-39-8P
 733775-40-1P 733775-41-2P 733775-42-3P
 733775-43-4P 733775-44-5P 733775-45-6P
 733775-46-7P 733775-49-0P 733775-50-3P
 733775-51-4P 733775-52-5P 733775-53-6P
 733775-54-7P 733775-55-8P 733775-56-9P
 733775-57-0P 733775-58-1P 733775-59-2P
 733775-60-5P 733775-61-6P 733775-62-7P
 733775-63-8P 733775-64-9P 733775-65-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of pyrazolopyrimidines as a small conductance potassium channel
 (SK channel) blocking agents)

RN 733772-74-2 CAPLUS


CN Piperazine, 1-[4-[(diethylamino)methyl]-3-methylbenzoyl]-4-[1-[(3-
 ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
 (9CI) (CA INDEX NAME)



RN 733772-75-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(1-methyl-4-piperidiny)acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733772-76-4 CAPLUS
 CN Piperazine, 1-[(1-cyclopentyl-4-piperidiny)acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733772-77-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-(1-propyl-4-piperidinyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl


RN 733772-78-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(2-methoxyethyl)-4-piperidinyl]acetyl]-, hydrochloride (9CI)
 (CA INDEX NAME)




●x HCl

RN 733772-79-7 CAPLUS
 CN Piperazine, 1-[3-(1-butyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733772-80-0 CAPLUS
 CN Piperazine, 1-[3-(1-cyclopentyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733772-82-2 CAPLUS
 CN Piperazine, 1- [1- [(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4- [[1-(1-ethylpropyl)-4-piperidiny]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733772-84-4 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-(1-methyl-4-piperidinyl)-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733772-86-6 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-(1-ethyl-4-piperidinyl)-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733772-87-7 CAPLUS
 CN Piperazine, 1-[3-[1-[2-(dimethylamino)ethyl]-4-piperidinyl]-1-oxopropyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733772-88-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(2-methoxyethyl)-4-piperidiny]-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733772-89-9 CAPLUS


CN Piperazine, 1-[[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-piperidyl]acetyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 733772-92-4 CAPLUS

CN Piperazine, 1-[[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-ethylpropyl)-1-piperazinyl]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733772-95-7 CAPLUS

CN Piperazine, 1-[(1-butyl-4-piperidyl)acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733772-98-0 CAPLUS

CN Piperazine, 1-[[[(3R)-1-[2-(dimethylamino)ethyl]-3-piperidyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazine]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



●x HCl


RN 733772-99-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-methylethyl)-1-piperazinyl]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733773-02-9 CAPLUS
 CN Piperazine, 1-[(4-cyclopentyl-1-piperazinyl)acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl


RN 733773-04-1 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(2-methoxyethyl)-4-piperidinyl]carbonyl]-, hydrochloride (9CI)
 (CA INDEX NAME)



RN 733773-06-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl] [trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 733773-08-5 CAPLUS

CN Piperazine, 1-[(1-cyclopentyl-4-piperidinyl)acetyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-10-9 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-(1-propyl-4-piperidinyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-12-1 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[1-(2-methoxyethyl)-4-piperidinyl]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733773-14-3 CAPLUS
 CN Piperazine, 1-[3-[1-(1-ethylpropyl)-4-piperidinyl]-1-oxopropyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-16-5 CAPLUS
 CN Piperazine, 1-[3-(1-butyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-18-7 CAPLUS
 CN Piperazine, 1-[3-[1-[2-(dimethylamino)ethyl]-4-piperidiny]-1-oxopropyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733773-20-1 CAPLUS

CN Piperazine, 1-[[1-(1-ethylpropyl)-4-piperidinyl]acetyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 733773-22-3 CAPLUS

CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-(1-methyl-4-piperidinyl)-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-24-5 CAPLUS
 CN Piperazine, 1-[3-(1-ethyl-4-piperidinyloxy)-1-oxopropyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-26-7 CAPLUS
 CN Piperazine, 1-[3-(1-cyclopentyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-28-9 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(2-methoxyethyl)-4-piperidinyl]-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-30-3 CAPLUS
 CN Piperazine, 1-[[1-[2-(dimethylamino)ethyl]-4-piperidinyl]acetyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733773-32-5 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[4-(1-methylethyl)-1-piperazinyl]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
F

●x HCl

RN 733773-34-7 CAPLUS
CN Piperazine, 1-[[4-(1-ethylpropyl)-1-piperazinyl]acetyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
F


●x HCl

RN 733773-36-9 CAPLUS
CN Piperazine, 1-[(4-cyclopentyl-1-piperazinyl)acetyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-38-1 CAPLUS
CN Piperazine, 1-[(1-cyclopentyl-4-piperidinyl)acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-40-5 CAPLUS
 CN Piperazine, 1-[1-oxo-3-(1-propyl-4-piperidinyl)propyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-42-7 CAPLUS
 CN Piperazine, 1-[3-[1-(1-ethylpropyl)-4-piperidinyl]-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-44-9 CAPLUS
 CN Piperazine, 1-[3-(1-butyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-46-1 CAPLUS
 CN Piperazine, 1-[3-(1-cyclopentyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




PAGE 2-A



●x HCl


RN	733773-48-3	CAPLUS
CN	Piperazine, 1-[[1-(1-ethylpropyl)-4-piperidinyl]acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)	




RN 733773-50-7 CAPLUS

CN Piperazine, 1-[3-(1-methyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-52-9 CAPLUS
 CN Piperazine, 1-[3-(1-ethyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733773-53-0 CAPLUS
 CN Piperazine, 1-[3-[1-(2-methoxyethyl)-4-piperidinyl]-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-55-2 CAPLUS
 CN Piperazine, 1-[[1-[2-(dimethylamino)ethyl]-4-piperidinyl]acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733773-57-4 CAPLUS
 CN Piperazine, 1-[[4-(1-ethylpropyl)-1-piperazinyl]acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733773-59-6 CAPLUS

CN Piperazine, 1-[(1-butyl-4-piperidiny)acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)




RN 733773-60-9 CAPLUS

CN Piperazine, 1-[[4-(1-methylethyl)-1-piperazinyl]acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)




RN 733773-61-0 CAPLUS
 CN Piperazine, 1-[(4-cyclopentyl-1-piperazinyl)acetyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-62-1 CAPLUS
 CN Piperazine, 1-[3-[1-[2-(dimethylamino)ethyl]-4-piperidinyl]-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-63-2 CAPLUS
 CN Piperazine, 1-[(1-cyclopentyl-4-piperidinyl)acetyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-64-3 CAPLUS
 CN Piperazine, 1-[3-[1-(1-ethylpropyl)-4-piperidinyl]-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-65-4 CAPLUS
 CN Piperazine, 1-[3-(1-butyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-67-6 CAPLUS
CN Piperazine, 1-[1-oxo-3-(1-propyl-4-piperidinyl)propyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-68-7 CAPLUS
 CN Piperazine, 1-[3-(1-cyclopentyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-69-8 CAPLUS
 CN Piperazine, 1-[[1-(1-ethylpropyl)-4-piperidinyl]acetyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-70-1 CAPLUS
CN Piperazine, 1-[3-(1-methyl-4-piperidiny)-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-71-2 CAPLUS
CN Piperazine, 1-[3-(1-ethyl-4-piperidinyl)-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-72-3 CAPLUS
 CN Piperazine, 1-[3-[1-[2-(dimethylamino)ethyl]-4-piperidinyl]-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-73-4 CAPLUS
 CN Piperazine, 1-[3-[1-(2-methoxyethyl)-4-piperidinyl]-1-oxopropyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-74-5 CAPLUS
 CN Piperazine, 1-[[4-(1-ethylpropyl)-1-piperazinyl]acetyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-75-6 CAPLUS
 CN Piperazine, 1-[(1-butyl-4-piperidinyl)acetyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-76-7 CAPLUS
 CN Piperazine, 1-[[1-(2-methoxyethyl)-4-piperidinyl]acetyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-77-8 CAPLUS
 CN Piperazine, 1-[(4-cyclopentyl-1-piperazinyl)acetyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733773-78-9 CAPLUS

CN Piperazine, 1-[4-[[bis(1-methylethyl)amino]methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733773-79-0 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[bis(1-methylethyl)amino]methyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


● 2 HCl

RN 733773-80-3 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-furanyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733773-81-4 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733773-82-5 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733773-83-6 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-thienyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733773-84-7 CAPLUS
 CN Piperazine, 1-[[5-[[[(butylamino)carbonyl][2-(dimethylamino)ethyl]amino]-3-thienyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733773-85-8 CAPLUS
 CN Piperazine, 1-[[5-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]-3-thienyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733773-86-9 CAPLUS
 CN 2-Thiophenecarboxamide, 5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-N-[2-(1-piperidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733773-87-0 CAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(dimethylamino)ethyl]-5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733773-88-1 CAPLUS


CN 2-Thiophenecarboxamide, N-[2-(dimethylamino)ethyl]-5-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 733773-89-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[5-[(4-methyl-1-piperazinyl)carbonyl]-2-thienyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●_x HCl

RN 733773-90-5 CAPLUS
 CN Piperazine, 1-[(4-butyl-1-piperazinyl)acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733773-91-6 CAPLUS

CN Piperazine, 1-[[1-[2-(dimethylamino)ethyl]-4-piperidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733773-92-7 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(1-propyl-4-piperidinyl)acetyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733773-93-8 CAPLUS

CN Piperazine, 1-[[4-[2-(dimethylamino)ethyl]-1-piperazinyl]acetyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733773-94-9 CAPLUS

CN Piperazine, 1-[(1-cyclopentyl-4-piperidiny]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733773-95-0 CAPLUS


CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 733773-96-1 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)





●x HCl

RN 733773-97-2 CAPLUS

CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






●x HCl

RN 733773-98-3 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 733773-99-4 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●_x HCl

RN 733774-00-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-01-1 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 733774-02-2 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-03-3 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-04-4 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-05-5 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]benzoyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-06-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-07-7 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● x HCl

RN 733774-08-8 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-09-9 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-10-2 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-11-3 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733774-12-4 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl


RN 733774-13-5 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733774-14-6 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)




RN 733774-15-7 CAPLUS
 CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733774-16-8 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733774-17-9 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-18-0 CAPLUS
 CN Piperazine, 1- [1- [(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4- [3- [1- (1-methylethyl)-4-piperidinyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733774-19-1 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-20-4 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-21-5 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733774-22-6 CAPLUS


CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-23-7 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(6-ethoxy-2-


pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733774-24-8 CAPLUS
CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-25-9 CAPLUS
CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-26-0 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-27-1 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 733774-28-2 CAPLUS

CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]benzoyl]-4-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733774-29-3 CAPLUS


CN Piperazine, 1-[4-[(dimethylamino)methyl]-3-methoxybenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733774-30-6 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(ethylmethylamino)methyl]-3-methoxybenzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733774-31-7 CAPLUS


CN Piperazine, 1-[4-[(diethylamino)methyl]-3-methoxybenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733774-32-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-methoxy-4-(1-pyrrolidinylmethyl)benzoyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●2 HCl

RN 733774-33-9 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-methoxy-4-(1-piperidinylmethyl)benzoyl]-, dihydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●2 HCl

RN 733774-34-0 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-methoxy-4-[[methyl(1-methylethyl)amino]methyl]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 733774-35-1 CAPLUS
CN Piperazine, 1-[[5-[(dimethylamino)methyl]-2-thienyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 733774-36-2 CAPLUS
 CN Piperazine, 1-[[5-[(diethylamino)methyl]-2-thienyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
 (9CI) (CA INDEX NAME)




●2 HCl

RN 733774-37-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[5-(1-pyrrolidinylmethyl)-2-thienyl]carbonyl]-, dihydrochloride
 (9CI) (CA INDEX NAME)




RN 733774-38-4 CAPLUS
 CN Piperazine, 1-[[5-[(dimethylamino)methyl]-2-furanyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733774-39-5 CAPLUS
 CN Piperazine, 1-[[5-[(diethylamino)methyl]-2-furanyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 733774-40-8 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[5-(1-pyrrolidinylmethyl)-2-furanyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 733774-41-9 CAPLUS

CN Piperazine, 1-[4-[(dimethylamino)methyl]-3-methoxybenzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride


(9CI) (CA INDEX NAME)




●2 HCl

RN 733774-42-0 CAPLUS
 CN Acetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733774-43-1 CAPLUS

CN 2-Furancarboxamide, N-[3-(dimethylamino)propyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733774-44-2 CAPLUS

CN Acetamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733774-45-3 CAPLUS

CN Pentanamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733774-46-4 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-47-5 CAPLUS
 CN Acetamide, N-[2-(diethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



RN 733774-48-6 CAPLUS


CN Acetamide, N-[2-(diethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733774-49-7 CAPLUS

CN 2-Furancarboxamide, N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN	733774-50-0	CAPLUS
CN	Acetamide, N-[3-(dimethylamino)propyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)	



RN 733774-51-1 CAPLUS


CN Pentanamide, N-[3-(dimethylamino)propyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733774-52-2 CAPLUS

CN Cyclopropanecarboxamide, N-[3-(dimethylamino)propyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-53-3 CAPLUS
 CN Acetamide, N-[3-(dimethylamino)propyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-2-methoxy-, hydrochloride (9CI) . (CA INDEX NAME)



RN 733774-54-4 CAPLUS


CN Pentanamide, N-[2-(diethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733774-55-5 CAPLUS

CN Cyclopropanecarboxamide, N-[2-(diethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733774-56-6 CAPLUS
 CN 2-Furancarboxamide, N-[2-(diethylamino)ethyl]-N-[4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733774-57-7 CAPLUS

CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● x HCl

RN 733774-58-8 CAPLUS
 CN Piperazine, 1-[4-[2-(diethylamino)ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733774-59-9 CAPLUS
 CN Piperazine, 1-[4-[2-(dimethylamino)-2-methylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733774-60-2 CAPLUS
 CN Piperazine, 1-[4-[3-(diethylamino)propoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733774-61-3 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-(1-pyrrolidinyl)ethoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



●x HCl

RN 733774-62-4 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-(4-morpholinyl)ethoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733774-63-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A


●x HCl

RN 733774-64-6 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-[1-(1-methylethyl)-4-piperidinyl]ethoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-65-7 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-[methyl(phenylmethyl)amino]ethoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733774-66-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(1-methyl-2-piperidinyl)methoxy]benzoyl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-67-9 CAPLUS
 CN Piperazine, 1-[[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[[1-(1-methylethyl)-4-piperidinyl]methoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-68-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(1-methyl-1H-imidazol-2-yl)methoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-69-1 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)propoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733774-70-4 CAPLUS
 CN Piperazine, 1-[4-[2-[bis(1-methylethyl)amino]ethoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●x HCl

RN 733774-71-5 CAPLUS
 CN Piperazine, 1-[4-[2-(diethylamino)-2-methylpropoxy]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

●x HCl

RN 733774-72-6 CAPLUS
 CN Piperazine, 1-[4-[2-(diethylamino)ethoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733774-73-7 CAPLUS
 CN Piperazine, 1-[4-[3-(diethylamino)propoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)



RN 733774-74-8 CAPLUS
 CN Piperazine, 1-[4-[2-[bis(1-methylethyl)amino]ethoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


●x HCl

RN 733774-75-9 CAPLUS
 CN Piperazine, 1-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[2-(1-pyrrolidinyl)ethoxy]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733774-76-0 CAPLUS
 CN Piperazine, 1-[4-[2-(4-morpholinyl)ethoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733774-77-1 CAPLUS
 CN Piperazine, 1-[4-[[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A




PAGE 2-A

●x HCl

RN 733774-78-2 CAPLUS
 CN Piperazine, 1-[4-[2-(dimethylamino)-2-methylpropoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733774-79-3 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

n-Pr


●x HCl

RN 733774-80-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(4-piperidinylloxy)benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● 2 HCl

RN 733774-81-7 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(2S)-2-pyrrolidinylmethoxy]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733774-82-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(methylamino)propoxy]benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



● 2 HCl

RN 733774-85-1 CAPLUS

CN Piperazine, 1-[4-(aminomethyl)benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733774-86-2 CAPLUS


CN Piperazine, 1-[[trans-4-(aminomethyl)cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 733774-90-8 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-(4-piperidinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 733774-92-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-(4-piperidinylacetyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733774-94-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[1-oxo-3-(4-piperidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733774-97-5 CAPLUS

CN Acetamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733774-99-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733775-01-4 CAPLUS
 CN 2-Butenamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A




PAGE 2-A

●2 HCl

RN 733775-03-6 CAPLUS
 CN 2-Furancarboxamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-05-8 CAPLUS
 CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-07-0 CAPLUS
 CN Piperazine, 1-[[trans-4-[[2-(dimethylamino)ethyl][(methylamino)thioxomethyl]amino]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-09-2 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(ethylmethylamino)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-10-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[methyl(1-methylethyl)amino]cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-11-6 CAPLUS
CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(methylpropylamino)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-12-7 CAPLUS
CN Acetamide, 2-(dimethylamino)-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733775-13-8 CAPLUS

CN Acetamide, 2- (diethylamino) -N- [trans-4- [[4- [1- [(3-ethoxyphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] -1-piperazinyl]carbonyl]cyclohexyl] -, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733775-14-9 CAPLUS

CN 1-Pyrrolidineacetamide, N- [trans-4- [[4- [1- [(3-ethoxyphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] -1-piperazinyl]carbonyl]cyclohexyl] -, dihydrochloride (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


Relative stereochemistry.



● 2 HCl

RN 733775-15-0 CAPLUS
CN Propanamide, 3-(dimethylamino)-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733775-16-1 CAPLUS
CN Propanamide, 3-(diethylamino)-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-,
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 2 HCl

RN 733775-17-2 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-,
dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




● 2 HCl

RN 733775-18-3 CAPLUS

CN Acetamide, 2-(diethylamino)-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-19-4 CAPLUS

CN Propanamide, 3-(dimethylamino)-N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-20-7 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]-N-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733775-21-8 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidiny)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-22-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(3S)-3-hydroxy-1-pyrrolidinyl]cyclohexyl]carbonyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 733775-23-0 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


yl]-4-[[trans-4-[(3S)-3-hydroxy-1-pyrrolidinyl]cyclohexyl]carbonyl]-,
(2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 733775-22-9

CMF C29 H39 N7 O3

Absolute stereochemistry.




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 733775-24-1 CAPLUS


CN Piperazine, 1-[4-[(ethylamino)methyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride
(9CI) (CA INDEX NAME)



● 2 HCl

RN 733775-25-2 CAPLUS


CN Piperazine, 1-[4-[(ethylamino)methyl]benzoyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 733775-26-3 CAPLUS

CN Piperazine, 1-[4-[(ethylamino)methyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 733775-27-4 CAPLUS
 CN Piperazine, 1-[[trans-4-(cyclopentylamino)cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733775-28-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(1-methylethyl)amino]cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 733775-30-9 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(ethylamino)cyclohexyl]carbonyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 733775-31-0 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 733775-32-1 CAPLUS

CN Piperazine, 1-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 733775-33-2 CAPLUS

CN Piperazine, 1-[1-[(4-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733775-34-3 CAPLUS
 CN Piperazine, 1-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733775-35-4 CAPLUS
CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733775-36-5 CAPLUS
CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

●x HCl

RN 733775-37-6 CAPLUS
 CN Piperazine, 1-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733775-38-7 CAPLUS
 CN Piperazine, 1-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

NAME)


Relative stereochemistry.



RN 733775-39-8 CAPLUS

CN Piperazine, 1-[1-[[3-(1-methylethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 733775-40-1 CAPLUS

CN Piperazine, 1-[1-[[6-ethyl-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, dihydrochloride
(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-41-2 CAPLUS
 CN Piperazine, 1-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●2 HCl

RN 733775-42-3 CAPLUS

CN Piperazine, 1-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, dihydrochloride (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A


●2 HCl

RN 733775-43-4 CAPLUS

CN Piperazine, 1-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-44-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[cis-4-(1-pyrrolidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-45-6 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]amino]-3-methylbenzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


PAGE 1-A



PAGE 2-A

● 2 HCl


RN 733775-46-7 CAPLUS
 CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]amino]-3-methylbenzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733775-49-0 CAPLUS


CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]amino]-3-methylbenzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 733775-50-3 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]amino]-3-methylbenzoyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 733775-51-4 CAPLUS


CN Piperazine, 1-[4-[2-(dimethylamino)ethoxy]-5,6-dimethylfuro[2,3-d]pyrimidin-2-yl]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-

pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733775-52-5 CAPLUS

CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(4-methyl-1-piperazinyl)-3-nitrobenzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl

RN 733775-53-6 CAPLUS
 CN Piperazine, 1-[[1-ethyl-1,4-dihydro-4-oxo-7-(1-pyrrolidinylmethyl)-3-quinolinyl]carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

RN 733775-55-8 CAPLUS
CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[[6-[(1E)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propenyl]-4-oxo-4H-pyran-3-yl]oxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A


●x HCl

RN 733775-56-9 CAPLUS
CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN	733775-57-0	CAPLUS
CN	Piperazine, 1-[2-methyl-1-oxo-3-[4-(1-pyrrolidinylmethyl)phenyl]-2-propenyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-58-1 CAPLUS
 CN Piperazine, 1-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-59-2 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-(4-methyl-1-piperazinyl)-3-nitrobenzoyl]-, hydrochloride (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733775-60-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[2-methyl-1-oxo-3-[4-(1-pyrrolidinylmethyl)phenyl]-2-propenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-61-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[6-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]carbonyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733775-62-7 CAPLUS
 CN Piperazine, 1-[4-(4-methyl-1-piperazinyl)-3-nitrobenzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl


RN 733775-63-8 CAPLUS
 CN Piperazine, 1-[[1-ethyl-1,4-dihydro-4-oxo-7-(1-pyrrolidinylmethyl)-3-quinolinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733775-64-9 CAPLUS
 CN Piperazine, 1-[2-methyl-1-oxo-3-[4-(1-pyrrolidinylmethyl)phenyl]-2-propenyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● x HCl

RN 733775-65-0 CAPLUS
 CN Piperazine, 1-methyl-4-[1-oxo-3-[4-oxo-5-[2-oxo-2-[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]ethoxy]-4H-pyran-2-yl]-2-propenyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





●_x HCl

IT 733775-66-1P 733775-67-2P 733775-68-3P
733775-69-4P 733775-70-7P 733775-71-8P
733775-72-9P 733775-73-0P 733775-74-1P
733775-75-2P 733775-76-3P 733775-77-4P
733775-78-5P 733775-79-6P 733775-80-9P
733775-81-0P 733775-82-1P 733775-83-2P
733775-84-3P 733775-85-4P 733775-86-5P
733775-87-6P 733775-88-7P 733775-89-8P
733775-90-1P 733775-91-2P 733775-92-3P
733775-93-4P 733775-94-5P 733775-95-6P
733775-96-7P 733775-97-8P 733775-98-9P
733775-99-0P 733776-00-6P 733776-01-7P
733776-02-8P 733776-03-9P 733776-04-0P
733776-05-1P 733776-06-2P 733776-07-3P
733776-08-4P 733776-09-5P 733776-10-8P
733776-11-9P 733776-12-0P 733776-13-1P
733776-14-2P 733776-15-3P 733776-16-4P
733776-17-5P 733776-18-6P 733776-19-7P
733776-20-0P 733776-21-1P 733776-22-2P
733776-23-3P 733776-24-4P 733776-25-5P
733776-26-6P 733776-27-7P 733776-28-8P
733776-29-9P 733776-30-2P 733776-31-3P
733776-32-4P 733776-33-5P 733776-34-6P
733776-35-7P 733776-36-8P 733776-37-9P
733776-38-0P 733776-39-1P 733776-40-4P
733776-41-5P 733776-43-7P 733776-44-8P
733776-46-0P 733776-47-1P 733776-48-2P
733776-49-3P 733776-50-6P 733776-52-8P
733776-53-9P 733776-54-0P 733776-55-1P
733776-56-2P 733776-57-3P 733776-58-4P
733776-59-5P 733776-60-8P 733776-61-9P
733776-62-0P 733776-63-1P 733776-64-2P
733776-65-3P 733776-66-4P 733776-67-5P
733776-68-6P 733776-69-7P 733776-70-0P
733776-71-1P 733776-72-2P 733776-73-3P
733776-74-4P 733776-75-5P 733776-76-6P

733776-77-7P 733776-78-8P 733776-79-9P
 733776-80-2P 733776-81-3P 733776-82-4P
 733776-83-5P 733776-84-6P 733776-85-7P
 733776-86-8P 733776-87-9P 733776-88-0P
 733776-89-1P 733776-90-4P 733776-91-5P
 733776-92-6P 733776-93-7P 733776-94-8P
 733776-95-9P 733776-96-0P 733776-97-1P
 733776-98-2P 733776-99-3P 733777-00-9P
 733777-01-0P 733777-02-1P 733777-03-2P
 733777-04-3P 733777-05-4P 733777-06-5P
 733777-07-6P 733777-08-7P 733777-09-8P
 733777-10-1P 733777-11-2P 733777-12-3P
 733777-13-4P 733777-14-5P 733777-15-6P
 733777-16-7P 733777-17-8P 733777-18-9P
 733777-19-0P 733777-20-3P 733777-21-4P
 733777-22-5P 733777-23-6P 733777-24-7P
 733777-25-8P 733777-26-9P 733777-27-0P
 733777-28-1P 733777-29-2P 733777-30-5P
 733777-31-6P 733777-32-7P 733777-33-8P
 733777-34-9P 733777-35-0P 733777-36-1P
 733777-37-2P 733777-38-3P 733777-39-4P
 733777-40-7P 733777-41-8P 733777-42-9P
 733777-43-0P 733777-44-1P 733777-45-2P
 733777-46-3P 733777-47-4P 733777-48-5P
 733777-49-6P 733777-50-9P 733777-51-0P
 733777-52-1P 733777-53-2P 733777-54-3P
 733777-55-4P 733777-56-5P 733777-57-6P
 733777-58-7P 733777-59-8P 733777-60-1P
 733777-61-2P 733777-62-3P 733777-63-4P
 733777-64-5P 733777-65-6P 733777-66-7P
 733777-67-8P 733777-68-9P 733777-69-0P
 733777-70-3P 733777-71-4P 733777-72-5P
 733777-73-6P 733777-74-7P 733777-75-8P
 733777-76-9P 733777-77-0P 733777-78-1P
 733777-79-2P 733777-80-5P 733777-81-6P
 733777-82-7P 733777-83-8P 733777-84-9P
 733777-86-1P 733777-88-3P 733777-90-7P
 733777-92-9P 733777-94-1P 733777-96-3P
 733777-98-5P 733778-00-2P 733778-02-4P
 733778-04-6P 733778-06-8P 733778-07-9P
 733778-08-0P 733778-10-4P 733778-12-6P
 733778-14-8P 733778-16-0P 733778-18-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolopyrimidines as a small conductance potassium channel
 (SK channel) blocking agents)


RN 733775-66-1 CAPLUS

CN Piperazine, 1-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]-4-[[6-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]carbonyl]-,
 hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




●x HCl


RN 733775-67-2 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[[4-oxo-6-(1-pyrrolidinylmethyl)-4H-pyran-3-yl]oxy]acetyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●x HCl

RN 733775-68-3 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
 OEt

RN 733775-69-4 CAPLUS
 CN Piperazine, 1- [4- [3- (dimethylamino) -2,2-dimethylpropoxy] benzoyl] -4- [1- [(2-
 fluoro-3-methylphenyl)methyl] -1H-pyrazolo[3,4-d]pyrimidin-4-yl] -,
 hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● x HCl

RN 733775-70-7 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

Et


RN 733775-71-8 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 733775-72-9 CAPLUS

CN Piperazine, 1-[4-[3-(dimethylamino)-2,2-dimethylpropoxy]benzoyl]-4-[1-[(2-fluoro-3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


● x HCl

RN 733775-73-0 CAPLUS
 CN Piperazine, 1-[1-[[3-(1-methylethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733775-74-1 CAPLUS
 CN Piperazine, 1-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]-, hydrochloride
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-75-2 CAPLUS
 CN Piperazine, 1-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733775-76-3 CAPLUS
 CN Piperazine, 1-[1-[(4-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[(1-methylethyl)-4-piperidyl]-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-77-4 CAPLUS
 CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733775-78-5 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 733775-79-6 CAPLUS

CN Piperazine, 1-[3-[1-(1-methylethyl)-4-piperidiny]]-1-oxopropyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-80-9 CAPLUS
 CN Piperazine, 1-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidinyl]-1-oxopropyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733775-81-0 CAPLUS
 CN Piperazine, 1-[1-[(2-fluoro-3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[3-[1-(1-methylethyl)-4-piperidyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 733775-82-1 CAPLUS

CN Piperazine, 1-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-83-2 CAPLUS

CN Piperazine, 1-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 733775-84-3 CAPLUS

CN Piperazine, 1-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]-4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 733775-85-4 CAPLUS

CN Piperazine, 1-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 733775-86-5 CAPLUS

CN Piperazine, 1-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]-4-[[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 733775-87-6 CAPLUS

CN Piperazine, 1-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]-4-[1-[(3-propoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-88-7 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-89-8 CAPLUS

CN Piperazine, 1-[1-[(2-fluoro-3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-piperidinyl)cyclohexyl]carbonyl]- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 733775-90-1 CAPLUS

CN Piperazine, 1-[4-[[2-(dimethylamino)ethyl]thio]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 733775-91-2 CAPLUS
 CN Piperazine, 1-[[trans-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-92-3 CAPLUS
 CN Piperazine, 1-[[trans-4-[[methyl(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86




RN 733775-93-4 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(4-methyl-1-piperazinyl)methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733775-94-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733775-95-6 CAPLUS
 CN Piperazine, 1-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinylmethyl)cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733775-96-7 CAPLUS
 CN Piperazine, 1-[[trans-4-[(diethylamino)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-97-8 CAPLUS

CN Piperazine, 1-[[trans-4-[[2-methoxyethyl)methylamino)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-98-9 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-(1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733775-99-0 CAPLUS

CN Piperazine, 1-[[trans-4-[[methyl[2-(1-piperidinyl)ethyl]amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-00-6 CAPLUS

CN Piperazine, 1-[[trans-4-[[[2-(dimethylamino)ethyl]methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-(n-propyl)-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-01-7 CAPLUS

CN Piperazine, 1-[[trans-4-[[[2-(diethylamino)ethyl]methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-02-8 CAPLUS

CN Piperazine, 1-[[trans-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-03-9 CAPLUS

CN Piperazine, 1-[[trans-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-04-0 CAPLUS

CN Piperazine, 1-[[trans-4-[[[(2-methoxyethyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-05-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[trans-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-06-2 CAPLUS

CN Piperazine, 1-[[trans-4-[(diethylamino)methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-07-3 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[methyl(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-08-4 CAPLUS


CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[2-methoxyethyl)methylamino]methyl]cyclohexyl]carbonyl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 733776-09-5 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[methyl[2-(1-piperidinyl)ethyl]amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733776-10-8 CAPLUS
 CN Piperazine, 1-[[trans-4-[[[2-(diethylamino)ethyl]methylamino]methyl]cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-11-9 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-12-0 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-4-[[[(2-methoxyethyl)(1-methylethyl)amino]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-13-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[trans-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-14-2 CAPLUS

CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




●x HCl

RN 733776-15-3 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733776-16-4 CAPLUS
 CN Piperazine, 1-[[2-[[2-(dimethylamino)ethyl]methylamino]-4-(trifluoromethyl)-5-pyrimidinyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)



RN 733776-17-5 CAPLUS
 CN Piperazine, 1-[4-[(1Z)-3-(dimethylamino)-1-propenyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86




● x HCl

RN 733776-18-6 CAPLUS

CN Piperazine, 1-[4-[(1Z)-3-(dimethylamino)-1-propenyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● x HCl

RN 733776-19-7 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(1-pyrrolidinyl)-1-propynyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 733776-20-0 CAPLUS

CN Piperazine, 1-[4-[(1Z)-3-(diethylamino)-1-propenyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●x HCl

RN 733776-21-1 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[(1Z)-3-(1-pyrrolidinyl)-1-propenyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.


PAGE 1-A



PAGE 2-A

●x HCl

RN 733776-22-2 CAPLUS
 CN Piperazine, 1-[4-[3-(dimethylamino)propyl]benzoyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI)
 (CA INDEX NAME)




●x HCl

RN 733776-23-3 CAPLUS


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

CN Piperazine, 1-[4-[3-(dimethylamino)propyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733776-24-4 CAPLUS

CN Piperazine, 1-[4-[3-(dimethylamino)propyl]benzoyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 733776-25-5 CAPLUS


CN Piperazine, 1-[4-[3-(diethylamino)propyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



RN 733776-26-6 CAPLUS
 CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[4-[3-(1-pyrrolidinyl)propyl]benzoyl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● x HCl

RN 733776-27-7 CAPLUS

CN Piperazine, 1-[[trans-4-(dipropylamino)cyclohexyl]carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 733776-28-8 CAPLUS

CN Piperazine, 1-[[trans-4-(dipropylamino)cyclohexyl]carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




●x HCl

RN 733776-29-9 CAPLUS

CN Piperazine, 1-[[trans-4-(dipropylamino)cyclohexyl]carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 733776-30-2 CAPLUS

CN Piperazine, 1-[3,5-dibromo-4-[(dimethylamino)methyl]benzoyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)

tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-
[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-
pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-,
(2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470429-86-8


CMF C50 H62 N10 O8

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




CM 2

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



RN 470438-03-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-02-9 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[[2-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470429-84-6

CMF C51 H62 F3 N9 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-01-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470429-83-5

CMF C49 H62 N10 O6

Relative stereochemistry.

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-00-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470429-70-0

CMF C49 H62 N10 O6


Relative stereochemistry.

RN 470437-98-0 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470429-43-7
 CMF C38 H48 N8 O4


Relative stereochemistry.



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 470437-99-1 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470429-44-8
 CMF C38 H47 N9 O6




RN 470437-96-8 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470429-41-5
 CMF C38 H47 Cl N8 O4


Relative stereochemistry.




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



Prepared by: Mary Hale @2-2507 Rem Bldg 1D86




RN 470437-52-6 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-4-[[4-[1-[(2-methyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A



RN 470437-51-5 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-49-1 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-50-4 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-47-9 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-48-0 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-4-[[4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-45-7 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-46-8 CAPLUS


CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[(methylamino)acetyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-44-6 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[[2-(ethoxymethyl)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.







RN 470437-43-5 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 470437-41-3 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 [[4-[1-[[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-
 4-yl]-1-piperazinyl]carbonyl]-6'-ethoxy-3',4'-dihydro-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.



RN 470437-42-4 CAPLUS
 CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[[trans-2'-[(dimethylamino)acetyl]-6'-
 ethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-
 yl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-,
 methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-40-2 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[(5-ethyl-2-furanyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



470439-42-0P 470439-43-1P 470439-44-2P
 470439-46-4P 470439-47-5P 470439-48-6P
 470439-50-0P 470439-51-1P 470439-52-2P
 470439-53-3P 470439-54-4P 470439-55-5P
 470439-56-6P 470439-57-7P 470439-58-8P
 470439-59-9P 470439-60-2P 470439-61-3P
 470439-62-4P 470439-63-5P 470439-64-6P
 470439-65-7P 470439-66-8P 470439-67-9P
 470439-68-0P 470439-69-1P 470439-70-4P
 470439-71-5P 470439-72-6P 470439-73-7P
 470439-74-8P 470439-75-9P 470439-76-0P
 470439-77-1P 470439-78-2P 470439-79-3P
 470439-80-6P 470439-81-7P 470439-82-8P
 470439-83-9P 470439-84-0P 470439-85-1P
 470439-86-2P 470439-87-3P 470439-88-4P
 470439-89-5P 470439-90-8P 470439-91-9P
 470439-92-0P 470439-93-1P 470439-94-2P
 470439-95-3P 470439-96-4P 470439-97-5P
 470439-98-6P 470439-99-7P 470440-00-7P
 470440-01-8P 470440-02-9P 470440-03-0P
 470440-04-1P 470440-05-2P 470440-06-3P
 470440-07-4P 470440-08-5P 470440-09-6P
 470440-10-9P 470440-11-0P 470440-12-1P
 470440-13-2P 470440-14-3P 470440-15-4P
 470440-16-5P 470440-17-6P 470440-18-7P
 470440-19-8P 470440-20-1P 470440-21-2P
 470440-22-3P 470440-23-4P 470440-24-5P
 470440-25-6P 470440-26-7P 470440-27-8P
 470440-28-9P 470440-29-0P 470440-30-3P
 470440-31-4P 470440-32-5P 470440-33-6P
 470440-34-7P 470440-35-8P 470440-36-9P
 470440-37-0P 470440-38-1P 470440-39-2P
 470440-40-5P 470440-41-6P 470440-42-7P
 470440-43-8P 470440-44-9P 470440-45-0P
 470440-46-1P 470440-47-2P 470440-48-3P
 470440-49-4P 470440-50-7P 470440-51-8P
 470440-52-9P 470440-54-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of spiroisoquinolines as small-conductance Ca²⁺-activated K⁺
 channel blockers and acetylcholine esterase inhibitors for treatment of
 diseases)


RN 470437-39-9 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 [[4-[1-[3-(dimethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
 1-piperazinyl]carbonyl]-6'-ethoxy-3',4'-dihydro-, trans- (9CI) (CA INDEX
 NAME)

Relative stereochemistry.




IT 470437-39-9P 470437-40-2P 470437-41-3P
 470437-42-4P 470437-43-5P 470437-44-6P
 470437-45-7P 470437-46-8P 470437-47-9P
 470437-48-0P 470437-49-1P 470437-50-4P
 470437-51-5P 470437-52-6P 470437-96-8P
 470437-98-0P 470437-99-1P 470438-00-7P
 470438-01-8P 470438-02-9P 470438-03-0P
 470438-08-5P 470438-09-6P 470438-10-9P
 470438-11-0P 470438-21-2P 470438-22-3P
 470438-23-4P 470438-24-5P 470438-25-6P
 470438-26-7P 470438-28-9P 470438-31-4P
 470438-32-5P 470438-33-6P 470438-40-5P
 470438-48-3P 470438-49-4P 470438-50-7P
 470438-51-8P 470438-52-9P 470438-53-0P
 470438-54-1P 470438-55-2P 470438-56-3P
 470438-57-4P 470438-58-5P 470438-59-6P
 470438-60-9P 470438-61-0P 470438-62-1P
 470438-63-2P 470438-65-4P 470438-66-5P
 470438-67-6P 470438-68-7P 470438-69-8P
 470438-70-1P 470438-71-2P 470438-72-3P
 470438-73-4P 470438-74-5P 470438-75-6P
 470438-76-7P 470438-77-8P 470438-86-9P
 470438-87-0P 470438-89-2P 470438-90-5P
 470438-92-7P 470438-94-9P 470438-96-1P
 470438-97-2P 470438-98-3P 470438-99-4P
 470439-00-0P 470439-01-1P 470439-02-2P
 470439-03-3P 470439-04-4P 470439-05-5P
 470439-06-6P 470439-07-7P 470439-08-8P
 470439-09-9P 470439-10-2P 470439-11-3P
 470439-12-4P 470439-13-5P 470439-14-6P
 470439-15-7P 470439-16-8P 470439-17-9P
 470439-18-0P 470439-19-1P 470439-20-4P
 470439-21-5P 470439-22-6P 470439-26-0P
 470439-27-1P 470439-28-2P 470439-29-3P
 470439-30-6P 470439-31-7P 470439-32-8P
 470439-33-9P 470439-34-0P 470439-35-1P
 470439-36-2P 470439-37-3P 470439-38-4P
 470439-39-5P 470439-40-8P 470439-41-9P



RN 470437-37-7 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-38-8 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[[3-(ethoxymethyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470437-36-6 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-4-[[4-[1-[(2-propyl-4-pyrimidinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-34-4 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-4-[[4-[1-[[6-(methoxy)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-35-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-4-[[4-[1-[[2-propyl-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-32-2 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-33-3 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470437-31-1 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470437-29-7 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-30-0 CAPLUS


CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-27-5 CAPLUS
 CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470437-28-6 CAPLUS
 CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-26-4 CAPLUS


CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 470437-25-3 CAPLUS
 CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470437-24-2 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[[2-(ethoxymethyl)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-22-0 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[[trans-6',7'-diethoxy-2'-[3-[(ethoxycarbonyl)amino]propyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-23-1 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-20-8 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[[6-[(dimethylamino)methyl]-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-21-9 CAPLUS


CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470437-19-5 CAPLUS
 CN Carbamic acid, [3-[trans-4-[[4-[1-[[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-17-3 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[3-(dimethylamino)phenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-18-4 CAPLUS


CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[(5-ethyl-2-furanyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470437-16-2 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-14-0 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[(2-propyl-4-pyrimidinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-15-1 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-12-8 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[[6-(ethoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-13-9 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[(4-chloro-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-10-6 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[[6-(hydroxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-11-7 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-08-2 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-09-3 CAPLUS

CN Carbamic acid, [3-[trans-6',7'-diethoxy-4-[[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470437-06-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470437-07-1 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A




PAGE 2-A




RN 470437-05-9 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470437-04-8 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 6',7'-diethoxy-3',4'-dihydro-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.




RN 470437-02-6 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 470437-03-7 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 470437-01-5 CAPLUS
 CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 6',7'-diethoxy-4-[[4-[1-[[2-(ethoxymethyl)-4-thiazolyl]methyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-,
 trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.







RN 470437-00-4 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470436-98-7 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[[trans-2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-99-8 CAPLUS

CN 2-Pyridinecarboxamide, 6-[[4-[4-[[trans-2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-N-ethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-96-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-97-6 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(1,2-dihydro-1-methyl-2-oxo-3-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-6',7'-diethoxy-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470436-95-4 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'--[(dimethylamino)acetyl]-4-
 [[4-[1-[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-
 4-yl]-1-piperazinyl]carbonyl]-6',7'-diethoxy-3',4'-dihydro-, trans- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 470436-93-2 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[[3-(dimethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-6',7'-diethoxy-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-94-3 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[(5-ethyl-2-furanyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-91-0 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 470436-92-1 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6',7'-diethoxy-4-[[4-[1-[[3-(ethoxymethyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI)
 (CA INDEX NAME)


Relative stereochemistry.



RN 470436-90-9 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[2-(ethoxymethyl)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 470436-89-6 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl] - (9CI)
 (CA INDEX NAME)

Relative stereochemistry.







RN 470436-88-5 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2,3-dihydro-3-oxo-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 470436-87-4 CAPLUS
 CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-, methyl ester (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




RN 470436-85-2 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(3-(ethoxymethyl)phenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-86-3 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(5-ethyl-2-furanyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-83-0 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-pyrimidinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470436-84-1 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470436-82-9 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470436-80-7 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-81-8 CAPLUS


CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-78-3 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470436-79-4 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-77-2 CAPLUS


CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A



RN 470436-76-1 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(5-ethoxy-3-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-74-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-, methyl ester (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470436-75-0 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-72-7 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-73-8 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470436-71-6 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470436-69-2 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-70-5 CAPLUS


CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470436-68-1 CAPLUS
 CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470436-67-0 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-65-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
[[4-[1-[(5-ethoxy-3-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 470436-66-9 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
[[4-[1-[[2-(ethoxymethyl)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-
4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry..



RN 470436-64-7 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 [[4-[1-[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-
 yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.







RN 470436-63-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2,3-dihydro-2-oxo-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470436-61-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[[trans-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-62-5 CAPLUS

CN 2-Pyridinecarboxamide, 6-[[4-[4-[[trans-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-N-ethyl-, (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470436-59-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
[[4-[1-[[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-
4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470436-60-3 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(1,2-dihydro-1-methyl-
2-oxo-3-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-
dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470436-58-9 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 [[4-[1-[(5-ethyl-2-furanyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470436-56-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[[3-(ethoxymethyl)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-57-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[[3-(dimethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-54-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-propyl-4-pyrimidinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-55-6 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470436-53-4 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 470436-51-2 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.




RN 470436-52-3 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[[6-(methylamino)-2-
 pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-49-8 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470436-50-1 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[[6-ethoxy-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-47-6 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-48-7 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(1,2-dihydro-1-methyl-2-oxo-3-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-45-4 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-46-5 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(dimethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470436-44-3 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-pyrimidinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-42-1 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-43-2 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-40-9 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-41-0 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-38-5 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-pyrimidinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-39-6 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470436-37-4 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A





RN 470436-35-2 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-propyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470436-36-3 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470436-34-1 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470436-33-0 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-31-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 6-[[4-[4-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-1-piperazinyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-, methyl ester (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 470436-32-9 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[2-(ethylamino)-4-thiazolyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470436-30-7 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(dimethylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-28-3 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(ethylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470436-29-4 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(5-ethyl-2-furanyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470436-27-2 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A





RN 470436-25-0 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-26-1 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[6-(methylamino)-2-pyridinyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 2-A




RN 470436-24-9 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
[[4-[1-[2-(2-ethyl-4-thiazolyl)ethyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470436-23-8 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[2-(2-methyl-4-thiazolyl)ethyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 470436-22-7 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 [[4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.







RN 470436-21-6 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
 3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-methyl-4-thiazolyl)methyl]-1H-
 pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470436-19-2 CAPLUS

CN Piperazine, 1-[1-[(4-chloro-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-20-5 CAPLUS

CN Piperazine, 1-[1-[(4-chloro-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-17-0 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(4-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-18-1 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(4-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-15-8 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(4-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-16-9 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(4-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-11-4 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-12-5 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-
3',4'-dihydro-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-
4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-09-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-10-3 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-07-8 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-08-9 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-05-6 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-06-7 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

NAME)


Relative stereochemistry.



RN 470436-03-4 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-04-5 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-01-2 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470436-02-3 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

dihydrospiro[cyclohexane-1,1' (2'H) -isoquinolin]-4-yl) carbonyl]-4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-99-5 CAPLUS

CN Piperazine, 1-[1-(2-cyclohexylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1' (2'H) -isoquinolin]-4-yl) carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470436-00-1 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-


Relative stereochemistry.



RN 470435-97-3 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-98-4 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-


Relative stereochemistry.



RN 470435-95-1 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-96-2 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

yl]-4-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-93-9 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-94-0 CAPLUS

CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-2'-yl]propyl]-,
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-91-7 CAPLUS


CN Piperazine, 1-[(trans-6',7'-diethoxy-2'-ethyl-3',4'-
dihydrospiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-
methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX
NAME)

Relative stereochemistry.



RN 470435-92-8 CAPLUS


CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-



RN 470435-88-2 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-methyl-3-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-90-6 CAPLUS


CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-



RN 470435-86-0 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470435-87-1 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-84-8 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-85-9 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-82-6 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-4-[[4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470435-83-7 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-80-4 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470435-81-5 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(4-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470435-79-1 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470435-78-0 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-76-8 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-77-9 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-thiazolylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


PAGE 2-A



RN 470435-74-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-75-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Relative stereochemistry.





RN 470435-73-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470435-71-3 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470435-72-4 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)


PAGE 2-A



RN 470435-69-9 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-propynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-70-2 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-4-[[4-[1-(2-fluoroethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-68-8 CAPLUS


CN Spiro[cyclohexane-1,1' (2'H) -isoquinoline], 4-[[4-[1-(cyclopentylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 1-A



PAGE 2-A




RN 470435-67-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470435-66-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-(cyclopropylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 470435-64-4 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-65-5 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-(cyclobutylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

RN 470435-62-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[2,2-dicyano-1-(methylamino)ethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-63-3 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-4-[[4-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470435-61-1 CAPLUS

CN Piperazine, 1-[[[trans-2'-[3-[[2,2-dicyano-1-(dimethylamino)ethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 470435-59-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[2,2-dicyano-1-(methylthio)ethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-60-0 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[(1-amino-2,2-dicyanoethenyl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-

RN 470435-57-5 CAPLUS
 CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[2-(methylamino)-3,4-dioxo-1-cyclobuten-1-yl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-58-6 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[(2-amino-3,4-dioxo-1-cyclobuten-1-yl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

CN Piperazine, 1-[[trans-2'-[3-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-56-4 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[2-(dimethylamino)-3,4-dioxo-1-cyclobuten-1-yl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-54-2 CAPLUS


CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-55-3 CAPLUS


Relative stereochemistry.



RN 470435-52-0 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[(butylamino) carbonyl] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-53-1 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[(ethylamino) carbonyl] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 470435-50-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[(butylamino) thioxomethyl] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470435-51-9 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[(methylamino) thioxomethyl] amino] propyl] spiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 470435-49-5 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[[(1,1-dimethylethyl)amino]thioxomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-47-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 470435-48-4 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


RN 470435-45-1 CAPLUS

CN Piperazine, 1-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 2-A



RN 470435-46-2 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.

CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[[(cyanoamino)(dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-44-0 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl[1-(methylamino)-2-nitroethenyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry unknown.



4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-42-8 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-43-9 CAPLUS


Relative stereochemistry.



RN 470435-40-6 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[(butylamino) (cyanoamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H) -isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl) methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-41-7 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[(cyanoamino) (ethylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H) -isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl) methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 470435-38-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(diethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470435-39-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(propylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 470435-37-1 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(cyclopropylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-35-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-36-0 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(cyclohexylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 2-A




RN 470435-34-8 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




RN 470435-33-7 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470435-32-6 CAPLUS
 CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



Relative stereochemistry.




RN 470435-31-5 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




Relative stereochemistry.



RN 470435-29-1 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (methylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H) -isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-30-4 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (methylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H) -isoquinolin]-4-yl]carbonyl]-4-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-27-9 CAPLUS

CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-28-0 CAPLUS

CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-25-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylimino)methyl]methylamino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-26-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

yl]propyl]amino]carbonyl]oxy]ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-23-5 CAPLUS

CN Carbamic acid, dimethyl-, [[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-24-6 CAPLUS

CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino)(methylimino)methyl]methylamino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]]-. (9CI) (CA INDEX NAME)

yl]propyl]amino]carbonyl]oxy]ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-21-3 CAPLUS

CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-22-4 CAPLUS

CN Carbamic acid, dimethyl-, 2-[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-

yl]propyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-19-9 CAPLUS

CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-ethoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-20-2 CAPLUS

CN Carbamic acid, dimethyl-, 2-[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-ethoxy- (9CI) (CA INDEX NAME)

yl]propyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-17-7 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-18-8 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-

yl]propyl]-4-oxo- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-15-5 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-16-6 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-

pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-13-3 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-oxopropyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-14-4 CAPLUS

CN Pentanamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-oxopropyl ester (9CI) (CA INDEX NAME)

nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-oxopropyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-11-1 CAPLUS

CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-12-2 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-methoxy- (9CI) (CA INDEX NAME)

yl]propyl]-2-methoxy-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-09-7 CAPLUS

CN Pentanamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-4-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-10-0 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-4-oxo- (9CI) (CA INDEX NAME)

yl]propyl]-2-ethoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-07-5 CAPLUS

CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470435-08-6 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-methoxy- (9CI) (CA INDEX NAME)

yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-05-3 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-06-4 CAPLUS

CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-


Relative stereochemistry.



RN 470435-03-1 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, butyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470435-04-2 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, butyl ester (9CI) (CA INDEX NAME)

470435-93-9P 470435-94-0P 470435-95-1P
 470435-96-2P 470435-97-3P 470435-98-4P
 470435-99-5P 470436-00-1P 470436-01-2P
 470436-02-3P 470436-03-4P 470436-04-5P
 470436-05-6P 470436-06-7P 470436-07-8P
 470436-08-9P 470436-09-0P 470436-10-3P
 470436-11-4P 470436-12-5P 470436-15-8P
 470436-16-9P 470436-17-0P 470436-18-1P
 470436-19-2P 470436-20-5P 470436-21-6P
 470436-22-7P 470436-23-8P 470436-24-9P
 470436-25-0P 470436-26-1P 470436-27-2P
 470436-28-3P 470436-29-4P 470436-30-7P
 470436-31-8P 470436-32-9P 470436-33-0P
 470436-34-1P 470436-35-2P 470436-36-3P
 470436-37-4P 470436-38-5P 470436-39-6P
 470436-40-9P 470436-41-0P 470436-42-1P
 470436-43-2P 470436-44-3P 470436-45-4P
 470436-46-5P 470436-47-6P 470436-48-7P
 470436-49-8P 470436-50-1P 470436-51-2P
 470436-52-3P 470436-53-4P 470436-54-5P
 470436-55-6P 470436-56-7P 470436-57-8P
 470436-58-9P 470436-59-0P 470436-60-3P
 470436-61-4P 470436-62-5P 470436-63-6P
 470436-64-7P 470436-65-8P 470436-66-9P
 470436-67-0P 470436-68-1P 470436-69-2P
 470436-70-5P 470436-71-6P 470436-72-7P
 470436-73-8P 470436-74-9P 470436-75-0P
 470436-76-1P 470436-77-2P 470436-78-3P
 470436-79-4P 470436-80-7P 470436-81-8P
 470436-82-9P 470436-83-0P 470436-84-1P
 470436-85-2P 470436-86-3P 470436-87-4P
 470436-88-5P 470436-89-6P 470436-90-9P
 470436-91-0P 470436-92-1P 470436-93-2P
 470436-94-3P 470436-95-4P 470436-96-5P
 470436-97-6P 470436-98-7P 470436-99-8P
 470437-00-4P 470437-01-5P 470437-02-6P
 470437-03-7P 470437-04-8P 470437-05-9P
 470437-06-0P 470437-07-1P 470437-08-2P
 470437-09-3P 470437-10-6P 470437-11-7P
 470437-12-8P 470437-13-9P 470437-14-0P
 470437-15-1P 470437-16-2P 470437-17-3P
 470437-18-4P 470437-19-5P 470437-20-8P
 470437-21-9P 470437-22-0P 470437-23-1P
 470437-24-2P 470437-25-3P 470437-26-4P
 470437-27-5P 470437-28-6P 470437-29-7P
 470437-30-0P 470437-31-1P 470437-32-2P
 470437-33-3P 470437-34-4P 470437-35-5P
 470437-36-6P 470437-37-7P 470437-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of spiroisoquinolines as small-conductance Ca²⁺-activated K⁺
 channel blockers and acetylcholine esterase inhibitors for treatment of
 diseases)

RN 470435-02-0 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-
 dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl
 ester (9CI) (CA INDEX NAME)

CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 470435-02-0P 470435-03-1P 470435-04-2P
 470435-05-3P 470435-06-4P 470435-07-5P
 470435-08-6P 470435-09-7P 470435-10-0P
 470435-11-1P 470435-12-2P 470435-13-3P
 470435-14-4P 470435-15-5P 470435-16-6P
 470435-17-7P 470435-18-8P 470435-19-9P
 470435-20-2P 470435-21-3P 470435-22-4P
 470435-23-5P 470435-24-6P 470435-25-7P
 470435-26-8P 470435-27-9P 470435-28-0P
 470435-29-1P 470435-30-4P 470435-31-5P
 470435-32-6P 470435-33-7P 470435-34-8P
 470435-35-9P 470435-36-0P 470435-37-1P
 470435-38-2P 470435-39-3P 470435-40-6P
 470435-41-7P 470435-42-8P 470435-43-9P
 470435-44-0P 470435-45-1P 470435-46-2P
 470435-47-3P 470435-48-4P 470435-49-5P
 470435-50-8P 470435-51-9P 470435-52-0P
 470435-53-1P 470435-54-2P 470435-55-3P
 470435-56-4P 470435-57-5P 470435-58-6P
 470435-59-7P 470435-60-0P 470435-61-1P
 470435-62-2P 470435-63-3P 470435-64-4P
 470435-65-5P 470435-66-6P 470435-67-7P
 470435-68-8P 470435-69-9P 470435-70-2P
 470435-71-3P 470435-72-4P 470435-73-5P
 470435-74-6P 470435-75-7P 470435-76-8P
 470435-77-9P 470435-78-0P 470435-79-1P
 470435-80-4P 470435-81-5P 470435-82-6P
 470435-83-7P 470435-84-8P 470435-85-9P
 470435-86-0P 470435-87-1P 470435-88-2P
 470435-90-6P 470435-91-7P 470435-92-8P

piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-00-8 CAPLUS

CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470435-01-9 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-98-1 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-99-2 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-96-9 CAPLUS

CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-97-0 CAPLUS

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


Relative stereochemistry.



RN 470434-94-7 CAPLUS


CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 5'-chloro-2'-
 [(dimethylamino)acetyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-
 d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6'-methoxy-,
 trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-95-8 CAPLUS


CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 5'-chloro-2'-
 [(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-4-[[4-[1-[(6-methyl-2-



RN 470434-92-5 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 5'-chloro-2'-
 [(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-4-[[4-[1-[(3-
 methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-93-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 5'-chloro-2'-
 [(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-4-[[4-[1-[(3-
 nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 470434-91-4 CAPLUS
 CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 5'-chloro-4-[[4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-89-0 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-90-3 CAPLUS
 CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 5'-chloro-2'-[(dimethylamino)acetyl]-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6'-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

d[pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-87-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-88-9 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6'-methoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

piperazinyllcarbonyl]-3',4'-dihydro-6'-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-85-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyllcarbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-86-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyllcarbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6'-methoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-83-4 CAPLUS


CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-84-5 CAPLUS


CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-



RN 470434-81-2 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-82-3 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 470434-79-8 CAPLUS
 CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-80-1 CAPLUS
 CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470434-78-7 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470434-76-5 CAPLUS

CN Piperazine, 1-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-2'-ethyl-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-77-6 CAPLUS


CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-74-3 CAPLUS
 CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-75-4 CAPLUS
 CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-72-1 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-73-2 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-2'-ethyl-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470434-70-9 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-71-0 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470434-68-5 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-69-6 CAPLUS

CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470434-67-4 CAPLUS
 CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[1-(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-65-2 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-66-3 CAPLUS


CN Piperazine, 1-[(trans-5'-chloro-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-63-0 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-64-1 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-61-8 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-62-9 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-59-4 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-2'-ethyl-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-60-7 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-3',4'-dihydro-6'-methoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-57-2 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-4-[[4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-58-3 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-55-0 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-56-1 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-53-8 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-3',4'-dihydro-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-54-9 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-51-6 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-52-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-6'-ethoxy-4-[[4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-49-2 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-50-5 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-47-0 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-48-1 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydro-2'-methylspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-45-8 CAPLUS

CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-46-9 CAPLUS


CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470434-44-7 CAPLUS
 CN Piperazine, 1-[(trans-6'-ethoxy-3',4'-dihydrospiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 2-A



RN 470434-42-5 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-43-6 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(4-thiazolylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470434-41-4 CAPLUS
 CN Piperazine, 1-[1-(cyclopentylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
 [[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-
 dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A




RN 470434-39-0 CAPLUS
 CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-40-3 CAPLUS
 CN Piperazine, 1-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470434-38-9 CAPLUS

CN Piperazine, 1-[1-(2-cyclopentylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-
[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-
dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl] - (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470434-36-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-37-8 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-hexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 470434-35-6 CAPLUS
 CN Piperazine, 1-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470434-33-4 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-34-5 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-32-3 CAPLUS


CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A



PAGE 1-A




PAGE 2-A




RN 470434-31-2 CAPLUS
 CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



RN 470434-30-1 CAPLUS


CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-28-7 CAPLUS
 CN Piperazine, 1-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 470434-29-8 CAPLUS
 CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.





RN 470434-27-6 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(1,3-dithiolan-2-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A






RN 470434-25-4 CAPLUS

CN Piperazine, 1-[[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-26-5 CAPLUS

CN Piperazine, 1-[[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-23-2 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-24-3 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-21-0 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-22-1 CAPLUS

CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Relative stereochemistry.



RN 470434-19-6 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 470434-20-9 CAPLUS

CN Piperazine, 1-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

NAME)


Relative stereochemistry.



RN 470434-17-4 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-18-5 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 470434-15-2 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-16-3 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl) carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 470434-13-0 CAPLUS

CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-14-1 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-11-8 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-12-9 CAPLUS

CN Piperazine, 1-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-09-4 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-10-7 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470434-07-2 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470434-08-3 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 2-A





RN 470434-06-1 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-methyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A







RN 470434-05-0 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


PAGE 1-A






RN 470434-03-8 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-ethoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-04-9 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-01-6 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.



RN 470434-02-7 CAPLUS
 CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[[4-fluoro-3-methylphenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-99-9 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470434-00-5 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Relative stereochemistry.



RN 470433-97-7 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-98-8 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-95-5 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-96-6 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-93-3 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-94-4 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Relative stereochemistry.



RN 470433-91-1 CAPLUS

CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-92-2 CAPLUS

CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)

NAME)


Relative stereochemistry.



RN 470433-89-7 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-90-0 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-87-5 CAPLUS


CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470433-88-6 CAPLUS


CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 470433-85-3 CAPLUS


CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 470433-86-4 CAPLUS


CN Piperazine, 1-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 470433-83-1 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-84-2 CAPLUS

CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-81-9 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-82-0 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-79-5 CAPLUS

CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-80-8 CAPLUS

CN Piperazine, 1-[1-[(3-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-77-3 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 {[4-[1-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
 INDEX NAME)


Relative stereochemistry.



RN 470433-78-4 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
 {[4-[1-[(6-ethyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
 piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
 INDEX NAME)


Relative stereochemistry.



RN 470433-75-1 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-
[[4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 470433-76-2 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(3-
chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-
dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-73-9 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[[3-(trifluoromethoxy)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-74-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-4-[[4-[1-[(4-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 470433-71-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2,3-dichlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 470433-72-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methyl-2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470438-08-5 CAPLUS
CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(-), (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-01-4
CMF C49 H62 N10 O6


Rotation (-). Absolute stereochemistry unknown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-09-6 CAPLUS
CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-


tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-(+), (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-02-5

CMF C49 H62 N10 O6

Rotation (+). Absolute stereochemistry unknown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-10-9 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-[(1-oxido-4-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-03-6

CMF C49 H62 N10 O7

Relative stereochemistry.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-11-0 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4R)-rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-04-7

CMF C49 H62 N10 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-21-2 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-38-7


CMF C46 H63 N9 O6

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-22-3 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-(1-butyl-1H-pyrazolo[3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-39-8


CMF C47 H65 N9 O6

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470438-23-4 CAPLUS
CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-40-1
CMF C48 H60 N10 O6

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-24-5 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-41-2


CMF C46 H63 N9 O6

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-25-6 CAPLUS
CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-4-[[4-(1-hexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-42-3


CMF C49 H69 N9 O6

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470438-26-7 CAPLUS
CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-43-4
CMF C51 H65 N9 O6

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-28-9 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-pentyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 470430-45-6

CMF C48 H67 N9 O6

Relative stereochemistry.



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-31-4 CAPLUS

CN Spiro[cyclohexane-1,1' (2'H)-isoquinoline], 4-[[4-(1-ethyl-1H-pyrazolo[3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

d[pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-48-9


CMF C45 H61 N9 O6

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470438-32-5 CAPLUS
CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-49-0
CMF C49 H61 N9 O6

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-33-6 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-50-3


CMF C47 H65 N9 O6

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-40-5 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-2'-
[3-(methylamino)-1-oxopropyl]-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-
d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-,
(2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470430-60-5


CMF C50 H63 N9 O6

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470438-48-3 CAPLUS
CN Piperazine, 1-[[trans-2'-(2-aminoethyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-83-2
CMF C35 H43 Cl N8 O3


Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-49-4 CAPLUS
CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-


chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-84-3

CMF C36 H45 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-50-7 CAPLUS


CN Piperazine, 1-[[[trans-2'-(4-aminobutyl)-3',4'-dihydro-6',7'-
dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-
chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-85-4

CMF C37 H47 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-51-8 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 470430-86-5

CMF C32 H46 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-52-9 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-87-6

CMF C35 H45 N9 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-53-0 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-88-7

CMF C36 H45 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-54-1 CAPLUS


CN Piperazine, 1-[[trans-2'-(4-aminobutyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-89-8

CMF C36 H47 N9 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-55-2 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-90-1

CMF C35 H45 N9 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-56-3 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-91-2

CMF C37 H45 N9 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-57-4 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-92-3

CMF C36 H45 Br N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-58-5 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-93-4

CMF C36 H47 N9 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-59-6 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-(dimethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-94-5

CMF C38 H49 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-60-9 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[2-(dimethylamino)ethyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-95-6

CMF C37 H47 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-61-0 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[4-(dimethylamino)butyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-96-7

CMF C39 H51 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-62-1 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-97-8

CMF C37 H45 Cl N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-63-2 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470430-98-9

CMF C37 H47 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-65-4 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[4-(methylamino)butyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-00-6

CMF C38 H49 Cl N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-66-5 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[cyanoamino]iminomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-01-7

CMF C38 H46 Cl N11 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-67-6 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[cyanoamino(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-02-8

CMF C39 H48 Cl N11 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-68-7 CAPLUS


CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[cyanoamino](dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-03-9

CMF C40 H50 Cl N11 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-69-8 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-04-0

CMF C40 H50 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-70-1 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)iminomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-05-1

CMF C38 H46 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-71-2 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-06-2

CMF C39 H48 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-72-3 CAPLUS


CN Piperazine, 1-[[trans-2'-[4-[[[(cyanoamino)iminomethyl]amino]butyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-07-3

CMF C38 H48 N12 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-73-4 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-
[[[(cyanoamino)(methylimino)methyl]methylamino]-1-oxopropyl]-2-[(1R)-2-
ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-
6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 470431-08-4

CMF C52 H65 N13 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-74-5 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-09-5

CMF C40 H51 Cl N10 O5

Relative stereochemistry.

Double bond geometry unknown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-75-6 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[1-(methylamino)-2-nitroethenyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-10-8

CMF C39 H49 Cl N10 O5

Relative stereochemistry.

Double bond geometry unknown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-76-7 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[(1-amino-2-nitroethenyl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-11-9

CMF C38 H47 Cl N10 O5

Relative stereochemistry.
Double bond geometry unknown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-77-8 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (1-oxopropoxy)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-18-6


CMF C54 H68 N10 O10

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470438-86-9 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 1-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]ethyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-32-4

CMF C54 H75 N9 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-87-0 CAPLUS



CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-33-5

CMF C56 H72 N10 O10

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470438-89-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(+)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-36-8

CMF C56 H72 N10 O10

Rotation (+). Absolute stereochemistry unknown.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-90-5 CAPLUS



CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(-)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-37-9

CMF C56 H72 N10 O10

Rotation (-). Absolute stereochemistry unknown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470438-92-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(-)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-39-1

CMF C56 H72 N10 O10

Rotation (-). Absolute stereochemistry unknown.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-94-9 CAPLUS



CN Propanoic acid, 2,2-dimethyl-, [3-[(1R,2R,4R)-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(+)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470438-93-8

CMF C57 H72 Cl N9 O10

Rotation (+). Absolute stereochemistry unknown.






CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-96-1 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-(+)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 470438-95-0
CMF C56 H72 N10 O10

Rotation (+). Absolute stereochemistry unknown.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470438-97-2 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-44-8

CMF C53 H73 N9 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-98-3 CAPLUS



CN Propanoic acid, 2,2-dimethyl-, [[[[[3-[(1R,2R,4R)-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-41-5

CMF C57 H72 Cl N9 O10

Relative stereochemistry.






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470438-99-4 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (benzoyloxy)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-46-0


CMF C58 H68 N10 O10

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-00-0 CAPLUS

CN Cyclohexanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-47-1

CMF C58 H74 N10 O10

Relative stereochemistry.

PAGE 1-A






CRN 110-17-8
CMF C4 H4 O4

OC(=O)/C=C/C(=O)O


CRN 470431-48-2
CMF C55 H70 N10 O10

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-02-2 CAPLUS

CN Propanoic acid, 2-methyl-, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-49-3

CMF C55 H70 N10 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-03-3 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (acetyloxy)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-50-6

CMF C53 H66 N10 O10

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

 —OAc


CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-04-4 CAPLUS

CN Cyclopropanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-52-8

CMF C55 H68 N10 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-05-5 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (1-oxopropoxy)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-53-9


CMF C51 H69 N9 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-06-6 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, butyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-54-0


CMF C51 H71 N9 O8

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470439-07-7 CAPLUS
CN Cyclopropanecarboxylic acid, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-55-1
CMF C52 H69 N9 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-08-8 CAPLUS

CN Butanoic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-56-2


CMF C52 H71 N9 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-09-9 CAPLUS

CN Pentanoic acid, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-57-3


CMF C53 H73 N9 O10

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470439-10-2 CAPLUS
CN Butanoic acid, 3,3-dimethyl-, [[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-58-4
CMF C54 H75 N9 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-11-3 CAPLUS

CN Propanoic acid, 2-methyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-59-5


CMF C52 H71 N9 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-12-4 CAPLUS

CN Cyclohexanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-
[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-
piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-
oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-60-8

CMF C55 H75 N9 O10

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-13-5 CAPLUS

CN Cyclopentanecarboxylic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-
tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-
[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-
piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-
oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-61-9


CMF C54 H73 N9 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-14-6 CAPLUS

CN Butanoic acid, 3-methyl-, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-62-0


CMF C53 H73 N9 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-15-7 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, [[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]amino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-63-1

CMF C43 H55 N9 O9

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-16-8 CAPLUS

CN Carbonic acid, ethyl [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-64-2

CMF C54 H68 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-17-9 CAPLUS

CN Carbonic acid, [[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl propyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-65-3


CMF C55 H70 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-18-0 CAPLUS

CN Carbonic acid, cyclohexyl [[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-66-4

CMF C58 H74 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-19-1 CAPLUS

CN Carbonic acid, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-67-5


CMF C53 H66 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-20-4 CAPLUS
 CN Carbonic acid, [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy)methyl 1-methylethyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-68-6

CMF C55 H70 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-21-5 CAPLUS

CN Carbonic acid, cyclopentyl [[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-69-7


CMF C57 H72 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-22-6 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-70-0

CMF C55 H66 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-26-0 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (2-oxo-5-phenyl-1,3-dioxol-4-yl)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-74-4


CMF C60 H68 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86




RN 470439-27-1 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [5-(1,1-dimethylethyl)-2-oxo-1,3-dioxol-4-yl]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-75-5
 CMF C58 H72 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-28-2 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-76-6


CMF C56 H68 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-29-3 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-77-7

CMF C57 H70 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-30-6 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (2-oxo-5-propyl-1,3-dioxol-4-yl)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-78-8


CMF C57 H70 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86



RN 470439-31-7 CAPLUS

CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-79-9

CMF C52 H67 N9 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 470439-32-8 CAPLUS
 CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [4-(acetyloxy)phenyl]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-80-2
 CMF C59 H70 N10 O10

Relative stereochemistry.



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-33-9 CAPLUS

Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, [4-(benzyloxy)phenyl]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-81-3


CMF C64 H72 N10 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-34-0 CAPLUS
 CN Butanoic acid, 3-methyl-, 4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-82-4

CMF C62 H76 N10 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-35-1 CAPLUS

CN Carbonic acid, ethyl 4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-83-5


CMF C60 H72 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-36-2 CAPLUS

CN Butanoic acid, 3-methyl-, 2-chloro-4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-84-6


CMF C62 H75 Cl N10 O10

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-37-3 CAPLUS
 CN Butanoic acid, 3-methyl-, 4-[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy)methyl]-2-methoxyphenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-85-7

CMF C63 H78 N10 O11

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-38-4 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, [4-[[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenoxy]methyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-86-8


CMF C63 H78 N10 O11

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




PAGE 2-B

Bu-t

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470439-39-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 4-[[[[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]carbonyl]oxy]methyl]phenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-87-9
CMF C62 H76 N10 O10

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-40-8 CAPLUS


CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-88-0

CMF C61 H73 N9 O9

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-41-9 CAPLUS


CN Benzamide, 2-[(acetyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-(1-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-89-1

CMF C56 H71 N9 O9

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-42-0 CAPLUS


CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-4-[[4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470431-90-4

CMF C62 H75 N9 O9

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-43-1 CAPLUS

CN Benzamide, 2-[(benzyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-91-5


CMF C64 H72 N10 O9

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-44-2 CAPLUS

CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-92-6


CMF C64 H72 N10 O9

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-46-4 CAPLUS
 CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-94-8

CMF C66 H75 N9 O9

Relative stereochemistry.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-47-5 CAPLUS

CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-95-9


CMF C64 H72 N10 O9

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-48-6 CAPLUS

CN Benzamide, 2-[(benzoyloxy)methyl]-N-[3-[(1R,2R,4R)-4-[[4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-
isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate
(1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470431-96-0


CMF C65 H72 Cl N9 O9

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-50-0 CAPLUS

CN 2-Propenamide, 3-[2-(acetyloxy)phenyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470431-98-2

CMF C60 H70 N10 O9

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-51-1 CAPLUS

CN Butanoic acid, 3-methyl-, 2-[3-[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]-3-oxo-1-propenyl]phenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 470431-99-3

CMF C63 H76 N10 O9


Relative stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-52-2 CAPLUS

CN 2-Propenamide, 3-[2-(benzoyloxy)phenyl]-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinoliny]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 470432-00-9


CMF C65 H72 N10 O9

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-53-3 CAPLUS
 CN Carbonic acid, ethyl 2-[3-[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]-3-oxo-1-propenyl]phenyl ester, rel-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1


CRN 470432-01-0

CMF C61 H72 N10 O10

Relative stereochemistry.
 Double bond geometry unknown.

PAGE 1-A






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-54-4 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2-[(1R)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-2'-[3-(formylmethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, (1S,2S,4S)-rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-02-1

CMF C50 H62 N10 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-55-5 CAPLUS


CN Carbamic acid, [3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methyl-, ethyl ester, rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-03-2

CMF C52 H66 N10 O8

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-56-6 CAPLUS


CN Acetamide, 2-amino-N-[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]-N-methyl-, rel-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-04-3

CMF C51 H65 N11 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-57-7 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-06-5

CMF C38 H48 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-58-8 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470432-69-0


CMF C34 H43 Cl N8 O3 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-59-9 CAPLUS

CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-70-3

CMF C37 H48 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-60-2 CAPLUS


CM Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-71-4

CMF C37 H48 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-61-3 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-72-5

CMF C37 H48 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-62-4 CAPLUS


CN Piperazine, 1-[[trans-2'-(3-aminopropyl)-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(methylthio)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470432-73-6

CMF C31 H44 N8 O3 S


Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470439-63-5 CAPLUS
CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-03-5
CMF C36 H47 N9 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-64-6 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[(1-methylethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-05-7

CMF C39 H51 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-65-7 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(dipropylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-06-8

CMF C42 H57 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-66-8 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[(2,2-dimethylpropyl)methylamino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-09-1

CMF C42 H57 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-67-9 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl(1-methylethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-10-4

CMF C40 H53 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-68-0 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl(phenylmethyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-11-5

CMF C44 H53 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-69-1 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(cyclohexylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470433-12-6


CMF C43 H57 N9 O5

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-70-4 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-(hexylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-13-7

CMF C43 H59 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-71-5 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylpropylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-14-8

CMF C40 H53 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-72-6 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(butylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-15-9

CMF C41 H55 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-73-7 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-(methylpentylamino)propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-16-0

CMF C42 H57 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-74-8 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl(2-methylpropyl)amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-17-1

CMF C41 H55 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17¹8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-75-9 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-(ethylmethylamino)propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-18-2

CMF C39 H51 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-76-0 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-54-6

CMF C36 H45 N9 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-77-1 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-55-7

CMF C37 H45 N9 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-78-2 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'--[(dimethylamino)acetyl]-4-
[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-56-8

CMF C37 H45 F N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-79-3 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-57-9

CMF C37 H44 F2 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-80-6 CAPLUS


CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-58-0

CMF C37 H46 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-81-7 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[[(dimethylamino)acetyl]-4-
[[4-[1-(2-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-
piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470433-59-1


CMF C35 H44 N8 O5

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-82-8 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-60-4

CMF C38 H45 N9 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-83-9 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-61-5

CMF C37 H45 N9 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-84-0 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470433-62-6


CMF C35 H44 N8 O4 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-85-1 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'--[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-63-7

CMF C36 H45 N9 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-86-2 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-64-8

CMF C37 H52 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-87-3 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-65-9

CMF C37 H45 Br N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-88-4 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470433-66-0


CMF C35 H44 N8 O4 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-89-5 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-,

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-67-1

CMF C35 H48 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-90-8 CAPLUS

CN Spiro[cyclohexane-1,1'(2'H)-isoquinoline], 4-[[4-[1-(cyclopentylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470433-68-2


CMF C36 H50 N8 O4

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-91-9 CAPLUS

CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[(dimethylamino)acetyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-,

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-69-3

CMF C38 H48 N8 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-92-0 CAPLUS


CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-88-6

CMF C35 H42 N8 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-93-1 CAPLUS


CN Piperazine, 1-[(trans-2'-ethyl-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-89-7

CMF C34 H42 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-94-2 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-95-5

CMF C36 H44 N8 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-95-3 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-propylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470433-96-6

CMF C35 H44 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-96-4 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470434-07-2

CMF C32 H38 N8 O3


Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470439-97-5 CAPLUS
CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1' (2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470434-16-3
CMF C34 H40 N8 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-98-6 CAPLUS


CN Piperazine, 1-[(trans-3',4'-dihydro-6',7'-dimethoxy-2'-methylspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl)carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470434-17-4

CMF C33 H40 N8 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470439-99-7 CAPLUS


CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, methyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470434-96-9

CMF C38 H47 N9 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-00-7 CAPLUS


CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, methyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470434-97-0

CMF C37 H47 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-01-8 CAPLUS


CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, butyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-03-1

CMF C41 H53 F N8 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-02-9 CAPLUS


CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-methoxy-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-07-5

CMF C39 H49 N9 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-03-0 CAPLUS


CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-methoxyethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-08-6

CMF C40 H51 N9 O8

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-04-1 CAPLUS


CN Pentanamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-4-oxo-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-09-7

CMF C41 H51 N9 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-05-2 CAPLUS


CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-oxopropyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-10-0

CMF C40 H49 N9 O8

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-06-3 CAPLUS


CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-2-methoxy-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-11-1

CMF C38 H49 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-07-4 CAPLUS


CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-methoxyethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-12-2

CMF C39 H51 N9 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-08-5 CAPLUS


CN Carbamic acid, [3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, 2-oxopropyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-13-3

CMF C39 H49 N9 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-09-6 CAPLUS


CN Pentanamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-4-oxo-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-14-4

CMF C40 H51 N9 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-10-9 CAPLUS


CN Carbamic acid, dimethyl-, 2-[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'-(2'H)-isoquinolin]-2'-yl]propyl]amino]carbonyl]oxy]ethyl ester, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 470435-20-2

CMF C42 H54 N10 O9

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-11-0 CAPLUS


CN Carbamic acid, dimethyl-, 2-[[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]amino]carbonyl]oxy]ethyl ester, (2E)-2-butenedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 470435-22-4

CMF C41 H54 N10 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-12-1 CAPLUS


CN Carbamic acid, dimethyl-, 2-[[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]amino]-2-oxoethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-23-5

CMF C40 H52 N10 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-13-2 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylimino)methyl]methylamino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-24-6

CMF C40 H50 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-14-3 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylimino)methyl]methylamino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-25-7

CMF C39 H50 N12 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-15-4 CAPLUS


CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-26-8

CMF C39 H49 N11 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-16-5 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (methylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-27-9

CMF C39 H48 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-17-6 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-28-0

CMF C39 H48 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-18-7 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[cyanoamino(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-29-1

CMF C39 H48 F N11 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-19-8 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (methylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2,6-difluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-30-4

CMF C39 H47 F2 N11 O3

Relative stereochemistry.




CM - 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-20-1 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-furanylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470435-32-6


CMF C37 H47 N11 O4

Relative stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-21-2 CAPLUS
CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-,

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470435-33-7


CMF C37 H47 N11 O3 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 470440-22-3 CAPLUS
 CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(3-thienylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 470435-34-8
 CMF C37 H47 N11 O3 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-23-4 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(methylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-35-9

CMF C38 H48 N12 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-24-5 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(cyclohexylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

]propyl}-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470435-36-0


CMF C44 H56 N12 O5

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-25-6 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (cyclopropylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-37-1

CMF C41 H50 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 470440-26-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (diethylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-38-2
CMF C42 H54 N12 O5


Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 470440-27-8 CAPLUS
CN Piperazine, 1-[[[trans-2'-[3-[[[(cyanoamino) (propylamino) methylene] amino] propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-39-3
CMF C41 H52 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-28-9 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(butylamino)(cyanoamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-40-6

CMF C42 H54 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-29-0 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino)(ethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-41-7

CMF C40 H50 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-30-3 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(cyanoamino) (dimethylamino)methylene] amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-42-8

CMF C41 H50 N12 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-31-4 CAPLUS


CN Piperazine, 1-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[[(cyanoamino)(dimethylamino)methylene]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-43-9

CMF C40 H50 Br N11 O3

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-32-5 CAPLUS

CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[methyl[1-(methylamino)-2-nitroethenyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470435-44-0

CMF C39 H51 N11 O5

Relative stereochemistry.

Double bond geometry unknown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-33-6 CAPLUS

CN Piperazine, 1-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470435-45-1


CMF C38 H49 Cl N10 O5 S

Relative stereochemistry.
Double bond geometry unknown.

PAGE 1-A




PAGE 2-A



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 470440-34-7 CAPLUS

CN Piperazine, 1-[[trans-2'-[3-[[1-(dimethylamino)-2-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-46-2

CMF C41 H54 N10 O5


Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 470440-35-8 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[1-(dimethylamino)-2-nitroethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'-(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-47-3

CMF C41 H54 N10 O5


Relative stereochemistry.
Double bond geometry unknown.



CM 2

CRN 77-92-9

CMF C6 H8 O7



RN 470440-36-9 CAPLUS

CN Piperazine, 1-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[[trans-2'-[3-[(cyclohexylamino)thioxomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 470435-48-4


CMF C43 H56 Cl N9 O3 S

Relative stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-37-0 CAPLUS

CN Piperazine, 1-[[[trans-2'-[3-[[[(1,1-dimethylethyl) amino]thioxomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86


d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-49-5

CMF C41 H54 N10 O5 S

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-38-1 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[butylamino)thioxomethyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-50-8

CMF C41 H54 N10 O5 S

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-39-2 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[[(methylamino)thioxomethyl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-51-9

CMF C38 H48 N10 O5 S

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-40-5 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(butylamino)carbonyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-52-0

CMF C41 H54 N10 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-41-6 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[[(ethylamino)carbonyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-53-1

CMF C39 H50 N10 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-42-7 CAPLUS


CN Acetamide, N-[3-[trans-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-54-2

CMF C38 H47 N9 O6

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-43-8 CAPLUS


CN Piperazine, 1-[[[trans-2'-[3-[[2-(dimethylamino)-3,4-dioxo-1-cyclobuten-1-yl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-56-4

CMF C42 H50 N10 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-44-9 CAPLUS


CN Piperazine, 1-[[trans-3',4'-dihydro-6',7'-dimethoxy-2'-[3-[[2-(methylamino)-3,4-dioxo-1-cyclobuten-1-yl]amino]propyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-57-5

CMF C41 H48 N10 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-45-0 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[(2-amino-3,4-dioxo-1-cyclobuten-1-yl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-58-6

CMF C40 H46 N10 O7

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-46-1 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[(1-amino-2,2-dicyanoethenyl)amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-60-0

CMF C40 H46 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-47-2 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[2,2-dicyano-1-(dimethylamino)ethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-61-1

CMF C42 H50 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-48-3 CAPLUS


CN Piperazine, 1-[[trans-2'-[3-[[2,2-dicyano-1-(methylamino)ethenyl]amino]propyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-4-yl]carbonyl]-4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-62-2

CMF C41 H48 N12 O5

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-49-4 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-85-9

CMF C37 H47 N9 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-50-7 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 4-[[4-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-86-0

CMF C38 H54 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-51-8 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-87-1

CMF C36 H50 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-52-9 CAPLUS


CN Spiro[cyclohexane-1,1'-(2'H)-isoquinoline], 2'-[3-(dimethylamino)-1-oxopropyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(3-methyl-3-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-, trans-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-88-2

CMF C36 H50 N8 O4

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 470440-54-1 CAPLUS


CN Carbamic acid, [3-[trans-4-[[4-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]-3',4'-dihydro-6',7'-dimethoxyspiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]propyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, trans-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 470435-90-6

CMF C42 H49 F N8 O8

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



IT 159599-52-7P 245450-02-6P 470440-64-3P
 470441-51-1P, 4-(4-Ethoxycarbonyl-1-piperazinyl)-1H-pyrazolo[3,4-
 d]pyrimidine 470441-52-2P, 1-(4-Pyridylmethyl)-4-(4-
 ethoxycarbonyl-1-piperazinyl)-1H-pyrazolo[3,4-d]pyrimidine
 470441-53-3P, 1-(4-Pyridylmethyl)-4-(1-piperazinyl)-1H-
 pyrazolo[3,4-d]pyrimidine 470442-15-0P 470442-16-1P
 470442-17-2P 470442-18-3P 470442-19-4P
 470442-20-7P 470442-21-8P 470442-22-9P
 470442-23-0P 470442-24-1P 470442-25-2P
 470442-26-3P 470442-27-4P 470442-28-5P
 470442-29-6P 470442-30-9P 470442-31-0P
 470442-32-1P 470442-33-2P 470442-34-3P
 470442-35-4P 470442-36-5P 470442-37-6P
 470442-38-7P 470442-39-8P 470442-40-1P
 470442-41-2P 470442-42-3P 470442-43-4P
 470442-44-5P 470442-45-6P 470442-46-7P
 470442-47-8P 470442-48-9P 470442-49-0P
 470442-50-3P 470442-51-4P 470442-52-5P
 470442-53-6P 470442-54-7P 470442-55-8P
 470442-56-9P 470442-57-0P 470442-58-1P
 470442-59-2P 470442-60-5P 470442-61-6P
 470442-62-7P 470442-63-8P 470442-64-9P
 470442-65-0P 470442-66-1P 470442-67-2P


470442-68-3P 470442-69-4P 470442-70-7P
 470442-71-8P 470442-72-9P 470442-73-0P
 470442-74-1P 470442-75-2P 470442-76-3P
 470442-77-4P 470442-78-5P 470442-79-6P
 470442-80-9P 470442-81-0P 470442-82-1P
 470442-83-2P 470442-84-3P 470442-85-4P
 470442-86-5P 470442-87-6P 470442-88-7P
 470442-89-8P 470442-90-1P 470442-91-2P
 470442-92-3P 470442-93-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spiroisoquinolines as small-conductance Ca^{2+} -activated K^{+} channel blockers and acetylcholine esterase inhibitors for treatment of diseases)


RN 159599-52-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 245450-02-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470440-64-3 CAPLUS

CN Carbamic acid, [2-[[3-[(1R,2R,4R)-2-[(1S)-2-ethyl-1,2,3,4-tetrahydro-6,7-

dimethoxy-1-isoquinolinyl]-3',4'-dihydro-6',7'-dimethoxy-4-[[4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1-piperazinyl]carbonyl]spiro[cyclohexane-1,1'(2'H)-isoquinolin]-2'-yl]-3-oxopropyl]methylamino]-2-oxoethyl]-, 1,1-dimethylethyl ester, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B


OBu-t

RN 470441-51-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-, ethyl


Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

ester (9CI) (CA INDEX NAME)




RN 470441-52-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(4-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 470441-53-3 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 470442-15-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-[(2-chlorophenyl)methyl]-1H-pyrazolo[3,4-

d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 470442-16-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(2-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 470442-17-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(3-pyridinylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 470442-18-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(1-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 470442-19-4 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-chlorophenyl)methyl]-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 470442-20-7 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-(2-pyridinylmethyl)-

(9CI) (CA INDEX NAME)




RN 470442-21-8 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-(3-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




RN 470442-22-9 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(phenylmethyl)-4-(1-piperazinyl)- (9CI)
(CA INDEX NAME)




RN 470442-23-0 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-butyl-4-(1-piperazinyl)- (9CI) (CA INDEX
NAME)




RN 470442-24-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 470442-25-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-methylphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 470442-26-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-[(5-chloro-2-thienyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

NAME)




RN 470442-27-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-28-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-29-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(cyclohexylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-30-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(3-methyl-2-butenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-31-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(1-cyclohexyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-32-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) -
 , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-33-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl) -
 , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-34-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(4-thiazolylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-35-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-36-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(3,4-dimethylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 470442-37-6 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(5-chloro-2-thienyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-38-7 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(4-methylphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-39-8 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-methylphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-40-1 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(cyclohexylmethyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 470442-41-2 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(3-methyl-2-butenyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

RN	470442-42-3	CAPLUS
CN	1H-Pyrazolo[3,4-d]pyrimidine, 1-cyclohexyl-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)	




RN	470442-43-4	CAPLUS
CN	1H-Pyrazolo[3,4-d]pyrimidine, 1-methyl-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)	




●2 HCl

RN 470442-44-5 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-ethyl-4-(1-piperazinyl)-, dihydrochloride
 (9CI) (CA INDEX NAME)



●2 HCl


RN 470442-45-6 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-(4-thiazolylmethyl)-,
 dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 470442-46-7 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-fluoro-3-methylphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 470442-47-8 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3,4-dimethylphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 470442-48-9 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(6-ethyl-2-pyridinyl)methyl]-4-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 470442-49-0 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(6-methyl-2-pyridinyl)methyl]-4-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 470442-50-3 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-(3-thienylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 470442-51-4 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(3-furanylmethyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 470442-52-5 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-(2-thienylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 470442-53-6 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-furanylmethyl)-4-(1-piperazinyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-54-7 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2,6-difluorophenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-55-8 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(4-nitrophenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 470442-56-9 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(3-methyl-3-butenyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 470442-57-0 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(cyclobutylmethyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 470442-58-1 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(cyclopentylmethyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 470442-59-2 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-(2-cyclopentylethyl)-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 470442-60-5 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-hexyl-4-(1-piperazinyl)-, dihydrochloride
 (9CI) (CA INDEX NAME)



●2 HCl


RN 470442-61-6 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-ethoxyphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-62-7 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-methyl-2-nitrophenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 470442-63-8 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[[6-(methoxymethyl)-2-pyridinyl]methyl]-4-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 470442-64-9 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-[(6-propyl-2-pyridinyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 470442-65-0 CAPLUS
 CN 2-Pyridinamine, N-methyl-6-[[4-(1-piperazinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 470442-66-1 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-[(2-propyl-4-pyrimidinyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 470442-67-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-ethyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 470442-68-3 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-ethyl-4-thiazolyl)methyl]-4-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 470442-69-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-70-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-cyanophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-71-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-bromophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-72-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(3-nitrophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-73-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(cyanomethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-74-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(3-methoxyphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-75-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(4-fluoro-3-methylphenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-76-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-methyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-77-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(2-propyl-4-thiazolyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 470442-78-5 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-nitrophenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-79-6 CAPLUS


CN Benzonitrile, 2-[[4-(1-piperazinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 470442-80-9 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-bromophenyl)methyl]-4-(1-piperazinyl)-

(9CI) (CA INDEX NAME)



RN 470442-81-0 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-nitrophenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-82-1 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine-1-acetonitrile, 4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-83-2 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(3-methoxyphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-84-3 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(4-fluoro-3-methylphenyl)methyl]-4-(1-piperazinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 470442-85-4 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(2-methyl-4-thiazolyl)methyl]-4-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 470442-86-5 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-piperazinyl)-1-[(2-propyl-4-thiazolyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 470442-87-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(6-bromo-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-88-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(6-ethoxy-2-pyridinyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 470442-89-8 CAPLUS


CN 1H-Pyrazolo[3,4-d]pyrimidine, 1-[(6-ethoxy-2-pyridinyl)methyl]-4-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 470442-90-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[(3-aminophenyl)methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-91-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[3-(formylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 470442-92-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[3-(ethylformylamino)phenyl]methyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 470442-93-4 CAPLUS

CN Benzenamine, N-ethyl-3-[[4-(1-piperazinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]- (9CI) (CA INDEX NAME)



=> dis his

(FILE 'HOME' ENTERED AT 12:14:02 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 12:14:10 ON 29 NOV 2005

L1 STR
L2 25 S L1
L3 2571 S L1 FUL

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 12:31:04 ON 29 NOV 2005

L4 0 FILE MEDLINE
L5 3 FILE BIOSIS
L6 3 FILE EMBASE
L7 453 FILE CAPLUS

TOTAL FOR ALL FILES

L8 459 S L3
L9 26 FILE MEDLINE
L10 79 FILE BIOSIS
L11 39 FILE EMBASE
L12 109 FILE CAPLUS

TOTAL FOR ALL FILES

L13 253 S PEYMAN A?/AU
L14 11 FILE MEDLINE
L15 25 FILE BIOSIS
L16 10 FILE EMBASE
L17 47 FILE CAPLUS

TOTAL FOR ALL FILES

L18 93 S SCHEUNEMANN K?/AU
L19 17 FILE MEDLINE
L20 76 FILE BIOSIS
L21 24 FILE EMBASE
L22 74 FILE CAPLUS

TOTAL FOR ALL FILES

L23 191 S GADEK T?/AU
L24 8 FILE MEDLINE
L25 33 FILE BIOSIS
L26 8 FILE EMBASE
L27 47 FILE CAPLUS

TOTAL FOR ALL FILES

L28 96 S GOURVEST J?/AU
L29 6 FILE MEDLINE
L30 22 FILE BIOSIS
L31 20 FILE EMBASE
L32 31 FILE CAPLUS

TOTAL FOR ALL FILES

L33 79 S RUXER J?/AU
L34 2 FILE MEDLINE
L35 4 FILE BIOSIS
L36 2 FILE EMBASE
L37 4 FILE CAPLUS

TOTAL FOR ALL FILES

L38 12 S L13 AND L18 AND L23 AND L28 AND L33
L39 6 DUP REM L38 (6 DUPLICATES REMOVED)
L40 0 FILE MEDLINE
L41 0 FILE BIOSIS
L42 0 FILE EMBASE
L43 4 FILE CAPLUS

TOTAL FOR ALL FILES

L44 4 S (L13 OR L18 OR L23 OR L28 OR L33) AND L8
 L45 0 FILE MEDLINE
 L46 0 FILE BIOSIS
 L47 0 FILE EMBASE
 L48 3 FILE CAPLUS
 TOTAL FOR ALL FILES
 L49 3 S L44 NOT L38

FILE 'CAPLUS' ENTERED AT 12:33:13 ON 29 NOV 2005

L50 366 S L3/P
 L51 14 S L50 AND PHARM? COMP?

FILE 'REGISTRY' ENTERED AT 12:33:57 ON 29 NOV 2005

L52 STR L1
 L53 50 S L52
 L54 3742 S L52 FUL

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 12:35:14 ON 29 NOV 2005

L55 0 FILE MEDLINE
 L56 0 FILE BIOSIS
 L57 0 FILE EMBASE
 L58 95 FILE CAPLUS

TOTAL FOR ALL FILES

L59 95 S L54
 L60 0 FILE MEDLINE
 L61 0 FILE BIOSIS
 L62 0 FILE EMBASE
 L63 0 FILE CAPLUS


TOTAL FOR ALL FILES

L64 0 S (L13 OR L18 OR L23 OR L28 OR L33) AND L59

FILE 'CAPLUS' ENTERED AT 12:35:55 ON 29 NOV 2005

L65 70 S L54/P
 L66 5 S L65 AND PHARM? COMP?

=> d l3 que stat;d l54 que stat
 L1 STR



C @11

VAR G1=C/N
 VAR G2=12/11
 VAR G3=X/CN/N/O/S/14/H/C
 VAR G4=H/N/X/O/S/N
 NODE ATTRIBUTES: "

Page 1730

NSPEC IS R AT 11
NSPEC IS R AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17


STEREO ATTRIBUTES: NONE
L3 2571 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 181353 ITERATIONS
SEARCH TIME: 00.00.07

2571 ANSWERS

L52

STR



C@11

VAR G2=12/11
VAR G4=H/N/X/O/S/N
NODE ATTRIBUTES:
NSPEC IS R AT 11
NSPEC IS R AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L54 3742 SEA FILE=REGISTRY SSS FUL L52

100.0% PROCESSED 12770 ITERATIONS
SEARCH TIME: 00.00.01

3742 ANSWERS

=> log y
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
30.28	854.00

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY

SESSION

-3.65

-17.52

STN INTERNATIONAL LOGOFF AT 12:38:26 ON 29 NOV 2005